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ABSTRACT 
Nasopharyngeal carcinoma (NPC) is a highly metastatic disease arising from the 
epithelial cells in the nasopharynx that is exceptionally prevalent in Southeast Asia and 
Southern China. NPC is classified into keratinising and non-keratinising carcinoma in 
which non-keratinising NPC is consistently associated with Epstein-Barr virus (EBV) 
infection; close to 100% of cases in endemic regions are EBV-associated. More than 
70% of NPC patients present with late stage disease and existing treatment for advanced 
disease is limited to concurrent chemo-radiotherapy. Approximately 30% of these 
patients develop distant metastases post therapy and due to the location of tumours in 
close proximity to many vital organs in the head and neck region, most NPC survivors 
have an impaired health-related quality of life. A better understanding of the molecular 
basis of NPC is required to inform innovations in the therapeutic approach. The present 
study was designed to investigate the biological significance of sphingosine-1-
phosphate (S1P) signalling in the pathogenesis of NPC and the contribution of EBV to 
the dysregulation of this pathway. S1P is a bioactive lipid produced by the activity of 
sphingosine kinases (SPHKs), which signals through a family of five G protein-coupled 
receptors, termed S1P receptors 1-5 (S1PR1-5), to trigger multiple pathways that 
regulate important biological processes. There is now compelling evidence to show that 
the SPHKs/S1P/S1PRs axis is a novel and attractive therapeutic target in cancer. High 
expression of SPHK1 has been shown in primary NPCs and therefore, elevated levels of 
S1P are likely to be present in NPC cells. The present study showed that treatment of 
NPC cells with exogenous S1P enhanced the migration and invasion and these effects 
were accompanied by the activation of AKT. Focusing on the migratory phenotype, 
shRNA knockdown of SPHK1 resulted in a reduction in the levels of phosphorylated 
AKT and inhibition of cell migration. Furthermore, re-analysis of two published 
microarray datasets revealed the over-expression of S1PR3 in primary NPC tissues 
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compared to non-malignant nasopharyngeal epithelium. Knockdown of S1PR3 inhibited 
the activation of AKT and the S1P-induced migration of NPC cells. The expression of 
constitutively active AKT was able to partially rescue the repressive effects of the 
knockdown of SPHK1 and S1PR3 on cell migration. In addition, the only EBV-positive 
NPC cell line, C666-1, expressed the highest levels of SPHK1 and S1PR3 compared to 
a panel of seven EBV-negative NPC cell lines. To elucidate the contribution of EBV to 
the deregulation of S1P signalling, the present study demonstrated that EBV infection or 
ectopic expression of EBV-encoded latent genes (EBNA1, LMP1 or LMP2A) can 
upregulate the expression of SPHK1 in NPC cells. Taken together, the results of the 
present study show for the first time that S1P induces NPC cell migration by activating 
AKT through S1PR3, and point to a central role of EBV infection in mediating the 
oncogenic effects of S1P in this disease. Therefore, targeting S1P signalling could be a 
promising therapeutic intervention for NPC. 
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ABSTRAK 
Kanser nasofarinks (NPC) adalah satu penyakit kanser metastatik yang berkembang 
daripada sel-sel epitelium dalam nasofarinks dan berleluasa di Asia Tenggara dan China 
Selatan. NPC dikelaskan kepada karsinoma berkeratin dan tanpa keratin. NPC tanpa 
keratin dikaitkan pula dengan jangkitan virus Epstein-Barr (EBV) secara konsisten di 
mana hampir 100% kes-kes NPC di kawasan-kawasan endemik berhubungkait dengan 
EBV. Lebih daripada 70% pesakit NPC hanya dapat dikesan pada tahap yang lewat dan 
rawatan bagi penyakit peringkat lewat adalah terhad kepada kombinasi kemoterapi dan 
radioterapi. Ketumbuhan dalam lebih kurang 30% pesakit di tahap lewat merebak ke 
bahagian-bahagian badan yang lain selepas terapi dan disebabkan oleh lokasi 
ketumbuhan yang berdekatan dengan banyak organ penting di bahagian kepala dan 
leher, kebanyakan pesakit kanser yang terselamat mempunyai kualiti hidup yang 
terjejas. Untuk menghasilkan inovasi dalam pendekatan terapeutik, pemahaman yang 
lebih mendalam tentang asas molekul NPC amat diperlukan. Kajian ini bertujuan untuk 
menyiasat kepentingan biologi isyarat sphingosine-1-fosfat (S1P) dalam patogenesis 
NPC dan sumbangan EBV kepada penyahkawalseliaan jalur isyarat ini. S1P adalah satu 
molekul lipid bioaktif yang dihasilkan oleh enzim-enzim sphingosine kinases (SPHKs) 
dan menghasilkan isyarat melalui famili yang mengandungi lima jenis G protein 
reseptor ditambah, bernama reseptor S1P 1-5 (S1PR1-5). Penghasilan isyarat ini 
mengaktifkan pelbagai jalur yang mengawal proses penting dalam sistem biologi 
manusia. Kini terdapat bukti kukuh yang menunjukkan bahawa paksi 
SPHKs/S1P/S1PRs adalah sasaran terapeutik yang novel dan menarik dalam kanser. 
Ekspresi tinggi SPHK1 telah ditunjukkan dalam tisu NPC. Oleh itu, peningkatan tahap 
S1P mungkin berlaku dalam sel-sel NPC. Kajian ini menunjukkan bahawa rawatan sel-
sel NPC dengan S1P meningkatkan migrasi dan invasi dalam sel-sel tersebut dan kesan-
kesan ini ditemani oleh pengaktifan AKT. Dengan memberi tumpuan kepada fenotip 
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migrasi, kesan SPHK1 knockdown oleh shRNA telah menyebabkan pengurangan 
fosforilasi AKT dan perencatan migrasi sel-sel NPC. Tambahan pula, hasil analisis dua 
set data microarray yang telah diterbitkan menunjukkan peningkatan ekspresi S1PR3 
dalam tisu NPC berbanding dengan epitelium nasofarinks yang bukan malignan. S1PR3 
knockdown menghalang pengaktifan AKT dan migrasi sel-sel NPC yang disebabkan 
oleh S1P. Ekspresi AKT yang aktif secara konstitutif dapat memulihkan sebahagian 
kesan perencatan migrasi sel yang berpunca daripada SPHK1 dan S1PR3 knockdown. 
Di samping itu, C666-1 yang merupakan satu barisan sel NPC yang EBV-positif sahaja, 
menunjukkan ekspresi SPHK1 dan S1PR3 yang tertinggi berbanding dengan tujuh 
barisan sel NPC lain yang EBV-negatif. Untuk menjelaskan sumbangan EBV dalam 
deregulasi jalur S1P, kajian ini telah menunjukkan bahawa jangkitan EBV atau ekspresi 
ektopik gen laten EBV (EBNA1, LMP1 atau LMP2A) dapat meningkatkan ekspresi 
SPHK1 dalam sel-sel NPC. Oleh itu, buat pertama kalinya, kajian ini menunjukkan bahwa 
S1P menyebabkan sel-sel NPC bermigrasi dengan mengaktifkan AKT melalui S1PR3, 
dan mengetengahkan peranan penting jangkitan EBV sebagai pengantara kesan 
onkogenik S1P dalam penyakit ini. Justeru, penyasaran jalur S1P menunjukkan potensi 
dalam intervensi secara terapeutik bagi menangani penyakit NPC. 
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CHAPTER 1: INTRODUCTION 
1.1 General Introduction 
Nasopharyngeal carcinoma (NPC) is a tumour arising in the nasopharynx (Figure 
1.1) that is particularly prevalent in Southern China and Southeast Asia (Razak et al., 
2010; Torre et al., 2015). Due to the unspecific symptoms of NPC, more than 70% 
patients are diagnosed at advanced stages (Razak et al., 2010) and approximately 30% 
of these patients develop distant metastases following initial treatment (Tao et al., 2007; 
Wu et al., 2016). The current mainstay of treatment for advanced NPC is concurrent 
chemoradiotherapy (Chua et al., 2015). Unfortunately, due to the close proximity of the 
tumours to many vital organs in the head and neck region, most NPC patients suffer 
from poor quality of life after the treatment (Du et al., 2015). Despite a developing 
understanding of the molecular basis of NPC, currently there no biomarkers or targeted 
therapies available in the clinic. Therefore, novel therapeutic strategies are urgently 
needed for a better management of NPC patients. 
NPC is divided into two histopathological types, namely keratinising squamous cell 
carcinoma and non-keratinising carcinoma. Non-keratinising NPC constitutes most, if 
not all, of the NPC cases in endemic regions and is consistently associated with Epstein-
Barr virus (EBV) infection (Young et al., 2014). The expression of EBV latent genes in 
NPC is restricted to Epstein-Barr nuclear antigen 1 (EBNA1), latent membrane proteins 
(LMP1 and LMP2), EBV-encoded RNAs (EBERs), BamHI-A rightward transcripts 
(BARTs) and BamHI-A Reading Frame-1 (BARF1). Although the exact pathogenic role 
of EBV in NPC remains enigmatic, EBV-encoded genes have been shown to alter a 
number of important cellular processes in nasopharyngeal epithelial cells, which 
contributes to the development of NPC (Tsao et al., 2015; Young et al., 2014). 
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Given that distant metastasis is the major cause of death in NPC patients, this study 
aimed to investigate the functional role of signalling pathways that contribute to the 
migratory and invasive properties of NPC cells, with a focus on sphingosine-1-
phosphate (S1P) signalling. S1P is a bioactive lipid produced by the phosphorylation of 
sphingosine by sphingosine kinases 1 and 2 (SPHK1 and SPHK2). Following binding of 
S1P to a family of G-protein coupled receptors (termed S1PR1 – S1PR5), diverse 
downstream signalling pathways are activated, which subsequently regulate a number of 
cellular processes in normal physiology, such as lymphocyte trafficking and vascular 
integrity (Spiegel et al., 2011). Accumulating evidence has shown that aberrant S1P 
signalling contributes to tumorigenesis and has identified an oncogenic role for SPHK1 
(Pyne et al., 2010). High expression of SPHK1 is associated with reduced patient 
survival in various types of cancer, including NPC (Li et al., 2015b; Pyne et al., 2016). 
High expression of SPHK1 in tumours results in elevated levels of S1P and this, in turn, 
promotes tumorigenesis by increasing cell migration, invasion, proliferation, survival 
and angiogenesis (Pitson, 2011).  
The oncogenic effects of S1P can occur as a result of alterations in the expression or 
function of the S1P receptors (Blaho et al., 2014). For example, S1PR1 and S1PR3 have 
been shown to promote cancer development, whereas S1PR2 is generally thought to 
inhibit migration, invasion and metastasis, although recent evidence suggests that 
S1PR2 can also have tumour-promoting effects by increasing cancer cell growth and 
migration (Adada et al., 2013; Beckham et al., 2013; Patmanathan et al., 2016; Takuwa 
et al., 2011). The roles of S1PR4 and S1PR5 in cancer remain largely unclear (Adada et 
al., 2013). Since aberrant activation of the S1P signalling pathway has been implicated 
in various malignancies, targeting the SPHK1/S1P/S1PR axis has emerged as a 
promising new strategy to treat cancer. Several drugs targeting this pathway have 
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undergone clinical trials in cancer and the new drugs with higher specificity and 
efficacy are being developed (Kunkel et al., 2013). 
High expression of SPHK1 in NPC has been reported previously (Li et al., 2015b), 
but the downstream biological consequences of elevated SPHK1 in NPC cells have not 
been studied. The aims of the present study were to investigate the functional 
consequences of aberrant activation of the SPHK1/S1P/S1PR axis in NPC and to 
examine the contribution of EBV infection to the deregulation of S1P signalling in this 
disease. 
1.2 General Aims 
EBV-associated NPC is a highly metastatic disease with poor patient prognosis 
(Khan et al., 2014) and thus there is a compelling need to identify novel therapeutic 
targets that can improve the management of NPC patients. Although the contribution of 
aberrant S1P signalling to tumorigenesis has been convincingly shown in various types 
of cancer, its involvement in NPC remains to be elucidated. Therefore, this study was 
initiated to investigate the role of S1P signalling in the pathogenesis of NPC and to 
determine whether EBV infection leads to the dysregulation of this pathway.   
Elevated levels of S1P are likely to be present in NPC as a consequence of high 
expression of SPHK1. Therefore, the first part of this study investigated whether 
exogenous S1P would affect the phenotypic characteristics (proliferation, migration and 
invasion) of NPC cells and whether these effects could be reversed by the knockdown 
of SPHK1. Focusing on the migratory phenotype, subsequent experiments aimed to 
identify which of the two well-known downstream targets of S1P [protein kinase B 
(AKT) and extracellular signal-regulated kinase (ERK)] might be involved.  
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Having confirmed S1P induced NPC cell migration through the activation of AKT, 
the second part of this study explored which S1P receptors might be responsible for 
these effects. Re-analysis of previous two microarray datasets identified S1PR2 and 
S1PR3 as candidate receptors based on their significantly higher expression in primary 
NPC tissues compared to non-malignant nasopharyngeal epithelium. Treatment of NPC 
cells with pharmacological drugs specific for these two receptors revealed the potential 
involvement of S1PR3. Knockdown experiments targeting S1PR3 were subsequently 
performed to confirm its role in S1P-induced migration and AKT activation. 
Given that all non-keratinising NPC cells carry EBV genomes, the final part of this 
study investigated whether EBV infection contributed to the aberrant activation of S1P 
signalling in NPC cells. Two NPC cell lines that expressed low levels of SPHK1 and 
S1PR3 were stably infected with a recombinant EBV (Akata strain). During the course 
of this study, a number of established EBV-infected nasopharyngeal epithelial cell lines 
were also obtained from collaborators. Using these cell models, the contribution of EBV 
infection and EBV-encoded latent genes to the expression of SPHK1 and S1PR3 was 
examined. 
1.3 Objectives 
The objectives of this study were as follows: 
(i) To determine the biological significance of exogenous sphingosine-1-
phosphate (S1P) and knockdown of sphingosine kinase 1 (SPHK1) on the 
behaviour of NPC cells in vitro 
(ii) To identify the S1P receptor(s) that is/are responsible for S1P-mediated 
migration in NPC 
(iii) To investigate the contribution of Epstein-Barr virus (EBV) infection to the 
expression of SPHK1 and S1P receptor 3 (S1PR3) in NPC cells 
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Figure 1.1: Regions of pharynx 
The location of the nasopharynx (brown), oropharynx (pink) and laryngopharynx (blue) 
is shown. 
Figure adapted from http://fau.pearlashes.com/anatomy. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 The biology of cancer 
Cancer is one of the leading causes of mortality worldwide (Mortality et al., 2015). 
Globally, it was estimated that an overall of 14.1 million of new cancer cases and 8.2 
million of cancer-related deaths occurred in 2012 (Torre et al., 2015). The development 
of cancer is a complex, multi-step process that ultimately leads to uncontrolled cell 
growth. Molecular alterations in oncogenes and tumour suppressor genes are well-
recognised as the major factors contributing to the malignant phenotype (Cairns et al., 
2011). 
In 2000, Hanahan and Weinberg proposed that all cancers share six common traits 
(“hallmarks”); cancer cells are self-sufficient in growth signals, insensitive to anti-
growth signals, able to evade apoptosis, have limitless replicative potential, can sustain 
angiogenesis and possess invasive and metastatic potentials (Hanahan et al., 2000). In 
2011, these authors proposed two additional hallmarks of cancer, namely 
reprogramming of cellular energy metabolism and evasion of immune destruction 
(Hanahan et al., 2011). The acquisition of these eight hallmarks of cancer was suggested 
to be facilitated by two enabling characteristics, which are genomic instability and 
mutation, and tumour-promoting inflammation (Hanahan et al., 2011).  
2.2 Nasopharyngeal carcinoma  
NPC is a malignancy arising from the epithelial cells in the nasopharynx. NPC is rare 
in most parts of the world with an incidence rate of less than 1 per 100,000 persons per 
year, but it is particularly prevalent in regions such as Southern China and Southeast 
Asia (Parkin et al., 2005). NPC is also found in Eskimos from Greenland and Alaska, 
and populations within North Africa (Parkin, 2006). The incidence rate of NPC peaks at 
the age of 50 to 59 years and is 2- to 3-fold higher in males compared to females 
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(Chang et al., 2006; Torre et al., 2015). In Malaysia, 940 new cases of NPC were 
diagnosed in 2007 with 685 cases in males (73%) and 255 cases in females (27%). 
Overall, NPC represented the fourth most common cancer and the third leading cancer 
among males in Malaysia (Omar, 2007). 
2.2.1 Histopathology 
In 1991, the WHO classified NPC into two histopathological types, namely 
keratinising squamous cell carcinoma and non-keratinising carcinoma, in which the 
latter is further subdivided into differentiated and undifferentiated carcinoma 
(Shanmugaratnam et al., 1991). Keratinising NPC is characterised by well-
differentiated histological features including the presence of intercellular bridges, 
keratin production and epithelial pearl formation. In contrast, non-keratinising NPC 
lacks keratinisation features and sheets of epithelial cells show syncytial architecture 
with lymphocytes intimately associated with the neoplastic cells. Undifferentiated NPC 
displays a prominent lymphocytic component and it is also referred as 
“lymphoepithelioma”. Keratinising NPC is usually seen in low incidence areas while 
non-keratinising NPC accounts for majority of the NPC cases in endemic regions (Lo et 
al., 2004b; Marcus et al., 2010). 
2.2.2 Aetiology 
Epidemiological studies suggest three major aetiological factors for NPC, namely 
genetic susceptibility, environmental factors and EBV infection (Lo et al., 2004b). 
These aetiological factors may contribute independently or jointly to the development of 
NPC (Chang et al., 2006).  
2.2.2.1 Genetic susceptibility 
The observation that second and third generation Chinese emigrants from endemic 
regions to low incidence areas have a higher risk of developing NPC than Caucasians 
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suggested that genetic susceptibility plays a critical role in the development of NPC 
(Buell, 1974). Early linkage studies on Chinese sib pairs with NPC revealed a NPC 
genetic susceptibility locus within the human leukocyte antigen (HLA) region (Lu et al., 
1990). The HLA genes encode proteins required for the identification and presentation 
of foreign antigens, including EBV-encoded peptides, to trigger host immune responses. 
Increased risk of NPC has been found to be associated with HLA alleles A2, B14 and 
B46, whilst alleles A11, B13 and B22 were found to have protective effects (Goldsmith 
et al., 2002). With the advances in genotyping technologies, a number of genome-wide 
association studies (GWAS) have also consistently revealed the association of NPC 
with HLA genes on chromosome 6p21 (HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ 
and HLA-F) (Bei et al., 2010; Tang et al., 2012; Tse et al., 2009; Zhao et al., 2012). 
Several non-HLA genes also located within the HLA region, including GABBR1, 
HCG9, MICA and HCP5, were also found to be associated with NPC (Tse et al., 2009; 
Tse et al., 2011). In addition, other genetic susceptibility loci for NPC identified from 
GWAS studies include TNFRSF19 (13q12), MDS1-EVI1 (3q26), CDKN2A (9p21), 
CDKN2B (9p21), ITGA9 (3p21) and MST1R (3p21) (Bei et al., 2010; Dai et al., 2016; 
Ng et al., 2009). 
Other potential susceptibility genes that have been shown to be associated with an 
increased risk of developing NPC include genes responsible for nitrosamine metabolism 
(CYP2E1, CYP2A6), detoxification of carcinogens (GSTM1), DNA repair (hOGG1, 
XRCC1), interleukins (IL1α, IL10, IL16, IL18) and  telomere maintenance 
(TERT/CLPTM1L)  (Bei et al., 2016; Cheng et al., 2014; Cho et al., 2003; Guo et al., 
2013; Hildesheim et al., 1997; Nazar-Stewart et al., 1999; Qin et al., 2014; Tiwawech et 
al., 2006; Tsai et al., 2014; Yee Ko et al., 2014). A systemic review of 83 published 
papers confirmed the correlation of increased NPC susceptibility with HLA genes and 
also identified several genes involved in DNA repair (RAD51L1), cell-cycle checkpoint 
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regulation (MDM2, TP53), cell adhesion and migration (MMP2) (Hildesheim et al., 
2012).  
2.2.2.2 Environmental factors 
Dietary habits are also thought to influence the risk of developing NPC. 
Consumption of salted fish, particularly during childhood, has been strongly associated 
with an increased NPC risk (Armstrong et al., 1983; Guo et al., 2009; Ning et al., 1990; 
Yu et al., 1986). This risk is also elevated with the intake of other preserved food such 
as fermented bean paste and preserved vegetables (Yu et al., 1989; Yu et al., 1988). The 
presence of carcinogenic volatile nitrosamines in preserved foods is believed to be the 
main contributing factors (Poirier et al., 1989; Yu et al., 1988; Zou et al., 1994). Usage 
of traditional herbal medicines has also been suggested to be a risk factor of NPC 
among Asian populations by stimulating the expression of EBV lytic antigens in the 
host (Furukawa et al., 1986; Hildesheim et al., 1992). In contrast, consumption of fresh 
fruits and/or vegetables, especially during childhood, is considered to have a protective 
effect (Chang et al., 2006; Yu et al., 1989).  
Some non-dietary factors have also been found to contribute to the risk of developing 
NPC and these include occupational exposure to toxic pollutants (formaldehyde) in the 
air, wood dust, and textiles, which possibly induce chronic irritation and inflammation 
in the nasopharynx (Armstrong et al., 1983; Chang et al., 2006; Li et al., 2006b; 
Sriamporn et al., 1992). While long term cigarette smoking has been associated with 
increased incidences of keratinising NPC in low-risk populations (Cheng et al., 1999; 
Vaughan et al., 1996; Zhu et al., 2002), its association with non-keratinising NPC in 
endemic areas remains controversial (Chen et al., 1990; Lanier et al., 1980; Sriamporn 
et al., 1992; Zou et al., 2000).  
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2.2.2.3 EBV infection 
Non-keratinising NPC is consistently associated with EBV infection (Niedobitek, 
2000). The association of NPC and EBV infection was initially suggested when Burkitt 
lymphoma antigen-specific antibodies were also detected in the serum of NPC patients 
(Old et al., 1966). Subsequent serological analyses showed a correlation between EBV 
antibody titres and NPC tumour stage, and identified viral capsid antigen (VCA)-
specific IgA as a prognostic marker (Henle et al., 1976; Zeng et al., 1982; Zong et al., 
1992).  
EBV establishes latent infection in NPC cells and the viral genome is maintained 
episomally (Niedobitek et al., 1996). The observation that EBV genomes were detected 
in pre-invasive dysplastic lesions or carcinoma in situ of the nasopharynx suggested that 
EBV infection might be an early event in the development of NPC (Pathmanathan et al., 
1995). The contribution of EBV infection and EBV-encoded genes to the pathogenesis 
of NPC is further discussed in Section 2.3. 
2.2.3 Clinical presentation, diagnosis and treatment 
The early clinical symptoms of NPC are usually unspecific, for example epistaxis, 
nasal obstruction and auditory complaints (Tabuchi et al., 2011) and this results in late 
presentation; the majority of the NPC cases are diagnosed at advanced stages (Razak et 
al., 2010). NPC is a highly metastatic disease with neck lumps being found in 
approximately three-quarters of patients and distant metastasis remains the major cause 
of death in NPC patients (Chua et al., 2015). In many cases, distant metastasis appears 
within 18 months after the presenting symptoms (Cvitkovic et al., 1993) and the median 
survival time of these patients is only approximately 9 – 12 months (Tao et al., 2007). 
Currently, the diagnosis of NPC depends on the pathological examination of biopsy 
specimens (Jeyakumar et al., 2006). Staging of NPC is determined according to the 
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tumour, node, metastasis (TNM) classification of the American Joint Committee on 
Cancer (Barnes et al., 2005).  Imaging modalities such as computed tomography (CT) 
scans and magnetic resonance of imaging (MRI) are widely used to assess tumour 
extension and disease stage (Brennan, 2006). Technological advances in recent years 
have allowed the invention of 
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F-2-fluoro-2-deoxy-d-glucose (FDG) positron emission 
tomography-computed tomography (PET/CT) that shows considerable promise in the 
diagnosis, therapy assessment and prognosis of the disease (Agarwal et al., 2013). Other 
molecular-based methods, such as EBV serological tests and quantitative analysis of 
EBV DNA have also been proposed as non-invasive and economic diagnostic tests for 
NPC and may be useful in the near future (Tao et al., 2007). 
The primary treatment for early stage NPC (stage I and IIa) is normally radiotherapy 
alone. With the advent of modern radiation technology, intensity-modulated 
radiotherapy (IMRT), which can provide tumourcidal doses to the tumour while 
minimising doses to the adjacent normal tissues, is currently the preferred treatment for 
NPC over standard 2D conventional radiotherapy (Xu et al., 2013). Concurrent 
chemoradiotherapy with or without adjuvant chemotherapy is the mainstay of treatment 
for locoregionally advanced diseases (Chua et al., 2015). The presence of EBV in all 
NPC cells has also provided opportunities for the development of novel therapeutic 
interventions such as EBV-based immunotherapies that may lead to a better 
management of NPC patients in the future (Tsang et al., 2014). 
2.2.4 Molecular basis of NPC 
Cytogenetic studies have revealed multiple chromosomal abnormalities in NPC; 
consistent genetic losses have been identified on chromosome 3p, 9p, 9q, 11q, 13q, 14q 
and 16q, while chromosomal gains occur on chromosome 1q, 3q, 7q, 8q, 11q, 12p, 12q, 
19p and 19q (Fang et al., 2001; Hui et al., 1999; Li et al., 2006c; Wong et al., 2003). 
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Loss of heterozygosity (LOH) on chromosome 3p and 9p occurs is thought to be an 
early event in the progression of NPC (Chan et al., 2002; Chan et al., 2000).  
The identification of the chromosomal loci that frequently harbour gross structural 
abnormalities informed studies that identified specific genes might be involved in the 
development of NPC. Deletion or promoter hypermethylation of RASSF1A on 
chromosome 3p and p16 (CDKN2A) on chromosome 9p are recognised as early events 
in NPC tumorigenesis (Kwong et al., 2002; Lo et al., 1996; Young et al., 2004). Other 
tumour suppressor genes on chromosome 3p (BLU/ZMYND10, DLEC1, PTPRG and 
FBLN2) (Cheung et al., 2008; Kwong et al., 2007; Law et al., 2012; Liu et al., 2003) 
and chromosome 11q (TSLC1, THY1, CRYAB) have also been identified (Hui et al., 
2003; Lung et al., 2005; Lung et al., 2008). Moreover, several oncogenes include BCL-
2, LTBR, CCDN1, PIK3CA, C-MYC, RAS and Bmi-1 have been shown to be amplified 
or exhibit gain-of-function mutations (Hui et al., 2005; Lo et al., 2012; Lu et al., 1993; 
Or et al., 2010; Or et al., 2006; Porter et al., 1994). Over-expression of some of the 
oncogenes such as LTBR and PIK3CA in pre-cancerous lesions or NPC tumours has 
been reported to be critical in the pathogenesis of NPC through activation of multiple 
signalling pathways, including nuclear factor-kappa B (NF-κB) and 
phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) (Lo et al., 2012). Recent 
whole exome sequencing (WES) studies of NPC have revealed particular genetic 
alterations, such as deletions and/or mutations of multiple genes involved in chromatin 
modification (ARID1A, BAP1), autophagy machinery (ATG2A, ATG7, ATG13), ERBB-
PI3K signalling pathway (PIK3CA, ERBB2, ERBB3), NF-кB signalling pathway 
(NFKBIA, CYLD, TNFAIP3) and apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide-like (APOBEC)-mediated signatures (APOBEC3A, APOBEC3B), that may 
contribute to the development of NPC (Lin et al., 2014a; Zheng et al., 2016). It is of 
interest that although earlier studies had reported infrequent TP53 mutations in NPC 
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(Spruck et al., 1992), these powerful WES approaches reveal TP53 is the most 
frequently mutated gene in NPC (7-10%), albeit the frequency is still much lower 
compared to other human cancers (Petitjean et al., 2007). 
 The role of EBV in the pathogenesis of NPC is thought to result from the aberrant 
establishment of virus latent infection in epithelial cells displaying pre-malignant 
changes, such as overexpression of cyclin D1 and/or p16 deletion (Tsang et al., 2012). 
Secretion of inflammatory cytokines by EBV-infected NPC cells has been suggested to 
support EBV latent infection and malignant transformation of the infected cells (Huang 
et al., 1999).  In particular, interleukin (IL) 6 has been shown to support the persistence 
of EBV latent infection in infected NPC cells. IL6 activates signal transducer and 
activator of transcription 3 (STAT3) signalling that in turn regulates the transcription of 
EBNA1 which governs the maintenance of the EBV episome in infected cells (Chen et 
al., 2003). A positive feedback loop to support EBV latent infection was also 
established between LMP1 and STAT3 in which LMP1 induces IL6 secretion to 
activate STAT3 and that in turn upregulates the expression LMP1 (Chen et al., 2003). 
EBV latent genes also deregulates a number of signalling pathways, promotes genetic 
instability, stimulates epigenetic changes, modulates tumour microenvironment and 
suppresses host immune response to provide growth and survival benefits to the NPC 
cells (Lo et al., 2012; Tsao et al., 2015). A possible model of NPC pathogenesis has 
been proposed and depicted in Figure 2.1. 
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Figure 2.1: Model of NPC pathogenesis 
A possible model of NPC pathogenesis. Activation of telomerase, loss of heterozygosity 
(LOH) on chromosome 3p and 9p, and inactivation of RASSF1A and CDKN2A occur 
early in the pathogenesis of NPC to promote the formation of low grade dysplasia. The 
accumulation of additional genetic and epigenetic changes may facilitate and support 
EBV latent infection. Acting together with stromal inflammation, further genetic and 
molecular alterations (for example mutations in NF-кB and ERBB-PI3K signalling 
pathways) in the nasopharyngeal epithelial cells ultimately lead to the development of 
NPC. 
Figure modified from Tsao et al., 2014. 
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2.3 Epstein-Barr virus 
EBV is a γ-herpesvirus that was discovered in 1964 from a Burkitt’s lymphoma (BL) 
biopsy (Epstein et al., 1964). EBV infects more than 90% of human population through 
bodily fluids, primarily saliva (Odumade et al., 2011). Once the host is infected, the 
infection remains lifelong (Henle et al., 1979). Primary infection with EBV usually 
occurs during early childhood and it is asymptomatic in most cases, particularly in 
developing countries (Biggar et al., 1978; Jenson, 2000). However, in most developed 
countries, primary infection is delayed into late adolescence or adulthood and this often 
results in a self-limiting lymphoproliferative disease called infectious mononucleosis 
(Henle et al., 1968; Niedobitek et al., 2001).  
The oncogenic potential of EBV was initially identified by its ability to transform 
normal resting B lymphocytes into permanently growing lymphoblastoid cell lines 
(LCLs) (Henle et al., 1967; Pope et al., 1968). In addition to BL, EBV infection was 
subsequently found to be associated with a number of malignancies of both lymphoid 
and epithelial origin, including Hodgkin’s lymphoma, extranodal natural killer 
(ENK)/T-cell lymphoma, NPC and gastric carcinoma (Murray et al., 2001). EBV 
infection is common in immunocompromised individuals, resulting in 
lymphoproliferative diseases, such as X-linked lymphoproliferative disease, post-
transplant lymphoproliferative disorder and AIDS-related lymphoproliferative disorder 
(Thompson et al., 2004). 
2.3.1 EBV genome and sequence variation 
The EBV genome is composed of linear double-stranded DNA, approximately 172 
kilobase pairs (kb) in length that encodes more than 85 genes. EBV (strain B95-8) was 
the first human herpesvirus to have its genome fully cloned and sequenced (Baer et al., 
1984). The EBV genome consists of a series of 0.5 kb terminal repeats at each terminus 
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and approximately 3 kb internal repeat sequences that divide the viral genome into 
unique, short and long regions (Baer et al., 1984; Cheung et al., 1982). When EBV 
infects a cell, the viral genome forms a circular episome through covalent fusion of the 
terminal repeat sequences (Figure 2.2) (Raab-Traub et al., 1986).  
There are two types of EBV, type 1 (EBV-1) and type 2 (EBV-2), which differ 
mainly in the sequences of EBNA2 and EBNA3 genes (Rowe et al., 1989; Sample et 
al., 1989). EBV-1 strains are more prevalent worldwide (Zimber et al., 1986) and have 
been shown to transform B cells more efficiently than EBV-2 in vitro (Rickinson et al., 
1987). This might be attributable to the greater ability of EBV-1 strains to maintain the 
growth of infected cells through the EBNA2-mediated expression of CXCR7 and LMP1 
(Cancian et al., 2011; Lucchesi et al., 2008; Tzellos et al., 2014).  
It has been hypothesized that EBV strain variations might account for the different 
incidence rates of EBV-associated diseases in different parts of the world, but this has 
so far not been conclusively proven. Eighteen years after the first complete sequence of 
EBV strain B95-8 was published (Baer et al., 1984), a “wild type” EBV sequence 
(EBVwt) was constructed using B95-8 as a backbone, while a 12-kb deleted segment 
(encoding some of the BART miRNA genes and one of the origins of lytic replication) 
was provided by the sequences from Raji strain (de Jesus et al., 2003). Finally, the 
current reference sequence of EBV that included three additional small open reading 
frames was released in 2010 as the RefSeq HHV4 (EBV) sequence (GenBank accession 
number NC_007605). Subsequently, complete sequences of two EBV strains (GD1 and 
AG876) were published using similar Sanger sequencing methods (Dolan et al., 2006; 
Zeng et al., 2005). With the advances in next generation sequencing (NGS) technology, 
the genome sequences of 18 additional EBV strains have been reported since 2011; 
eleven strains from NPC (GD2, M81 and HKNPC1 to HKNPC9) (Kwok et al., 2012; 
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Kwok et al., 2014; Liu et al., 2011; Tsai et al., 2014), two strains from BL (Akata and 
Mutu) (Lin et al., 2013), and five strains from immortalized B-lymphocyte cultures 
(K4123-Mi, K4413-Mi and three genomes from the 1000 Genome project) (Lei et al., 
2013a; Santpere et al., 2014). More recently, complete sequences of 71 geographically 
distinct EBV strains were published, representing the most comprehensive analysis to 
date (Palser et al., 2015). It has now become clear that while there is a high level of 
overall similarity among the virus strains, variations exist in some viral genes that might 
give rise to functional differences. In particular,  the M81 EBV strain isolated from a 
NPC patient has the tendency to spontaneously switch to lytic replication in B cells but 
exhibits high propensity to infect epithelial cells (Tsai et al., 2013). In general, NGS 
analyses have revealed latent genes harbour the highest variation, ranging from single 
base mutations to extensive insertions and deletions. These findings are in line with 
early studies showing that the EBV variant with a 30bp deletion in LMP1 has a higher 
transforming ability by increasing the activation of NF-κB and activator protein 1 (AP-
1) and it is associated with a higher risk of distant metastasis in NPC patients (Blake et 
al., 2001; Hu et al., 1993; Hu et al., 1991; Johnson et al., 1998; Pai et al., 2007). 
However, the differences in the biological properties of the variants and/or their disease 
association are yet to be further elucidated.  
2.3.2 EBV lytic and latent cycles 
EBV displays two distinct lifecycles, namely the latent cycle during persistent 
infection and the productive lytic phase. The lytic cycle can be activated by diverse 
stimuli including phorbol ester, 12-0-tetradecanoyl phorbol-13-acetate (TPA) and 
sodium butyrate (Kenney, 2007). The origin of lytic replication is known as oriLyt and 
the gene responsible for the latent to lytic switch is BZLF1 (Flemington et al., 1990; 
Hammerschmidt et al., 1988; Ragoczy et al., 1998). Induction of lytic cycle 
subsequently stimulates a temporal and ordered cascade of viral gene expression; the 
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early genes are required for viral DNA replication and nucleotide metabolism and the 
late genes encode structural proteins for virion packaging (Hislop et al., 2007). 
In contrast to lytic replication, latent infection of EBV does not produce progeny 
virions. In EBV-transformed LCLs, the EBV genome replicates along with the host 
DNA as an extrachromosomal episome and this process is initiated at the replication 
origin, oriP (Umar, 2006; Yates et al., 1985). During latent infection, a limited set of 
viral genes named latent genes are expressed, which comprise six nuclear antigens 
[EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C and EBNA-LP (leader protein)], 
three latent membrane proteins (LMP1, LMP2A and LMP2B), EBV-encoded RNAs 
(EBERs), BamHI-A rightward transcripts (BARTs) and BamHI-H rightward open 
reading frame 1 (BHRF1) micro-RNAs (miRNAs) (Amoroso et al., 2011; Kang et al., 
2015). This pattern of latent EBV gene expression is referred to as the latency III. 
During different stages of B cell differentiation in vivo, alternative forms of EBV 
latency were identified, namely latency II [expression of EBNA1, LMP1, LMP2, 
EBERs, BARTs and BamHI-A open reading frame 1 (BARF1)] or latency I (only 
EBNA1, EBERs and BARTs are expressed) (Thompson et al., 2004; Young et al., 
2014). EBV-associated B cell lymphomas express either latency I, II or III, whilst EBV-
associated epithelial cancers express a latency II programme (Table 2.1) (Young et al., 
2004). Deviations in the pattern of EBV gene expression from these classifications have 
also been observed. For example, a subset of BL tumours expresses additional viral 
genes including EBNA3A, EBNA3B, EBNA3C and EBNA-LP, together with an 
EBNA2 deletion (Kelly et al., 2002). This is referred to as “W promoter (Wp)-
restricted” latency because viral gene expression is driven from the Wp, rather than the 
Q promoter (Kelly et al., 2009). Compared to other BL cells, Wp-restricted BL cells are 
less sensitive to apoptosis due to the downregulation of Bim (a pro-apoptotic molecule) 
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by EBNA3A and EBNA3C, and the over-expression of BHRF1 (Anderton et al., 2008; 
Kelly et al., 2009; Rowe et al., 2009). 
2.3.3 EBV infection in asymptomatic hosts 
EBV is transmitted orally; infectious virus is shed at low levels in oropharyngeal 
secretions. Upon initial infection, EBV infects B lymphocytes within the oropharyngeal 
mucosa and eventually resides mainly in the long-lived memory B cells of 
asymptomatic carriers (Babcock et al., 1998). However, the mechanism by which EBV 
becomes resident in the memory B-cell compartment remains controversial (Roughan et 
al., 2009). One model suggests a direct infection of memory B-cells with EBV (Kurth et 
al., 2003; Kurth et al., 2000). Another model proposes that EBV infects naïve B cells to 
become proliferating blasts in which type III latency genes are expressed (“growth 
programme”). Many of these proliferating cells are eliminated by the primary T-cell 
response, but some escape and enter the germinal centre where type II latency (“default 
programme”) is established (Babcock et al., 2000b; Roughan et al., 2009). The latently 
infected cells are subsequently driven into a stable reservoir of resting memory B cells 
in the peripheral circulation where the expression of all EBV proteins is suppressed 
(“latency programme” or latency 0) and life-long infection is established (Babcock et 
al., 2000a). When the latently infected B cells divide to maintain memory B-cell 
homeostasis, EBNA1 is expressed (type I latency) (Hochberg et al., 2004; Thorley-
Lawson et al., 2004). The differentiation of memory B cells into plasma cells triggers 
the viral replication cycle, possibly at the oropharyngeal epithelium and this releases 
virions for transmission to new hosts (Thorley-Lawson et al., 2004). A summary of 
primary EBV infection is illustrated in Figure 2.3. 
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Figure 2.2: The EBV genome 
(A) Diagram showing the position and transcription of the EBV latent genes on the 
double-stranded viral DNA episome with the origins of replication, oriP (latent cycle) 
and oriLyt (lytic cycle) indicated. The solid rocket head arrows represent the coding 
exons for EBV latent proteins and the direction of transcription. The latent proteins 
include six nuclear antigens (EBNAs 1, 2, 3A, 3B and 3C, and EBNA-LP) and three 
latent membrane proteins (LMPs 1, 2A and 2B). EBNA-LP is transcribed from variable 
numbers of repetitive exons in the BamHI W fragment. LMP2A and LMP2B are 
composed of multiple exons located in the terminal repeat (TR) region, which is 
generated following circularisation of the linear DNA via fusion of terminal repeats. 
The long outer line represents the EBV transcripts in latency III where all the EBNAs 
are transcribed from either C promoter (Cp) or W promoter (Wp) whereas the short 
inner line shows the EBNA1 transcript originating from Q promoter (Qp) during latency 
I and latency II. The locations of highly transcribed small non-polyadenylated RNAs, 
EBER1 and EBER2 are shown here. BamHI-A rightward transcripts (BARTs) and 
BamHI-A rightward open reading frame 1 (BARF1) are located in the BamHI-A region. 
Figure modified from Young & Rickinson, 2004. 
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Table 2.1: EBV gene expression patterns in different types of latency  
EBV latency EBV gene expression Examples 
Type 0 EBERs Resting memory B cells 
Type I EBNA1, EBERs, BARTs  Burkitt’s lymphoma 
Type II EBNA1, LMP1, LMP2, EBERs, 
BARTs, BARF1 
Nasopharyngeal carcinoma, 
Hodgkin’s lymphoma, gastric 
carcinoma, extranodal natural 
killer (ENK)/T-cell lymphoma 
Type III EBNA1, EBNA2, EBNA3, 
EBNA-LP, LMP1, LMP2, 
EBERs, BARTs, BHRF1 
miRNAs 
Lymphoblastoid cell lines, post-
transplant lymphoproliferative 
disorders in immunodeficiency 
patients 
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Figure 2.3: EBV infection in healthy virus carriers 
Primary EBV infection begins in the tonsil compartment. EBV entry into B cells 
triggers the B-cell growth programme, leading to the proliferation of blasting B cells. In 
parallel, priming of naïve T cells by antigen-presenting cells occurs and many of the 
blasting B cells are destroyed by cytotoxic T lymphocytes. B cells that escape the T-cell 
response undergo a series of viral latency programme and eventually establish a stable 
reservoir of resting memory B cells in the blood circulation. Resting memory B cells are 
activated when differentiating into plasma cells and this induces viral lytic replication 
and shedding at the oropharyngeal epithelium.  
Figure modified from Odumade et al., 2011. 
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2.3.4 EBV entry mechanisms in B cells and epithelial cells 
EBV can infect both B cells and epithelial cells, but through different mechanisms. 
EBV enters B cells through the attachment of the viral envelope glycoprotein, 
gp350/220, to the complement receptor 2 (CR2/CD21) or CD35 on the surface of B 
cells (Nemerow et al., 1985; Ogembo et al., 2013). This brings the virus closer to the 
cell membrane where another viral glycoprotein, gp42, interacts with the cellular HLA 
class II molecules, HLA-DR, -DP and -DQ (Haan et al., 2000; Li et al., 1997). The 
gp42 also bind directly to gH, one of the components of the “core fusion machinery” 
which consists of a homotrimer gB and a heterodimer gHgL (Hutt-Fletcher, 2007; Li et 
al., 1995; Ogembo et al., 2013; Wang et al., 1998a). These interactions activate the core 
fusion machinery leading to the fusion of the virion envelope to the cellular plasma 
membrane (Chesnokova et al., 2014; Haan et al., 2000; Li et al., 1997).  
There is evidence to suggest that EBV can replicate in epithelial cells (Temple et al., 
2014). However, EBV infection of human epithelial cells in vitro is much less efficient 
as epithelial cells express neither CR2 nor HLA class II molecules (Hutt-Fletcher, 
2007). A number of studies have shown that EBV enters epithelial cells through the 
interaction of viral gH/gL with the host integrin complexes, αvβ5, αvβ6 and αvβ8, on 
the cell membrane (Chesnokova et al., 2011; Chesnokova et al., 2009). Additionally, 
the viral membrane protein BMRF2 has been implicated in EBV attachment to 
polarised epithelial cells by binding to host β1 integrins (Tugizov et al., 2003; Xiao et 
al., 2008). Recently, two cellular molecules, neuropilin 1 and nonmuscle myosin heavy 
chain IIA, have been identified as EBV entry factors into epithelial cells by interacting 
with gH/gL complex (Wang et al., 2015; Xiong et al., 2015). Furthermore, a novel “in-
cell infection” mechanism for EBV infection of nasopharyngeal epithelial cells was 
described. This process occurs through the invasion of EBV-positive B cells into 
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epithelial cells by forming cell-in-cell structures that subsequently results in the release 
of virus into epithelial cells (Ni et al., 2015).  
Interestingly, an EBV strain that lacks gp42 cannot infect B cells, but the expression 
of gp42 impedes EBV infection of epithelial cells (Wang et al., 1998a; Wang et al., 
1998b). It has been shown that EBV virions emerged from B cells lack gp42 and that 
aids EBV entry into epithelial cells while the virions released from epithelial cells are 
rich in gp42 that facilitate the infection of B cells (Borza et al., 2002). This dual cell 
tropism plays a critical role for EBV to shuttle between B cells and epithelial cells for 
the establishment of persistent infection in humans (Chesnokova et al., 2014). 
2.3.5 In vitro and in vivo models of EBV epithelial infection  
The ability of EBV to transform B lymphocytes into LCL in vitro has greatly 
facilitated the investigation of the viral transformation mechanisms in B cell tumours. 
However, one of the hurdles to establish truly representative NPC cell lines is retention 
of the EBV genome, which is commonly lost in culture (Chang et al., 1989; Glaser et 
al., 1989; Huang et al., 1980). In addition, epithelial cells are relatively refractory to 
EBV infection in vitro (Imai et al., 1998; Takada, 2000). Early studies attempted to 
increase EBV infection rates in epithelial cells by stably expressing CR2 but this often 
resulted in spontaneous lytic reactivation rather than persistent latent infection (Knox et 
al., 1996; Li et al., 1992). In 1998, successful infection of epithelial cells in vitro was 
achieved by cell-to-cell contact between epithelial cells and recombinant EBV-
producing BL-derived Akata cells (Imai et al., 1998). The production of the viruses in 
Akata cells can be induced by cell surface immunoglobulin G (IgG) cross-linking 
(Shimizu et al., 1996; Takada, 1984) and the recombinant EBV carries an antibiotic 
resistance marker that allows the selection of successfully infected-epithelial cells 
(Chang et al., 1999). Since then, this protocol has been commonly used to establish 
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EBV-infected NPC cell lines (Tsao et al., 2012). Although the cell-to-cell contact 
method was successfully used to establish stable EBV infection in NPC cell lines, low 
EBV infection rates and rapid loss of EBV genome were still observed in non-malignant 
nasopharyngeal epithelial cells (Tsang et al., 2012; Tsang et al., 2010). It was found that 
stable EBV infection could only be established in vitro in nasopharyngeal epithelial 
cells harbouring genetic alterations such as overexpression of cyclin D1 and deletion of 
p16 (Tsang et al., 2012).  
Due to the anatomical difference between humans and mice, orthotopic mouse 
models of NPC are not achievable. As an alternative, a number of EBV-positive patient-
derived xenografts (PDXs) have been successfully established as in vivo models for 
NPC. These xenograft models were generated by transplanting the tumours from  
patients into athymic nude mice or severe combined immunodeficiency (SCID) mice 
and then re-implanting into other mice to propagate the tumour cells (Morton et al., 
2007). Several EBV-positive NPC PDXs (e.g. C15, C17, xeno-2117 and xeno-666) are 
commonly used by the NPC research community and these PDXs are able to maintain 
the original tumour histological characteristics, representing useful resources for the 
study of EBV transformation mechanisms in nasopharyngeal epithelial cells (Bernheim 
et al., 1993; Busson et al., 1988; Huang et al., 1989; Tentler et al., 2012; Wong et al., 
2012).  
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2.3.6 Functions of EBV latent genes in NPC 
2.3.6.1 EBNA1 
EBNA1 is consistently found in all types of latency in EBV-associated malignancies 
(Young et al., 1988). It acts as a sequence-specific DNA binding protein which is 
responsible for the persistence of EBV genome in latently infected cells by governing 
the replication and maintenance of the genome (Yates et al., 1985).  EBNA1 can also 
act as a transcriptional transactivator to regulate its own expression and that of other 
EBV latent genes (LMP1 and C promoter-initiated EBNAs) (Gahn et al., 1995; 
Schlager et al., 1996; Sugden et al., 1989).  
Several studies have reported the ability of EBNA1 to induce oncogenesis in NPC. 
Expression of EBNA1 was initially found to induce B cell lymphoma in transgenic mice 
(Wilson et al., 1996) and similarly, expression of EBNA1 in NPC cells significantly 
promoted tumour formation and metastases following transplantation into nude mice 
(Sheu et al., 1996). Furthermore, EBNA1 binds to ubiquitin-specific protease 7 and 
disrupts promyelocytic leukaemia (PML) nuclear bodies that are important for cells to 
repair DNA damage (Sivachandran et al., 2010; Sivachandran et al., 2008). 
Consequently, EBNA1 enhances NPC cell survival with DNA damage by impairing 
p53 activation, apoptosis and DNA repair (Sivachandran et al., 2010; Sivachandran et 
al., 2008). EBNA1 can also promote genetic instability in NPC cells by inducing DNA 
damage, reactive oxygen species and upregulating the expression of oxidative stress 
response proteins SOD1 and Prx1 (Cao et al., 2012). In addition, EBNA1 contributes to 
angiogenesis by increasing the activity of AP-1 transcription factor, leading to an 
elevated expression of IL8, vascular endothelial growth factor (VEGF) and hypoxia-
inducible factor-1α (HIF-1α) (O'Neil et al., 2008). Moreover, EBNA1 has been shown 
to increase the levels of several proteins involved in metastases, including stathmin 1, 
maspin and Nm23-H1 (Cao et al., 2012). A role for EBNA1 in maintaining EBV 
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latency was also demonstrated by its ability to induce host let-7 miRNAs which, in turn, 
reduces the levels of Dicer, a protein that promotes EBV reactivation (Mansouri et al., 
2014). 
2.3.6.2 LMP1 
LMP1 is an integral membrane protein comprising a short cytoplasmic N-terminus, 
six hydrophobic transmembrane domains and a long cytoplasmic C-terminal tail 
(Fennewald et al., 1984). LMP1 is a classic oncogene that is able to induce 
transformation of rodent fibroblasts in vitro and tumour formation in nude mice (Wang 
et al., 1985). LMP1 acts as a constitutively activated member of the tumour necrosis 
factor receptor (TNFR) superfamily. It activates several signalling pathways including 
JNK/p-38, PI3K/AKT, MAPK/ERK, NF-κB and JAK/STAT, mainly via the two 
domains of its cytosolic C-terminus, C-terminal activation region 1 and 2 (CTAR1 and 
CTAR2), that collectively contribute to a range of tumour-promoting effects (Dawson et 
al., 2012). For example, LMP1 can promote the growth of NPC cells by upregulating 
growth factors or the receptors such as insulin-like growth factor 1 (IGF-1), epidermal 
growth factor receptor (EGFR) and c-Met (Horikawa et al., 2001; Miller et al., 1995; 
Tworkoski et al., 2015), as well as inhibiting cell cycle negative regulators, such as p16 
and p21 (Lo et al., 2004a). A key transforming ability of LMP1 is to modulate cell 
morphology and promote tumour metastasis. It has been shown that LMP1 can regulate 
the expression of many molecules that are involved in cell migration and invasion, 
including matrix metalloproteinase 9 (MMP9), cell division cycle 42 (Cdc42) and 
tumour necrosis factor alpha-induced protein 2 (TNFAIP2) (Chen et al., 2014; Liu et 
al., 2012a; Takeshita et al., 1999). Furthermore, LMP1 can induce epithelial-
mesenchymal transition (EMT) in NPC (Horikawa et al., 2007; Horikawa et al., 2011) 
and stimulate cancer stem/progenitor-like phenotype, possibly through the activation of 
Hedgehog signalling (Kondo et al., 2011; Port et al., 2013). In addition, LMP1 can 
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stimulate the secretion of pro-inflammatory cytokines in NPC cells, including IL-1α/β 
and tumour necrosis factor alpha (TNF-α) (Busson et al., 1987; Huang et al., 2010; 
Morris et al., 2008), suggesting a possible role in modulating the tumour 
microenvironment. Recent reports also revealed LMP1 is involved in energy 
metabolism of NPC cells by inhibiting the tumour suppressive liver kinase B1 (LKB1)-
AMP-activated protein kinase  (AMPK) pathway or promoting the aerobic glycolysis 
pathway (Lo et al., 2015; Lo et al., 2013; Xiao et al., 2014). Despite LMP1 exerting an 
array of effects that favour carcinogenesis, the expression of LMP1 in NPC appears to 
be variable and heterogeneous, with only approximately 50% of NPC cases staining 
positive for LMP1 by immunohistochemistry (Chen et al., 2015; Tsao et al., 2002a). 
2.3.6.3 LMP2 
The LMP2 gene encodes two mRNA products, LMP2A and LMP2B, which are 
transcribed across the fused terminal repeats of the EBV episome from two different 
promoters (Sample et al., 1989). LMP2A and LMP2B are highly similar in structure 
with 12 hydrophobic transmembrane spanning regions and a cytosolic C-terminus, but 
only LMP2A contains the immunoreceptor tyrosine-based activation motif (ITAM) 
within its N-terminal cytoplasmic domain that is responsible for many functional effects 
of LMP2 (Dawson et al., 2012; Raab-Traub, 2002; Sample et al., 1989; Tsao et al., 
2015). LMP2A has been reported to stimulate anchorage-independent growth, promote 
cell migration and invasion, and inhibit cell differentiation of NPC cells. Many of these 
effects are found to be the consequences of LMP2A-mediated activation of PI3K/AKT 
and β-catenin signalling (Fotheringham et al., 2012; Fukuda et al., 2007; Lan et al., 
2012; Morrison et al., 2004; Morrison et al., 2005; Scholle et al., 2000). The oncogenic 
effects of LMP2A have also been confirmed in vivo where the inoculation of LMP2A-
expressing cells in nude mice induced poorly differentiated tumours with high 
proliferative and metastatic potential (Scholle et al., 2000). Furthermore, LMP2A can 
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promote EMT, which is related to the acquisition of stem cell-like characteristics in 
NPC cells, via the induction of metastatic tumour antigen 1 (MTA1) through the mTOR 
pathway (Kong et al., 2010; Lin et al., 2014c). A novel feature of LMP2A was revealed 
recently in which LMP2A and LMP1 cooperate to modulate DNA damage signalling to 
provide a survival advantage for NPC cells (Wasil et al., 2015). Unlike LMP1, the 
expression of LMP2A is more consistent in NPC (Young et al., 2014). The expression 
of LMP2A mRNA is detected in more than 98% of NPC cases (Brooks et al., 1992; 
Busson et al., 1992) but LMP2A protein has only been confirmed in approximately 50% 
of NPC tumour samples (Kong et al., 2010). Low titres of IgG against LMP2A are 
present in the serum of the majority of the NPC patients, indicating that LMP2A protein 
is indeed present in NPC (Paramita et al., 2011). Therefore, the low detection rate of 
LMP2A protein in NPC samples might be an underestimate due to the insensitivity of 
the anti-LMP2A antibody. While the function of LMP2B remains elusive, it has been 
shown that both LMP2A and LMP2B can modulate interferon (IFN) signalling by 
increasing the turnover of IFN receptors and thus limiting the anti-viral response against 
EBV-infected cells (Shah et al., 2009). 
2.3.6.4 EBERs 
EBERs are the most abundantly expressed viral transcripts in latently EBV-infected 
cells. EBERs exist as EBER1 and EBER2 which are non-polyadenylated (non-coding) 
RNAs that form double-stranded RNA (dsRNA)-like structures (Glickman et al., 1988; 
Rosa et al., 1981). EBERs are shown to induce the production of type-I IFN through 
interaction with retinoic acid–inducible gene 1 (RIG-1) (Samanta et al., 2006) or 
activation of toll-like receptor 3 (TLR3) (Iwakiri et al., 2009), suggesting their 
involvement in activating the innate immunity. On the other hand, EBERs counteract 
the effects of IFN by directly binding and inhibiting dsRNA-activated protein kinase R 
(PKR), protecting EBV-infected cells from IFN-induced Fas-mediated apoptosis 
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(Nanbo et al., 2002; Nanbo et al., 2005; Yamamoto et al., 2000). EBERs have also been 
shown to stimulate the secretion of IGF-1 that contributed to the autocrine growth of 
EBV-infected NPC cells (Iwakiri et al., 2005). 
2.3.6.5 Transcripts of BamHI-A region 
Two transcripts are encoded from the BamHI A fragment of the EBV genome, 
namely BARTs and BARF1. BART transcripts are consistently detected in NPC 
biopsies, suggesting its important role in the development of NPC (Brooks et al., 1993; 
Tsang et al., 2015). BARTs encode two clusters of miRNAs comprising 44 mature 
miRNAs that are derived from 22 precursors (Cai et al., 2006; Chen et al., 2010; 
Grundhoff et al., 2006; Pfeffer et al., 2004). BART miRNAs contribute to the 
pathogenesis of NPC by regulating a number of viral and cellular genes. BART 
miRNAs has been shown to negatively regulate LMP1 and LMP2A proteins as well as 
reduce the sensitivity of LMP1-expressing cells to cisplatin (Lo et al., 2007). Moreover, 
BART miRNAs maintain viral latency by targeting viral lytic genes (e.g. BZLF1, 
BRLF1 and BALF5) (Barth et al., 2008; Iizasa et al., 2010; Jung et al., 2014; Lung et 
al., 2009), suggesting that these miRNAs contribute to the immune evasion by NPC 
cells. Compared to the viral gene targets, more cellular targets of the BART miRNAs 
have been identified. Importantly, BART miRNAs contribute to cell survival by 
targeting pro-apoptotic proteins, including p53 up-regulated modulator of apoptosis 
(PUMA) (Choy et al., 2008), Bim (Marquitz et al., 2011), translocase of outer 
mitochondrial membrane 22 (TOMM22) (Dolken et al., 2010), caspase 3 (Vereide et 
al., 2014) and Bid (Shinozaki-Ushiku et al., 2015). Furthermore, BART miRNAs can 
enhance the growth of NPC cells by suppressing the activity of the tumour suppressor, 
DICE1, (Lei et al., 2013b) and increase NPC cell migration and invasion by inhibiting 
the expression of E-cadherin (Hsu et al., 2014). Recent reports have also shown that 
BART miRNAs can drive tumour growth in vivo (Cai et al., 2015; Qiu et al., 2015), 
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further consolidating the contribution of these miRNAs to EBV oncogenesis. Due to 
their stability in serum, BART miRNAs have also been recognized as potential 
diagnostic and prognostic markers for NPC (Chan et al., 2012; Wong et al., 2012). 
BARF1 is a homologue of human colony stimulating factor 1 receptor (CSF1R) 
(Strockbine et al., 1998). BARF1 was initially thought to be a lytic gene as its 
expression was induced following the induction of lytic cycle in BL cell lines and the 
expression of BARF1 in a high proportion of NPC tissues was suggested to be a 
consequence of some cells undergoing spontaneous induction of the lytic cycle 
(Decaussin et al., 2000; Hayes et al., 1999; Zhang et al., 1988). It was later shown in 
primary NPC tissues that BARF1 was expressed in the absence of lytic gene expression, 
pointing to a role for BARF1 as a latent gene (Seto et al., 2005). Several reports have 
revealed the oncogenic potential of BARF1 by its ability to induce malignant 
transformation of rodent fibroblasts and increase NPC cell proliferation and survival in 
vitro as well as enhance tumorigenicity in mouse models (Seto et al., 2008; Sheng et al., 
2003; Wei et al., 1994; Wei et al., 1989). The combination of quantitative analysis of 
EBV DNA and detection of BARF1 mRNA in nasopharyngeal brushing samples has 
also been suggested as a useful, non-invasive and sensitive test for the diagnosis of NPC 
(Stevens et al., 2006). 
2.4 Sphingosine-1-phosphate  
Sphingolipids are essential components of the lipid bilayer in cellular membranes 
and provide a protective barrier by giving structural support and mechanical stability 
(Ogretmen et al., 2004). Many sphingolipids including ceramide, sphingosine, 
ceramide-1-phosphate, glycosylceramide, lyso-sphingomyelin and S1P are also 
bioactive lipids that are involved in signal transduction and regulate multiple cellular 
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processes such as cell growth, survival, senescence, migration, invasion, inflammation, 
angiogenesis and intracellular trafficking (Hannun et al., 2008; Ogretmen et al., 2004).  
S1P (C18H38NO5P) is a zwitterionic lysophospholipid which consists of a serine 
headgroup with additional dihydrogen phosphate and ammonium radical groups (Rosen 
et al., 2009). Emerging evidence has revealed the involvement of deregulated S1P 
signalling in a number of diseases, including cancer, multiple sclerosis, atherosclerosis, 
diabetes, osteoporosis, sickle cell disease and acute lung injury (Maceyka et al., 2012; 
Proia et al., 2015).  
2.4.1 Metabolism of S1P 
Cellular S1P levels are tightly regulated by the balance between its synthesis and 
degradation (Takabe et al., 2008) (Figure 2.4). The precursor of S1P, ceramide, can be 
synthesised de novo from serine and palmitoyl-CoA or hydrolysed from sphingomyelin. 
Ceramide is then degraded by ceramidase to produce sphingosine, which is 
subsequently converted to S1P by sphingosine kinases (SPHKs). S1P can either be 
reversibly dephosphorylated back to sphingosine by S1P phosphatase or irreversibly 
cleaved to hexadecenal and ethanolamine phosphate by S1P lyase (Pyne et al., 2000). 
The balance between ceramide/sphingosine and S1P levels, termed ceramide-
sphingosine-S1P rheostat or sphingolipid rheostat, determines cell fate where 
sphingosine and ceramide are associated with growth arrest and apoptosis, whereas S1P 
promotes cell proliferation and survival (Milstien et al., 2006).   
A wide variety of stimuli, including cytokines (e.g. TNF-α, TGF-β) (Xia et al., 1999; 
Yamanaka et al., 2004), growth factors (e.g. EGF, IGF, VEGF) (El-Shewy et al., 2006; 
Hait et al., 2005; Sarkar et al., 2005; Shu et al., 2002), GPCR agonists [e.g. N-formyl-
Met-Leu-Phe (FMLP)] (Alemany et al., 1999), hormones (e.g. estradiol) (Sukocheva et 
al., 2003), phorbol esters [e.g. phorbol 12-myristate 13-acetate (PMA)] (Buehrer et al., 
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1996) and vitamin D3 (Kleuser et al., 1998) can activate SPHKs. Two isoforms of 
SPHKs, SPHK1 and SPHK2, have been identified. The isoforms share approximately 
50% identity and 80% similarity and produce S1P, but they are expressed in different 
cellular compartments and possibly have distinct roles (Liu et al., 2000; Takabe et al., 
2008). SPHK1 is predominantly cytosolic; SPHK1 is principally phosphorylated by 
ERK1/2 (Pitson et al., 2003) and then translocates to the plasma membrane in a calcium 
and integrin-binding protein 1 (CIB1)-dependent manner to produce S1P (Jarman et al., 
2010). In contrast, depending on the cell type, SPHK2 is localised within different 
intracellular compartments, including endoplasmic reticulum, mitochondria and nuclei 
(Maceyka et al., 2012). S1P can shuttle between the cytosol and nucleus, an event that 
appears to be modulated through the phosphorylation by protein kinase D to export 
nuclear SPHK2 to the cytosol (Ding et al., 2007) and the activation of SPHK2 is also 
thought to be mediated by ERK-dependent phosphorylation (Hait et al., 2007). 
S1P is produced and secreted from various cell types, including epithelial cells 
(Johnson et al., 2002), cerebellar granule cells, cerebellar astrocytes (Anelli et al., 
2005), thrombocytes (Hanel et al., 2007), platelets (English et al., 2000), mast cells, 
dendritic cells and macrophages (Goetzl et al., 2004). Early studies reported that S1P 
was abundantly stored in platelets due to their high SPHK activity and absence of S1P 
lyase (Yatomi et al., 1997a; Yatomi et al., 1997b). It was later found that although 
erythrocytes have much weaker SPHK activity compared to platelets, they are the major 
storage sites of S1P, as they are much more abundant in blood and also lack the S1P-
degrading enzymes (Hanel et al., 2007; Ito et al., 2007). S1P is regularly released from 
these storage sites and thereby contribute to a high S1P concentration in the circulation 
(Hanel et al., 2007; Yatomi et al., 2000). By contrast, S1P levels in most tissues are 
extremely low because S1P is constantly dephosphorylated by S1P phosphatase or 
irreversibly degraded by S1P lyase (Rivera et al., 2008). The differences in the levels of 
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S1P between tissues and blood form a S1P gradient, which is essential for the regulation 
of various physiological and pathophysiological activities (Hla et al., 2008; Spiegel et 
al., 2011).   
2.4.2 S1P signalling 
S1P can act extracellularly through S1P receptors (S1PRs) and/or intracellularly 
through direct interaction with the intracellular targets (Maceyka et al., 2012).  
2.4.2.1 Extracellular action of S1P 
S1P is exported out of the cells by transporter proteins (ABCA1, ABCC1, ABCG2 
and SPNS2) and acts as a specific ligand for a family of five specific cognate G protein-
coupled receptors (GPCR), termed S1PR1 – S1PR5 (Rosen et al., 2005). All five S1PRs 
consist of an extracellular NH2 terminus and seven transmembrane domains with 
different hydrophilic extracellular and intracellular loops according to the receptor 
subtypes (Sanchez et al., 2004). S1PRs are ubiquitously expressed, albeit at different 
levels, in many tissues and cell types. S1PR1 (Edg-1), S1PR2 (Edg-5) and S1PR3 (Edg-
3) are widely expressed in various tissues, whereas S1PR4 (Edg-6) is confined to 
lymphoid and hematopoietic tissue and S1PR5 (Edg-8) is found in the central nervous 
system and NK cells (Sanchez et al., 2004; Takabe et al., 2008). 
Extracellular S1P binds S1PRs in a paracrine or autocrine manner to trigger a series 
of signal transduction pathways that are mediated by different heterotrimeric G proteins, 
a  process termed “inside-out” signalling (Figure 2.5) (Katoh et al., 1998; Takabe et al., 
2014). S1PR1 couples only to Gi, S1PR2 and S1PR3 couple to Gi, Gq and G12/13, 
whereas S1PR4 and S1PR5 couple to Gi and G12/13 (Taha et al., 2004). Activation of 
different G proteins stimulates downstream effectors that may exert entirely different 
functions in the cells (Wettschureck et al., 2005). 
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Figure 2.4: Scheme of sphingolipid metabolism 
S1P levels are tightly regulated by its synthesis and degradation. Ceramide can be 
generated through de novo synthesis from serine and palmitoyl-CoA or hydrolysis of 
sphingomyelin. Sphingosine is synthesised from ceramide by ceramidase and 
subsequently converted to S1P by sphingosine kinases. S1P can be converted back to 
sphingosine by sphingosine phosphatase or irreversibly cleaved to hexadecenal and 
ethanolamine phosphate by S1P lyase. The balance between ceramide/sphingosine and 
S1P levels, termed sphingolipid rheostat, determines cell fate. When the balance shifts 
towards ceramide and sphingosine, it results in growth arrest and apoptosis. In contrast, 
when the synthesis of S1P predominates, cell growth and survival are induced. 
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Figure 2.5: S1P receptors, G-protein-coupling and signalling pathways 
Binding of S1P to one or more of the five S1PRs activates G proteins (Gi, Gq and 
G12/13). The activated G proteins subsequently trigger downstream signalling pathways 
and regulate important cellular activities. 
PLC, phospholipase C; AC, adenylyl cyclase; PI3K, phosphatidylinositol-3-kinase; 
PKC, protein kinase C; cAMP, cyclic adenosine monophosphate; ERK, extracellular 
signal-regulated kinase; PKB/AKT, protein kinase B; Ca
2+
, intracellular free calcium 
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2.4.2.2 Intracellular action of S1P 
Although the majority of the known functions of S1P are attributable to its 
extracellular action through S1PRs, the lipid can also act as an intracellular second 
messenger by binding directly to a variety of proteins. These proteins include tumour 
necrosis factor (TNF) receptor-associated factor 2 (TRAF2) (Alvarez et al., 2010), 
histone deacetylases (HDAC1 and HDAC2) (Hait et al., 2009), β-site amyloid precursor 
protein cleaving enzyme 1 (BACE1) (Takasugi et al., 2011), prohibitin 2 (PHB2) (Strub 
et al., 2011).  Two additional intracellular targets of S1P were later discovered in 2015, 
namely peroxisome proliferator-activated receptor γ (PPARγ) (Parham et al., 2015) and 
human telomerase reverse transcriptase (hTERT) (Panneer Selvam et al., 2015). 
Although S1P produced by both SPHK1 and SPHK2 can act intracellularly, the 
intracellular actions of S1P signalling are thought to be mainly attributable to SPHK2-
derived S1P, possibly due to its predominant location in intracellular compartments 
(Spiegel et al., 2011; Zhang et al., 2013). 
2.4.3 S1P signalling in cancer 
There is a substantial body of evidence to show that aberrant activation of the 
SPHKs/S1P/S1PRs axis contributes to carcinogenesis. The oncogenic potential of the 
SPHKs was first revealed in 2000 by the observation that over-expression of SPHK 
induced the transformation of NIH3T3 fibroblasts and injection of SPHK-
overexpressing NIH3T3 cells subcutaneously into NOD/SCID mice resulted in tumour 
formation (Xia et al., 2000).  These studies were performed before the identification of 
the two SPHK isoforms.  Over-expression of SPHK1 was later found in various 
malignancies and its high expression was correlated to a number of clinicopathological 
characteristics in various types of cancer, including advanced staging, recurrence and 
reduced patient survival (Table 2.2) (Pyne et al., 2010). In contrast to SPHK1, the roles 
of SPHK2 in tumorigenesis are less well-defined. 
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High expression of SPHKs results in elevated levels of S1P and exogenous addition 
of S1P promotes the aggressiveness of cancer cells in vitro, for example by enhancing 
cell proliferation, migration and invasion, and by exerting anti-apoptotic effects (Pyne et 
al., 2010).  Furthermore, alterations in the expression or function of one or more of the 
five S1PRs have been shown to contribute to the oncogenic properties of the S1P 
signalling pathway (Blaho et al., 2014). Aberrant expression of S1PR1, S1PR2 and 
S1PR3 has been reported in various types of cancer and several studies have shown an 
association between the expression of these S1PRs with clinical outcomes, particularly 
poorer patient survival (Bien-Moller et al., 2016; Go et al., 2015; Lin et al., 2014b; 
Patmanathan et al., 2016; Watson et al., 2010).  The effects of S1P signalling on various 
cancer cell phenotypes are discussed below. 
2.4.3.1 Cell proliferation 
The role of S1P in regulating cell proliferation is complex, with evidence for both 
growth promoting and anti-proliferative effects of the lipid. S1P can promote cancer cell 
proliferation through the activation of several signalling pathways, including PI3K/AKT 
and MAPK/ERK (Datta et al., 2014; Goetzl et al., 1999; Nava et al., 2002; Sukocheva 
et al., 2009; Van Brocklyn et al., 2002; Xia et al., 2012). For example, over-expression 
of SPHK1 confers a mitogenic advantage to breast cancer cells through an estrogen-
dependent mechanism that is associated with the activation of ERK1/2 (Nava et al., 
2002). Similarly, silencing of SPHK1 inhibited the proliferation of gastric cancer cells 
through a mechanism that involves the suppression of AKT activation, as well as 
stimulation of Forkhead box O1 (FOXO1) activity and the expression of the cyclin-
dependent kinase inhibitors p21
Cip1 
and p27
Kip1
 (Xia et al., 2012). On the other hand, 
several studies have shown that S1P inhibited the growth of cells from a range of 
tumour types, including gastric, breast, ovarian and thyroid cancers and melanoma 
(Balthasar et al., 2006; Hong et al., 1999; Ling et al., 2011; Shin et al., 2007; Sultan et 
39 
al., 2013; Yamashita et al., 2006). However, the precise mechanisms by which S1P 
inhibits cell proliferation are unclear. The effects of S1P on cancer cell growth are 
suggested to be influenced by the expression profile of S1PRs (Adada et al., 2013). 
S1PR1 and S1PR3 are generally associated with increased proliferation of cancer cells 
(Emery et al., 2014; Hsu et al., 2012; Lee et al., 2010; Liu et al., 2012b), whilst S1PR2 
can exhibit either growth promoting (An et al., 2000; Beckham et al., 2013) or 
suppressive effects (Li et al., 2008b). Interestingly, S1P signalling via S1PR3 has been 
reported to promote the proliferation of breast cancer stem cells through the activation 
of Notch signalling (Hirata et al., 2014). 
2.4.3.2 Cell migration and invasion 
S1P can induce the migration and invasion of cancer cells from various 
malignancies, including gastric, breast and ovarian cancers and glioblastoma 
multiforme, via the activation of downstream signalling pathways such as Rac and 
MAPK/ERK (Arikawa et al., 2003; Bao et al., 2012; Kim et al., 2011; Park et al., 2007; 
Van Brocklyn et al., 2003; Yamaguchi et al., 2003; Yamashita et al., 2006).  
The effects of S1P on the migration and invasion of cancer cells requires the 
activation of Gi or Gq signalling, suggesting that these effects are also influenced by the 
expression profile of S1PRs (Van Brocklyn et al., 2003; Wang et al., 1999). Indeed, 
S1PR1 and S1PR3 have consistently been associated with enhanced migration and 
invasion of cancer cells (Pyne et al., 2012). For example, coupling with Gi or Gq 
stimulates the degradation of extracellular matrix by matrix metalloproteinases (e.g. 
MMP-1, MMP-2, MMP-9) and this occurs mainly via S1PR1 and S1PR3 (Kalhori et 
al., 2015; Kim et al., 2011; Nyalendo et al., 2007; Van Brocklyn et al., 2003). The 
migratory and invasive effects of S1PR1 can occur via several downstream 
mechanisms, for example activation of PI3K and Rac in Wilms tumours (Li et al., 
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2009a) or interaction with vascular endothelial growth factor receptor 2 (VEGFR-2) that 
activates ERK1/2 in thyroid cancer cells (Bergelin et al., 2010). In addition, 
SPHK1/S1P signalling can stimulate the accumulation of ERK1/2 and actin to 
membrane ruffles/lamellipodia through S1PR3, thereby promoting the migration of 
breast cancer cells (Long et al., 2010a). The S1P-induced migration of cancer cells can 
also be mediated via S1PR3 through the activation of HIF-1α, C-reactive protein (CRP) 
and EGFR (Hsu et al., 2012; Kalhori et al., 2013; Kim et al., 2014). While S1PR2 is 
generally thought to act as a suppressor of cancer cell migration/invasion via Rho/Rac 
signalling (Arikawa et al., 2003; Lepley et al., 2005; Malchinkhuu et al., 2008; 
Yamaguchi et al., 2003), its ability to promote a migratory phenotype has also been 
reported in various types of cancer in vitro and in vivo (Li et al., 2015a; Miller et al., 
2008; Patmanathan et al., 2016; Ponnusamy et al., 2012; Sekine et al., 2011; Wang et 
al., 2008).  
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Table 2.2: Over-expression of SPHK1 in cancer 
Cancer type Clinical parameters associated with high SPHK1 expression Reference(s) 
NPC 
Advanced disease stage, locoregional recurrence, distant metastasis and reduced patient 
survival 
(Li et al., 2015b) 
HNSCC Advanced disease stage, nodal involvement, recurrence and poorer patient survival 
(Facchinetti et al., 2010; Shirai et al., 
2011; Sinha et al., 2011) 
Breast cancer Reduced disease-free survival time and shorter time to recurrence in ER
+ 
patients 
(Long et al., 2010a; Ruckhaberle et al., 
2008; Watson et al., 2010) 
Astrocytoma Higher histological tumour grade and shorter patient survival 
(Li et al., 2008a; Van Brocklyn et al., 
2005) 
Esophageal 
cancer 
Increased tumour invasion depth, lymph node metastasis and poorer patient survival (Pan et al., 2011) 
Gastric cancer 
Advanced disease stage, increased tumour size, distant metastasis and reduced patient 
survival 
(Li et al., 2009b) 
Non-Hodgkin’s 
lymphoma 
Increased tumour clinical grade (Bayerl et al., 2008) 
Bladder cancer 
Higher histological tumour grade, advanced disease stage and reduced overall 5-year 
survival rates 
(Meng et al., 2014) 
Colon cancer Enhanced tumour metastasis (Kawamori et al., 2009) 
Cervical cancer 
Increased tumour size, invasion depth, disease stage, lymph node metastasis and 
lymphovascular invasion as well as reduced overall survival and recurrence-free survival  
(Kim et al., 2015) 
Thyroid cancer Advanced disease stage (Guan et al., 2011a) 
NPC, nasopharyngeal carcinoma; HNSCC, head and neck squamous cell carcinoma; SPHK1, sphingosine kinase; ER, estrogen receptor. 
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2.4.3.3 Other phenotypes  
In addition to cell proliferation and migration/invasion, aberrant S1P signalling has 
been implicated in regulating other malignant phenotypes, such as enhanced cell 
survival, angiogenesis and resistance to cancer therapy.  
The balance between the levels of ceramide and S1P is critical in regulating cell 
survival. High expression of SPHK1 leads to elevated levels of S1P with a reduction in 
ceramide levels and this results in the inhibition of ceramide-mediated apoptosis 
(Bektas et al., 2005; Cuvillier et al., 2001; Pchejetski et al., 2005). S1P can suppress 
cancer cell apoptosis mainly via S1PR1 through several mechanisms, including 
activation of PI3K/AKT, MAPK/ERK, NF-κB pathways and inducing the expression of 
anti-apoptotic proteins of the BCL-2 family (e.g. Bcl-2, Bcl-xL, Mcl-1) (Bektas et al., 
2005; Kapitonov et al., 2009; Li et al., 2007; Li et al., 2008c; Song et al., 2011; Xu et 
al., 2016), as well as inhibition of pro-apoptotic proteins (e.g. Bim, Bax) (Guan et al., 
2011b; Taha et al., 2006a).  
SPHK1/S1P signalling has been shown to induce tumour angiogenesis and 
lymphangiogenesis in vitro and/or in vivo in models of glioblastoma multiforme, as well 
as lung and breast cancers (Anelli et al., 2010; Chae et al., 2004; Kapitonov et al., 2009; 
Nagahashi et al., 2012). Increased expression of S1PR1 and S1PR3, and decreased 
expression of S1PR2 have been reported to be critical in mediating these effects (Chae 
et al., 2004; Du et al., 2010; Yoon et al., 2008). The S1P-induced angiogenesis and 
lymphangiogenesis in cancer cells have also been correlated to elevated expression of 
VEGF and HIF-1α (Ader et al., 2015; Anelli et al., 2010; Chae et al., 2004; Kalhori et 
al., 2013; Li et al., 2011).  
Another oncogenic function of S1P is increased resistance of cancer cells to 
chemotherapeutic drugs and -irradiation and these effects appear to be mediated 
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through S1PR1, S1PR2 and S1PR3 (Akao et al., 2006; Pyne et al., 2010; Salas et al., 
2011; Watson et al., 2010). High expression of SPHK1 correlated with a shorter time to 
recurrence in ER
+
 breast cancer patients receiving tamoxifen, indicating the induction of 
tamoxifen resistance (Long et al., 2010a). Furthermore, cancer cell lines that express 
high levels of SPHK1 are resistant to gemcitabine, camptothecin, tamoxifen and 
cetuximab (Akao et al., 2006; Guillermet-Guibert et al., 2009; Pchejetski et al., 2005; 
Rosa et al., 2012; Sukocheva et al., 2009). Over-expression of SPHK1 has also been 
shown to reduce sensitivity of tumour cells to chemotherapeutic drugs and radiation 
therapy in vivo (Pchejetski et al., 2005) (Sinha et al., 2011). 
2.4.3.4 In vivo studies  
Several key in vivo studies have confirmed the importance of aberrant S1P signalling 
in promoting tumorigenesis For example, knockout of SPHK1 in a mouse model of 
head and neck cancer decreased S1P formation and suppressed 4-nitroquinoline 1 oxide 
(4-NQO)-induced carcinogenesis through reduced tumour incidence, multiplicity and 
volume that was associated with decreased growth, survival and phosphorylation of 
AKT (Shirai et al., 2011). In addition, S1P enhances tumour growth and metastasis in 
vivo in the models of bladder cancer and colon cancer through persistent activation of 
STAT3 via S1PR1 (Lee et al., 2010; Liang et al., 2013). A possible feedback loop was 
induced in which binding of SPHK1-derived S1P to S1PR1 stimulated secretion of NF-
κB-regulated pro-inflammatory cytokine IL-6, leading to the activation of STAT3 that 
in turn upregulates the expression of S1PR1; decreased expression of SPHK1 and 
S1PR1 suppressed the NF-κB-IL-6-STAT3 amplification cascade and the development 
of colitis-associated cancer (Liang et al., 2013). Studies using melanoma mouse models 
have suggested that S1PR1/STAT3 signalling is also crucial in facilitating the formation 
of pre-metastatic niches and inducing myeloid cell colonisation at future metastatic sites 
(Deng et al., 2012).  
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Collectively, these studies highlight the potential of targeting the SPHK-S1P-S1PR 
axis for cancer therapeutics. The case for targeting this pathway is even more 
compelling following the report that SPHK1 expression in cancer-associated fibroblasts 
(CAFs) promotes the migration and metastatic dissemination of melanoma cells, via the 
upregulation of S1PR3 (Albinet et al., 2014). Furthermore, these authors show that 
conditioned media from SPHK1-expressing melanoma cells induces fibroblasts to 
differentiate into myofibroblasts and recently a critical role was reported for SPHK1 in 
mediating TGF-β-induced myofibroblast differentiation in ovarian cancer (Beach et al., 
2016). Therefore, SPHK1 appears to play a dual role by enhancing tumour cell 
migration and metastasis, whilst also stimulating the development of tumour promoting 
CAFs. This raises the exciting possibility that inhibitors of S1P signalling would 
simultaneously target both malignant cells and the tumour permissive 
microenvironment.  
2.4.4 Therapeutic agents targeting S1P signalling 
Targeting the S1P signalling pathway is now considered a promising therapeutic 
approach for the treatment of cancer. A number of strategies to target different 
molecules within the pathway have been established, including inhibition of SPHKs, 
neutralisation of S1P itself and targeting specific S1PRs (Kunkel et al., 2013).   
2.4.4.1 Inhibition of SPHKs 
Inhibition of SPHKs is a promising approach to reduce the levels of S1P and increase 
the levels of ceramide and sphingosine. The activity of SPHKs can be modulated using 
inhibitors, such as SKI-I (specific for SPHK1), PF-543 (selective for SPHK1), Safingol 
(putative SPHK1 inhibitor), ABC294640 (selective for SPHK2), SKI-II (ski; inhibits 
SPHK1 and SPHK2) and DMS (inhibits SPHK1 and SPHK2) (Kunkel et al., 2013; 
Pyne et al., 2010). SPHK inhibitors have been found to be effective in reducing S1P 
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levels and to inhibit the tumour-promoting effects of S1P both in vitro and in vivo 
(Beljanski et al., 2010; French et al., 2006; French et al., 2010; Gao et al., 2011; 
Kapitonov et al., 2009; Nagahashi et al., 2012; Paugh et al., 2008; Schnute et al., 2012; 
Sukocheva et al., 2009). Some of these inhibitors are now entering early stage of 
clinical trials. For example, a phase I clinical trial using Safingol for solid tumours has 
been completed and the results demonstrated that it can be administered to patients 
safely in conjunction with cisplatin, although reversible dose-dependent hepatic toxicity 
was observed (Dickson et al., 2011). Similarly, a phase I clinical trial using 
ABC294640 (formulated as YELIVA™) for pancreatic cancer and advanced solid 
tumours has also just been completed and the results showed that the drug is well-
tolerated (www.redhillbio.com).  
2.4.4.2 Sequestration of S1P 
A number of anti-S1P monoclonal antibodies have been developed to neutralise 
systemic S1P. An early in vitro study using an anti-S1P monoclonal antibody has 
demonstrated its efficacy in inhibiting S1P-mediated cancer progression and 
angiogenesis in lung, breast and colorectal cancer cell lines (Visentin et al., 2006). The 
anti-tumorigenic and anti-angiogenic effects of the antibody were also observed in 
mouse xenograft and allograft models (O'Brien et al., 2009; Ponnusamy et al., 2012; 
Visentin et al., 2006; Zhang et al., 2015). Two anti-S1P monoclonal antibodies, LT1002 
and LT1009 (the humanised form of LT1002), have been reported to have high affinity 
and specificity for S1P and do not cross-react with other structurally related lipids 
(O'Brien et al., 2009). LT1009 has been formulated as ASONEP™ by Lpath, Inc. and 
the Phase I clinical trials using this drug for advanced solid tumours was completed in 
2011 (Sabbadini, 2011). However, its Phase II clinical trial for unresectable and 
refractory renal cell carcinoma was terminated prematurely due to frequent occurrence 
of serious adverse events (clinicaltrials.gov). 
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2.4.4.3 Targeting of S1P receptors 
Several pharmacological drugs, including FTY720, JTE-013 and VPC23019, 
have been developed to target the S1PRs, although the majority of studies with these 
molecules are restricted to preclinical disease models. FTY720 (fingolimod) is a 
sphingosine analog that can bind and induce endocytosis of four S1PRs (S1PR1, 
S1PR3, S1PR4 and S1PR5) at concentrations lower than 0.1μM (Brinkmann et al., 
2002). This compound was initially found to have immunosuppressive effects by 
inhibiting the receptor signalling involved in lymphocyte egress (Mandala et al., 2002; 
Matloubian et al., 2004). These immunosuppressive effects were particularly 
demonstrated to be mediated by S1PR1 because FTY720 downregulated S1PR1 in 
lymphocytes resulting in lymphocyte sequestration (Matloubian et al., 2004). FTY720 
was later shown to inhibit cell growth, survival, migration and increase 
chemosensitivity in various types of cancer in vitro and in vivo (Azuma et al., 2002; Ho 
et al., 2005; LaMontagne et al., 2006; Matsuoka et al., 2003; Ubai et al., 2007). 
Formulated as Gilenya™, FTY720 was approved in September 2010 as the first oral 
treatment for relapsing and remitting multiple sclerosis (Brinkmann et al., 2010), and 
the re-purposing of this drug for cancer treatment is potentially a promising strategy 
(Patmanathan et al., 2015). 
JTE-013 is a S1PR2/S1PR4 antagonist. It has been shown to be effective in 
inhibiting S1PR2 at sub-micromolar concentrations (Ohmori et al., 2003; Osada et al., 
2002). Blockade of S1PR2 by JTE-013 enhanced the motility of melanoma and glioma 
cells (Arikawa et al., 2003; Li et al., 2015a) as well as promoted the growth of Wilm’s 
tumour cells (Li et al., 2008b). In contrast, several studies have shown that the 
migration of cancer cells, including ovarian cancer, prostate cancer and neuroblastoma, 
was inhibited following JTE-013 treatment (Li et al., 2015a; Miller et al., 2008; Sekine 
et al., 2011). JTE-013 has also been found to suppress the S1P-induced activation of 
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ERK1/2 via S1PR4 in breast cancer cells at a concentration of 10μM (Long et al., 
2010b).  
VPC23019 acts as a competitive inhibitor of S1P binding to S1PR1 and S1PR3 
(Davis et al., 2005). The actions of VPC23019 were demonstrated through competitive 
suppression of S1P-mediated calcium mobilisation in bladder carcinoma cells stably 
over-expressing S1PR3 and displacement of radiolabeled S1P binding at S1PR1 and 
S1PR3 in HEK293T cells (Davis et al., 2005). In the context of cancer research, 
VPC23019 significantly inhibited S1P-induced cell migration of ovarian cancer, 
prostate cancer, thyroid cancer and liver cancer (Bao et al., 2012; Bergelin et al., 2009; 
Park et al., 2007; Sekine et al., 2011; Wang et al., 2008).   
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CHAPTER 3: MATERIALS AND METHODS 
3.1 Cell lines 
Eight NPC cell lines, two immortalised nasopharyngeal epithelial cell lines, five 
EBV-infected NPC cell lines (CNE2/EBV, HK1/EBV, HONE1/EBV, SUNE1/EBV, 
TW01/EBV), an EBV-infected immortalised nasopharyngeal epithelial cell line 
(NP460hTert/EBV), an EBV-positive BL cell line (Akata), an LCL (X50-7) and two 
human embryonic kidney cell lines (HEK293 and HEK293T) were used in this study. 
The cell lines were kind gifts from Professor George Tsao, University of Hong Kong; 
Dr Christopher Dawson, University of Birmingham and Professor Chee Onn Leong, 
International Medical University. The characteristics and EBV status of NPC cell lines 
and immortalised nasopharyngeal epithelial cell lines are shown in Table 3.1.  
3.2 Materials 
S1P (D-erythro S1P, d18:1; Avanti Polar Lipids, USA) was dissolved in 95% 
methanol (Merck, Germany), dried under a stream of nitrogen gas and stored at -20ºC in 
aliquots of 100nmol. S1P was re-constituted in RPMI medium containing 4mg/ml fatty 
acid-free albumin (FAFA; Sigma-Aldrich, USA) at 37
o
C overnight prior to experiments. 
JTE-013 [1-[1,3-Dimethyl-4-(2-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-(3,5-
dichloro-4-pyridinyl)-semicarbazide] and VPC23019 (2-Amino-N-(3-octylphenyl)-3-
(phosphonooxy)-propanamaide) were obtained from Tocris Biosciences, UK. 
LY294002 (2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one) was obtained from 
Merck, Germany. CYM-5478 was a kind gift from Dr Deron Herr, National University 
of Singapore. JTE-013, LY294002 and CYM-5478 were dissolved in DMSO and 
VPC23019 was dissolved in acidified DMSO [5% 1N hydrochloric acid (HCl; Merck, 
Germany) in DMSO]. All compounds were stored at -20ºC in small aliquots. 
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Table 3.1: Characteristics of the NPC cell lines and immortalised 
nasopharyngeal epithelial cell lines 
Cell Lines Differentiation 
EBV 
Status 
References 
C666-1 Undifferentiated Positive (Cheung et al., 1999) 
CNE1 Well-differentiated Negative 
("Establishment of an 
epitheloid cell line and a 
fusiform cell line from a 
patient with 
nasopharyngeal 
carcinoma," 1978) 
CNE2 Poorly differentiated Negative (Sizhong et al., 1983) 
HK1 Well-differentiated Negative (Huang et al., 1980) 
HONE1 Poorly differentiated Negative (Glaser et al., 1989) 
SUNE1 Poorly differentiated Negative (Chen et al., 1998) 
TW01 Well-differentiated Negative (Lin et al., 1993) 
TW04 Poorly differentiated Negative (Lin et al., 1993) 
NP460hTert 
Non-malignant 
nasopharyngeal epithelium, 
immortalized using hTERT 
Negative (Li et al., 2006a) 
NP69 
Non-malignant 
nasopharyngeal epithelium, 
immortalised using SV40T 
Negative (Tsao et al., 2002b) 
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3.3 Cell culture 
3.3.1 Maintenance of cell lines 
NPC cell lines, Akata and X50-7 were cultured in Roswell Park Memorial Institute 
(RPMI) 1640 medium (Gibco Life Technologies, USA) supplemented with 10% fetal 
bovine serum (FBS) (Gibco Life Technologies, USA). NP69 was cultured in 
keratinocyte serum-free medium (KSFM; Gibco Life Technologies, USA) containing 
25µg/ml of bovine pituitary extract (Gibco Life Technologies, USA), 0.2ng/ml of 
epidermal growth factor (Gibco Life Technologies, USA) and 0.3mM of calcium 
chloride and NP460hTert was grown in a 1:1 mixture of defined KFSM (Gibco Life 
Technologies, USA) and Epilife® medium with growth supplements (Cascade 
Biologics, USA). HEK293 and HEK293T were cultured in Dulbecco's Modified Eagle's 
medium (DMEM) medium (Gibco Life Technologies, USA) supplemented with 10% 
FBS (Gibco Life Technologies, USA). All cultures were maintained in a 37°C CO2 
incubator (Binder, Germany) supplied with 5% CO2. 
3.3.2 Sub-culturing and Cell Number Determination 
Cells were sub-cultured when they reached 80-90% confluency. To sub-culture 
adherent cells, cells were washed with PBS (Gibco Life Technologies, USA) and 
trypsinised with 0.25% trypsin-EDTA (Gibco Life Technologies, USA). An equal 
volume of complete growth medium was added to neutralize the enzymatic action and cells 
were pelleted by centrifugation at 1,000rpm for 8 minutes. For suspension cells, cells 
were directly pelleted by centrifugation at 300rpm for 5 minutes. Cell pellets were re-
suspended in fresh medium and the cell number was determined using a Luna automated 
cell counter (Logos Biosystems, Korea). Cells were mixed 1:1 with Trypan Blue (Gibco 
Life Technologies, USA) and 10μl of the mixture was pipetted into Luna cell counting 
chamber (Logos Biosystems, Korea). The number of viable cells was determined and 
cells were seeded at required densities according to the experimental design. 
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3.3.3 Cryopreservation and recovery of cells 
1x10
6
 cells were re-suspended in FBS containing 10% DMSO (Sigma-Aldrich, USA) 
and transferred into cryovials (Nunc, USA). The cryovials were stored in MrFrosty™ 
Cryo 1°C Freezing Container (Nalgene, USA) at -80°C freezer overnight before 
transferring to liquid nitrogen for long term storage. 
Cryopreserved cells were recovered by rapid thawing at 37
o
C. Cells were transferred 
into 9ml complete growth medium and centrifuged at 1,000rpm for 8 minutes. The 
supernatant was discarded and cell pellet was re-suspended with fresh medium. Cells 
were grown in a 25cm
2 
flask in 5ml of medium. 
3.3.4 Transient transfection of cell lines 
Four genes (SPHK1, constitutively active AKT, LMP1 and LMP2A) were transiently 
expressed in cultured cells using a FuGENE
®
 HD Transfection Reagent (Promega, 
USA) according to the manufacturer’s protocol. Briefly, cells were seeded at 
appropriate densities to reach 60% confluence prior to the experiments. Cells were 
washed with PBS and replenished with fresh growth medium. A 3:1 ratio of FuGENE
®
 
HD Transfection Reagent and plasmid DNA was added to complete growth medium 
and incubated at room temperature for 10 minutes. The mixture was added drop-wise to 
the cells and the cells were incubated for 24-72 hours according to the experimental 
design. Plasmid DNAs used were pCMV6_XL4/SPHK1, pCDNA3.1/myr-AKT, 
pCDNA3.1/LMP1 and pSG5/LMP2A.   
3.3.5 Knockdown of SPHK1 in NPC cell lines 
3.3.5.1 Generation of puromycin kill curves 
Cells were seeded in 6-well plates at appropriate densities one day prior to the 
experiments to obtain a confluency of 60%. Various concentrations of puromycin (0, 
0.25, 0.5, 1, 2.5, 5μg/ml) (Fisher Scientific, USA) were added to the cells and incubated 
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for 4 days. The minimum concentration of puromycin that killed 90% of the cells was 
used for subsequent experiments. 
3.3.5.2 Collection of lentiviral supernatants 
Lentiviral vector system was used to knock down SPHK1 in HONE1 and C666-1 
cells. Two SPHK1 shRNA lentiviral plasmids (pLKO.1/shSPHK1_S1, 
pLKO.1/shSPHK1_S2) and the non-targeting (control) shRNA (pLKO.1/NS) were 
kindly provided by Prof Chee-Onn Leong (International Medical University, Malaysia). 
1x10
7
 HEK293T cells were seeded in a 150cm
2
 flask one day before the experiments 
and cultured until 80-90% confluence. 40μg lentiviral construct, 10μg envelope plasmid 
(pMD2.G) and 30μg packaging plasmid (psPAX2) were added to 5ml of Opti-MEM® 
(Gibco Life Technologies, USA) and filtered through a 0.2μm filter (Sartorius, 
Germany). 1μl of 10mM stock of polyethylenimine (PEI) (Sigma-Aldrich, USA) was 
added to another 5ml of Opti-MEM
®
 and filtered through a 0.2μm filter. Plasmid DNA 
and PEI solutions were then mixed at 1:1 ratio and incubated at room temperature for 20 
minutes. HEK293T cells were washed with Opti-MEM
®
 and 10ml of the plasmid DNA 
and PEI complexes were added to the cells. Cells were incubated at 37
o
C, 5% CO2 for 4 
hours and the medium was replaced with complete DMEM. The lentiviral supernatant 
was collected after 48 hours and filtered through a 0.45μm filter. The lentiviral 
supernatant were stored at -80
o
C in aliquots until use. 
3.3.5.3  Lentiviral transduction of NPC cells 
3x10
5
 HONE1 cells or 8x10
5
 C666-1 cells were seeded in 25cm
2
 flasks one day 
before the experiments and cultured until 60% confluence. Lentiviral supernatant was 
reconstituted with fresh RPMI medium at 1:1 ratio. Polybrene was added to the 
lentiviral supernatant at a final concentration of 7.5μg/ml. The lentivirus/polybrene 
mixture was added to cells and incubated at 37
o
C, 5% CO2 for 18 hours. Cells were then 
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cultured in fresh complete growth medium containing puromycin for a week to select 
stable transfectants. 
3.3.6 Knockdown of S1PR3 in SUNE1 cells 
SMARTpool ON-TARGETplus S1PR3 siRNA (LU-005208-00; Dharmacon, USA) 
and ON-TARGETplus non-targeting siRNA pool (Dharmacon, USA) were re-
suspended according to the manufacturer’s protocol. Briefly, 1x siRNA buffer 
(Dharmacon, USA) was added to the siRNAs to acquire a stock concentration of 20μM. 
The solution was mixed well and placed on an orbital shaker at room temperature for 30 
minutes. The tubes were briefly centrifuged and the siRNAs were aliquoted and stored 
at -80
o
C until use. 
3x10
5
 SUNE1 cells were seeded into 6-well plates one day before the experiments to 
reach a confluency of 60%. Transfection of cells was performed according to the 
manufacturer’s protocol. Briefly, siRNAs at desired concentrations and DharmaFECT 1 
transfection reagent (Dharmacon, USA) were diluted with serum-free medium 
separately and incubated at room temperature for 5 minutes. The diluted siRNAs were 
then mixed with the diluted DharmaFECT 1 transfection reagent and incubated at room 
temperature for 20 minutes. The mixture was added to cells and the cells were incubated 
at 37
o
C, 5% CO2 for 48-72 hours according to the experimental design. 
3.4 EBV infection 
Successful EBV infection of epithelial cells in vitro can be achieved through cell-to-
cell contact method by co-culturing epithelial cells with recombinant EBV-producing 
Akata cells (Chang et al., 1999; Imai et al., 1998). The recombinant EBV carries a 
neomycin resistance marker, allowing the selection of successfully infected cells (Imai 
et al., 1998). Two NPC cell lines (CNE1 and TW04) were selected to be stably infected 
with EBV based on their low levels of SPHK1 and S1PR3. Akata cells were cultured at 
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a density of 2x10
6
 cells/ml and treated with an anti-human IgG antibody (1:1000 
dilution; MP Biomedicals, USA) for 72 hours prior to co-culturing with the NPC cells. 
3x10
5
 NPC cells were seeded in 6-well plates one day before the experiments. 1.5x10
6
 
anti-IgG-treated Akata cells were added to NPC cells and co-cultivated for 3 days. The 
Akata cells were then removed and the NPC cells were washed with PBS. The NPC 
cells were grown in complete RPMI medium containing G418 (Biowest, France) for a 
week to select stable transfectants. 
3.5 In vitro assays 
3.5.1 Cell proliferation assays 
1 – 3x103 cells were seeded in 96-well plates and allowed to adhere overnight. For 
experiments investigating the effects of exogenous S1P, cells were serum-starved 
overnight and treated with a range of S1P concentrations (0 – 10μM) for a period of 2 
days. At the desired time point, MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrasodium bromide; 5mg/ml; Merck, Germany) was added to the cells and incubated 
for 4 hours, followed by the addition of 10% sodium dodecyl sulphate (SDS; Thermo 
Scientific, USA)/0.01M HCl. After overnight solubilisation of the formazan, cell viability 
was assessed by measuring the absorbance of the dissolved formazan solution at a 
wavelength of 575nm with a reference wavelength of 650nm using an Infinite 200 Pro 
NanoQuant microplate reader (Tecan, Switzerland). To generate kill curves of the 
pharmacological drugs, cells were treated with a range of drug concentrations (0 – 
10μM) for 24 hours. 
To determine the proliferation of EBV-infected cells, 2 – 3x104 cells were seeded in 
6-well plates and allowed to adhere overnight. Cells in triplicate wells were trypsinized 
and counted using a Luna automated cell counter as previously described (Section 3.3.2) 
every day for six consecutive days. The medium was changed every two days. 
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3.5.2 Transwell migration assays 
Transwell migration assays were performed using polycarbonate inserts (8μm pore 
size, Transwell, Corning, USA) coated with 10μg/ml fibronectin (Gibco Life 
Technologies, USA). 3x10
5
 cells were grown in a 75cm
2
 flask for two days until 80% 
confluence. Cells were serum-starved overnight, followed by treatment with 10μg/ml 
mitomycin C (Merck, Germany) for 2 hours to limit cell proliferation. Transwell inserts 
were placed in 24-well plates to create upper and lower chambers. For experiments 
using S1P, 5x10
4 
cells were re-suspended in 200μl migration buffer (RPMI medium 
containing 0.1% FBS and 0.25mg/ml FAFA) and seeded into the upper chambers; 500μl 
migration buffer containing S1P (0, 1 or 5μM) was added to the lower chambers. For 
experiments using pharmacological drugs, migration buffer containing the desired 
concentrations of the pharmacological drugs was added to both the upper and lower 
chambers of the Transwell inserts. For experiments using the EBV-infected cells, 5x10
4 
– 1x105 cells in 200μl RPMI medium containing 0.1% FBS were seeded into upper 
chambers and 500μl RPMI medium containing 10% FBS was added to the lower 
chambers. The cells were allowed to migrate for 19 hours and cells remained in the 
upper chambers were removed with cotton buds. Cells migrated through the membrane 
were stained with 0.1% crystal violet (Merck, Germany) in 20% methanol for 2 hours 
and counted in five random fields at 20X magnification. 
3.5.3 Transwell invasion assays 
Cell invasion assays were performed using polycarbonate inserts (8μm pore size, 
Transwell, Corning, USA) coated with 250μg/ml BD matrigel basement membrane 
matrix (BD Biosciences, USA). 3x10
5
 cells were grown in a 75cm
2
 flask for two days 
until 80% confluence. Cells were serum starved overnight and treated with 10μg/ml 
mitomycin C two hours prior to the experiments. For experiments using S1P, 8x10
4 
cells were re-suspended in 500μl migration buffer and seeded into the upper chambers; 
56 
750μl migration buffer containing S1P (0 or 5μM) was added to the lower chambers. 
For experiments using the EBV-infected cells, 2 – 4x105 cells in 500μl RPMI medium 
containing 0.1% FBS were seeded into upper chambers and 750μl RPMI medium 
containing 10% FBS was added to the lower chambers. After 48 hours of incubation, 
the non-invaded cells in the upper chambers were removed with a cotton swab and the 
invaded cells in the lower chambers were stained and counted as described above 
(Section 3.5.2).  
3.6 Molecular biology  
3.6.1 Total RNA isolation 
Cells were cultured until 60% confluence and the total RNA was extracted using an 
RNeasy
®
 mini kit (Qiagen, Germany) according to the manufacturer’s protocol. Briefly, 
cells were lysed and the lysate was homogenised using a QIAshredder spin column 
(Qiagen, Germany). 70% ethanol (Merck, Germany) was added to the flow-through and 
the mixture was loaded to an RNeasy
®
 spin column. After centrifugation, the spin 
column membrane was then washed with wash buffer and DNase I incubation mix 
(RNase-Free DNase Set; Qiagen, Germany) was applied directly to the spin column 
membrane. Following DNA digestion, wash buffer was added to the column and RNA 
was eluted in 50μl RNase-free water. The concentration of RNA was determined using 
a Nanodrop 2000 spectrophotometer (Thermo Scientific, USA). 
3.6.2 cDNA synthesis 
Single-stranded cDNA was synthesised using a High-Capacity cDNA Reverse 
Transcription kit (Applied Biosystems, USA) according to the manufacturer’s protocol. 
RNase-free water was added to 1μg of RNA to a final volume of 10μl. The reverse 
transcription master mix containing 2μl of 10X RT Random Primers, 2μl of 10X RT 
Buffer, 0.8μl of 100mM deoxyribonucleotide triphosphates (dNTP) mix, 1μl of 
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MultiScribe™ Reverse Transcriptase and 4.2μl RNase-free water was added to the 
RNA sample and mixed well. The tubes were briefly centrifuged and cDNA synthesis 
was carried out in a thermal cycler (Applied Biosystems, USA) using the following 
conditions: 25
o
C for 10 minutes, 37
o
C for 2 hours, 85
o
C for 5 minutes and hold at 4
o
C. 
3.6.3 Real time quantitative polymerase chain reaction (Q-PCR) 
FastStart Universal Probe Master (Rox) was purchased from Roche, Switzerland and 
the commercially available TaqMan
®
 Gene Expression Assays for SPHK1 
(Hs00184211_m1), S1PR1 (Hs01922614_s1), S1PR2 (A139R4J), S1PR3 
(Hs00245464_s1), S1PR4 (Hs02330084_s1), S1PR5 (Hs00928195_s1) and GAPDH 
(4326317E) were purchased from Applied Biosystems, USA. The primer and probe 
sequences of EBNA1, LMP1 and LMP2A (Table 3.2) were synthesised as previously 
described (Bell et al., 2006) and all probes were labelled with a FAM reporter dye at 5’ 
end and a TAMRA quencher dye at 3’ end. The synthesised cDNA was diluted using 
nuclease-free water (Gibco Life Technologies, USA) at a 1:20 ratio prior to the 
experiments. The reaction mixture for Q-PCR using commercially available TaqMan
®
 
Gene Expression Assays consisted of 5μl diluted cDNA, 10μl FastStart Universal 
Probe Master (Rox), 1μl TaqMan® Gene Expression Assay, 1μl human GAPDH 
primer/probe and 3μl nuclease-free water. The master mix for the detection of EBNA1, 
LMP1 and LMP2A gene expression consisted of 5μl diluted cDNA, 12.5μl FastStart 
Universal Probe Master (Rox), 2.5μl 5’ primer (3μM), 2.5μl 3’ primer (3μM), 1μl probe 
(5μM), 1μl human GAPDH primer/probe and 0.5μl nuclease-free water. The 
experiments were performed in triplicate for each reaction using an ABI 7500 Fast 
Real-Time PCR System (Applied Biosystems, USA). The data were analysed using the 
delta-delta Ct (ΔΔCt) method in the 7500 Software v2.0 (Applied Biosystems, USA) 
This method involves normalization of the sample cycle threshold (Ct) values against an 
endogenous control (ΔCt) and subsequently using this value relative to a selected 
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reference sample (corresponding to baseline value) to yield an absolute value of fold 
change. For analyses where reference samples were not applicable, normalized 
expression values were calculated using the following formula: 2
-ΔCt
. 
Table 3.2: Primer and probe sequences for EBNA1, LMP1 and LMP2A genes 
Gene Sequences 
EBNA1 
5’ primer     GTGCGCTACCGGATGGC 
3’ primer     CATGATTCACACTTAAAGGAGACGG 
Probe           TCCTCTGGAGCCTGACCTGTGATCG 
LMP1 
5’ primer     AATTTGCACGGACAGGCATT 
3’ primer     AAGGCCAAAAGCTGCCAGAT 
Probe           TCCAGATACCTAAGACAAGTAAGCACCCGAAGAT 
LMP2A 
5’ primer     CGGGATGACTCATCTCAACACATA 
3’ primer     GGCGGTCACAACGGTACTAACT 
Probe           CAGTATGCCTGCCTGTAATTGTTGCGC 
 
3.6.4 Plasmid Preparation 
3.6.4.1 Bacterial transformation and propagation 
Agar plates containing terrific broth (TB) (Fisher Scientific, USA), 1.5% agar (Fisher 
Scientific, USA) and 100μg/ml carbenicillin (Fisher Scientific, USA) were prepared and 
kept at 4
o
C one day before the experiments. For bacterial transformation, DH5α 
competent E. coli cells were taken from -80
o
C and thawed on ice. 300ng of the plasmid 
DNA was added to 40μl of the competent cells and the mixture was incubated on ice for 
30 minutes. Cells were heat shocked by placing in a thermomixer (Eppendorf, 
Germany) at 42
o
C for 45 seconds and returned to ice for 2 minutes. 260μl of TB was 
added to the cells and cultured in the thermomixer at 250rpm, 37
oC for 1 hour. 50μl of 
the transformed cells were plated on the agar plates and incubated overnight at 37
o
C. 
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The next day, a single colony of the bacterial culture was picked and grown in TB 
containing 100μg/ml carbenicillin overnight on an orbital shaker at 37oC. 
3.6.4.2 Purification of plasmid DNA 
Plasmid DNA was purified from the bacterial culture using a NucleoBond
®
 Xtra 
Midi kit (Macherey-Nagel, Germany) according to the manufacturer’s protocol. Briefly, 
bacterial cells were pelleted by centrifugation at 4500x g for 15 minutes and the 
supernatant was discarded. Cells were then lysed and the lysate was filtered through a 
NucleoBond
®
 Xtra Column. The eluate was collected in a 15ml tube and room 
temperature isopropanol was added to the eluate. The plasmid DNA/isopropanol 
mixture was filtered through a NucleoBond
®
 Finalizer and the precipitated plasmid 
DNA was bound to the filter membrane. The plasmid DNA was then washed with 70% 
ethanol, dried at room temperature for 5 minutes and eluted in 500μl of 5mM Tris/HCl 
buffer. Concentration of the plasmid DNA was measured using a NanoDrop 2000 
spectrophotometer. 
3.7 Western blotting 
3.7.1 Protein extraction 
Cells were grown in 100mm
2
 dishes or 6-well plates until 80% confluence. Cells 
were washed with PBS, scraped and pelleted by centrifugation at 10,000rpm for 1 
minute. Cells were then lysed in NP40 lysis buffer [150mM NaCl, 1% IGEPAL
®
 CA-
630 (Sigma-Aldrich, USA), 50mM Tris-HCl (pH8.0), Protease Inhibitor Cocktail Set III 
(Calbiochem, Germany) and Halt Phosphatase Inhibitor Cocktail (Thermo Scientific, 
USA)] on ice for 30 minutes, followed by centrifugation at 13,200rpm, 4
o
C for 30 
minutes. The protein lysates (supernatant) were transferred to chilled 1.5ml tubes and 
stored at -80
o
C.  
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3.7.2 Determination of protein concentration 
Protein concentration was determined using a Bradford Protein Assay kit (Bio-rad, 
USA) according to the manufacturer’s protocol. Bovine Serum Albumin (BSA) 
standard set (Bio-Rad, CA, USA), which consists of 7 different concentrations of BSA 
(0.125, 0.25, 0.5, 0.75, 1, 1.5 and 2mg/ml), was used to construct a standard curve. The 
harvested protein lysate was diluted 1:10 with PBS. 250μl of 1x dye reagent was added 
to 5μl of diluted protein samples, PBS and BSA standards in a 96-well plate and 
incubated at room temperature for 5 minutes. The absorbance was measured at 595nm 
using a microplate reader. Protein concentration of the samples was determined from 
the standard linear curve plotted using the BSA standards. 
3.7.3 Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
50μg protein lysate was mixed with 2x Laemmli sample buffer (Bio-rad, USA) 
containing 5% β-mercaptoethanol (Bio-basic, Canada) and boiled at 70oC for 10 
minutes. Bio-rad apparatus was used for SDS-PAGE. 10% resolving gel was prepared 
and poured into the gel cassettes. Once the gel had set, 4% stacking gel was prepared 
and poured on top of the resolving gel with a gel comb inserted. The gel comb was 
removed after the gel had solidified. The gel was placed in the electrophoresis tank 
containing 1x running buffer (Thermo Scientific, USA). The denatured protein lysate 
and 5μl of Precision Plus Protein All Blue standard (Bio-rad, USA) were loaded into the 
wells. The proteins were separated in the stacking gel at 80V for 20 minutes, followed 
by 110V for 1 hour in the resolving gel. 
3.7.4 Transferring and detection of protein 
Following electrophoresis, the separated proteins were transferred to a 
polyvinylidene difluoride (PVDF) membrane (0.45μm pore size; Merck Milipore, 
Germany). Prior to the transfer, the PVDF membrane was hydrated by soaking in 
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methanol for 15 seconds followed by 2 minutes in ultrapure water and 5 minutes in 1X 
TG Buffer (Bio-rad, USA) containing 20% methanol. Protein transfer was carried out 
using a Trans-Blot
®
 Turbo Transfer System (Bio-Rad, CA, USA) at 25V for 30 
minutes. The membrane was then blocked in 5% non-fat milk or 5% BSA (Bio-basic, 
Canada) in Tris-buffered Saline (TBS) [150mM NaCl, 50mM Tris-HCl (pH7.6)] with 
0.1% Tween-20 (TBST) for 1 hour at room temperature followed by incubation with 
primary antibodies overnight at 4
o
C. The following day, the PVDF membrane were 
washed three times for 5 minutes each in TBST prior to 1 hour incubation with 
horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG (1:5000; Sigma-Aldrich, 
USA) or goat anti-mouse IgG (1:5000; Sigma-Aldrich, USA) diluted in 5% non-fat 
milk/TBST at room temperature. After further washes in TBST (3 x 5 minutes) and a 5-
minute wash in TBS, the membrane was incubated with WesternBright Sirius enhanced 
chemiluminescene (ECL) reagent (Advansta, USA) and the target proteins were 
visualised using an Odyssey Fc Imaging System (LI-COR Biosciences, USA). The list 
of primary antibodies and the conditions used are listed in Table 3.3. 
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Table 3.3: List of primary antibodies for western blotting 
Antibody Species Dilution Blocking Buffer Manufacturer 
Anti-phospho-
SPHK1 (Ser 225) 
Rabbit 
polyclonal 
1:1000 
5% non-fat 
milk/TBST 
ECM Biosciences, 
USA 
Anti-total 
SPHK1 
Rabbit 
polyclonal 
1:1000 5% BSA/TBST 
Cell Signaling 
Technology, USA 
Anti-phospho-
AKT (Ser473) 
Rabbit 
polyclonal 
1:1000 5% BSA/TBST 
Cell Signaling 
Technology, USA 
Anti-total AKT 
Rabbit 
polyclonal 
1:1000 5% BSA/TBST 
Cell Signaling 
Technology, USA 
Anti-phospho-
p44/42 MAPK 
(ERK1/2) 
Rabbit 
polyclonal 
1:1000 5% BSA/TBST 
Cell Signaling 
Technology, USA 
Anti-total p44/42 
MAPK (ERK1/2) 
Rabbit 
polyclonal 
1:1000 5% BSA/TBST 
Cell Signaling 
Technology, USA 
Anti-α-tubulin 
Mouse 
monoclonal 
1:10000 
5% non-fat 
milk/TBST 
Sigma-Aldrich, USA 
Anti-β-actin 
Mouse 
monoclonal 
1:5000 
5% non-fat 
milk/TBST 
Sigma-Aldrich, USA 
 
3.8 Immunofluorescence  
Shandon multi-spot slides (Thermo Scientific, USA) were coated with 10μg/ml 
fibronectin overnight at 4
o
C. Fibronectin was removed from the slide and 1.5 – 2x104 
cells were seeded onto each spot of the slides and allowed to adhere overnight at 37
o
C. 
The following day, cells were washed with PBS gently and fixed with 100% ice-cold 
methanol for 15 minutes. The fixed cells were rinsed 3 times with PBS and blocked 
with 20% heat-inactivated normal goat serum (HINGS) diluted in PBS for 1 hour at 
room temperature. Primary antibodies [rabbit anti-EBNA1 (R4 rabbit serum; 1:1000; 
gift from Dr Christopher Dawson); mouse anti-LMP1 (1:50; Dako, Denmark); human 
anti-LMP2 (human NPC reference serum SK; 1:100; gift from Dr Christopher 
Dawson)] diluted in 20% HINGS/PBS were applied to the cells and incubated overnight 
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at 4
o
C. Following 4 washes of 15 minutes each in PBS, the cells were incubated with 
AlexaFluor 488-conjugated goat anti-rabbit, anti-mouse or anti-human IgG (1:1000; 
Molecular Probes, USA) in 20% HINGS/PBS for 1 hour at room temperature. The cells 
were further washed in PBS (4 x 15 minutes) and mounted with 1,4-
diazabicyclo[2.2.2]octane (DABCO) anti-fading agent for visualisation under a 
fluorescence microscope. 
3.9 Statistical analysis 
The data presented were representative of the experiments performed in triplicate. 
All the statistical analyses were carried out using GraphPad PRISM 5.0 software 
(GraphPad, USA). For Q-PCR analyses and in vitro assays, statistical differences 
between experimental groups were evaluated by Student’s t-test or one-way analysis of 
variance (ANOVA)/Dunnett’s test. Spearman’s correlation was performed to examine 
the relationship between SPHK1 and S1PR3 in EBV-infected cells. p values <0.05 were 
considered as statistically significant. 
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CHAPTER 4:  
THE PHENOTYPIC IMPACT OF EXOGENOUS S1P AND SPHK1 
KNOCKDOWN ON NPC CELLS 
4.1 Introduction 
S1P is produced from sphingosine by sphingosine kinases (SPHK1 or SPHK2) and 
sphingosine is generated from ceramide by ceramidase. S1P is reversibly de-
phosphorylated to sphingosine by S1P phosphatase or irreversibly converted to 
hexadecenal and ethanolamine phosphate by S1P lyase (Leong et al., 2010). The 
balance between the levels of ceramide/sphingosine and S1P, termed sphingolipid 
rheostat, determines the cell fate. High levels of ceramide and sphingosine have been 
shown to exhibit anti-proliferative and pro-apoptotic effects in cancer cells (Pyne et al., 
2010). In contrast, the accumulation of S1P promotes cancer cell growth, survival, 
migration, invasion and angiogenesis (Takabe et al., 2014). 
The accumulation of S1P during carcinogenesis can often be attributed to the 
aberrant activation of SPHK1. SPHK1 is activated and then translocates to the plasma 
membrane through interaction with CIB1 to generate S1P (Jarman et al., 2010). 
Accumulating evidence has shown that high expression of SPHK1 increased cell 
proliferation, survival and motility in various types of malignancies, such as cancers of 
colon, breast, kidney, ovary and lung (Shida et al., 2008b). Overexpression of SPHK1 
has recently been reported in NPC and was related to poor patient survival (Li et al., 
2015b). However, the functional roles of SPHK1 and S1P in the pathogenesis of NPC 
have not been studied.  
The work in this chapter aimed to determine the phenotypic consequences of 
exogenous S1P and SPHK1 knockdown on NPC cells in vitro. The mechanisms 
associated with the phenotypic changes were also explored. 
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4.2 Effects of S1P on the phenotypes of NPC cells 
To determine whether S1P affects the malignant phenotype of NPC cells, three 
different assays of cell behaviour were performed to examine cell proliferation, 
migration and invasion.  
4.2.1 Cell proliferation 
Four NPC cell lines, CNE1, HK1, HONE1 and TW04, were treated with a range of 
S1P concentrations (0.5, 1, 2.5, 5 and 10μM) and cell growth was measured by MTT 
assays. Since FBS contains S1P, the experiments were performed either in serum-free 
conditions or in media containing 0.1% or 0.5% FBS for 24 hours and 48 hours. 
Although there were some variations in the responses to S1P among the cell lines, in 
general, S1P inhibited the proliferation of all four cell lines examined irrespective of the 
serum concentrations (Figure 4.1). 
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Figure 4.1: S1P inhibited the proliferation of NPC cells  
The growth of (A) CNE1, (B) HK1, (C) HONE1 and (D) TW04 cells was examined in the absence or presence of FBS (0.1% or 0.5%) following S1P 
treatment at various concentrations (0, 0.5, 1, 2.5, 5 and 10μM) for 24 and 48 hours. In general, exogenous addition of S1P significantly reduced the 
growth of all four NPC cell lines. The data presented are representative of three independent experiments. *** denotes p<0.001, ** denotes p<0.01, * 
denotes p<0.05. 
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Figure 4.1, continued 
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4.2.2 Cell migration 
Three NPC cell lines, TW04, HONE1 and SUNE1, were used to determine the effect 
of S1P on the migratory ability of NPC cells. Transwell migration assays with 
fibronectin-coated membranes were performed in the absence or presence of S1P (1μM 
or 5μM) in the lower chamber. Following addition of 1μM S1P, the migration of TW04, 
HONE1 and SUNE1 cells increased by 67%, 74% and 41%, respectively, compared to 
the controls. The migration of these cells was further increased by approximately 80% 
following addition of 5μM S1P (p<0.001; Figure 4.2). These results showed that S1P 
significantly promoted the migration of NPC cells in vitro. 
4.2.3 Cell invasion 
Given that cancer metastasis involves cell migration and invasion, transwell invasion 
assays were performed in a NPC cell line to determine whether S1P could also promote 
cell invasion in vitro. SUNE1 cells were treated with 5μM S1P and their invasive ability 
was measured using matrigel-coated Transwells. The results showed that S1P markedly 
enhanced the invasion of SUNE1 cells compared to the controls (p<0.001; Figure 4.3).  
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Figure 4.3: S1P increased NPC cell invasion 
The invasive ability of SUNE1 cells was examined using matrigel-coated Transwell 
assays in the absence or presence of S1P (5μM). S1P markedly enhanced the invasion 
of SUNE1 cells. The data presented are representative of two independent experiments. 
*** denotes p<0.001. 
  
 
 
Figure 4.2: S1P promoted NPC cell migration 
The migration of TW04, HONE1 and SUNE1 cells was examined using Transwell 
assays in the absence or presence of S1P (1 or 5μM). S1P significantly enhanced the 
migration of the three cell lines examined. The data presented are representative of two 
independent experiments. *** denotes p<0.001. 
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4.3 Biological significance of SPHK1 knockdown on NPC cell behaviour 
Having shown that S1P influenced the phenotypes of NPC cells, I next examined 
whether knockdown of SPHK1, the key enzyme that produces S1P, would produce the 
opposite effects on cell proliferation and migration as the addition of exogenous S1P.  
4.3.1 Validation of anti-SPHK1 antibodies 
In order to determine the levels of SPHK1 protein in the NPC cells, two antibodies 
against SPHK1 were used: anti-phospho-SPHK1 antibody that only detects SPHK1 
protein when it is phosphorylated at Ser225 and anti-total SPHK1 antibody that detects 
both the phosphorylated and non-phosphorylated forms of SPHK1 proteins. The 
specificity of the two antibodies was validated in HEK293 cells transfected with a 
vector that expressed the coding region of SPHK1 (pCMV6_XL4/SPHK1). Compared 
to the vector control (pCMV6_XL4), in western blots, a distinct band at 45kDa 
corresponding to the predicted molecular weight of SPHK1 protein was detected in 
HEK293 cells transfected with pCMV6_XL4/SPHK1, confirming that both antibodies 
were specific (Figure 4.4). 
4.3.2 Expression of SPHK1 in NPC cell lines  
 To select cell lines for SPHK1 knockdown, I first compared the expression of 
SPHK1 in eight NPC cell lines with that in the immortalized nasopharyngeal cell line, 
NP69. The expression of SPHK1 mRNA was significantly higher in three NPC cell 
lines (C666-1, HONE1 and TW01) (p<0.001; Figure 4.5), and an increase in the total 
SPHK1 protein was also observed in the two cell lines (C666-1 and HONE1) that 
expressed the highest levels of SPHK1 transcript (p<0.05; Figure 4.6).   
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Figure 4.4: Validation of the specificity of antibodies against phosphorylated 
SPHK1 (Ser225) and total SPHK1 proteins 
Western blot analyses of HEK293 cells transfected with pCMV6_XL4/SPHK1 showed 
a distinct band corresponding to the predicted molecular weight of SPHK1 (45kDa), 
confirming the specificity of the antibodies. Representative western blot images of two 
independent experiments are presented. 
 
 
 
 
Figure 4.5: SPHK1 mRNA expression in NPC cell lines  
Q-PCR analyses showed that compared to the immortalised nasopharyngeal epithelial 
cell line NP69, three NPC cell lines (C666-1, HONE1 and TW01) expressed 
significantly higher levels of SPHK1 mRNA. The data presented are representative of 
two independent experiments. *** denotes p<0.001.  
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Figure 4.6: SPHK1 protein expression in NPC cell lines  
Western blot analyses showed that C666-1 and HONE1 cells had higher protein levels 
of total SPHK1 compared to NP69. The densitometric data are expressed as the mean 
relative density (normalised to β-actin) ±SD from two independent experiments. ** 
denotes p<0.01, * denotes p<0.05. 
 
  
C
66
6-
1
C
N
E
1
C
N
E
2
H
K
1
H
O
N
E
1
SU
N
E1
TW
01
TW
04
N
P6
9
0
1
2
3
4
5 **
*
R
e
la
ti
v
e
 D
e
n
s
it
y
(T
o
ta
l 
S
P
H
K
1
 /

-a
c
ti
n
)
73 
4.3.3 Knockdown of SPHK1 in C666-1 and HONE1 cells 
Two NPC cell lines, C666-1 and HONE1, were selected to perform the knockdown 
experiments based on their high levels of SPHK1. C666-1 and HONE1 cells were stably 
transduced with plasmids carrying two independent sequences of SPHK1 shRNAs 
(shSPHK1_S1 and shSPHK1_S2) or a non-targeting shRNA sequence (NS). Compared 
to NS, the SPHK1 mRNA levels in C666-1/shSPHK1_S1 and C666-1/shSPHK1_S2 
were reduced by approximately 40% whereas the SPHK1 mRNA levels in 
HONE1/shSPHK1_S1 and HONE1/shSPHK1_S2 were reduced by 62% and 93%, 
respectively (p<0.001; Figure 4.7). In agreement with these data, knockdown of SPHK1 
which would reduce the levels of endogenous S1P, also led to a decrease in both the 
phosphorylated and total SPHK1 proteins (Figure 4.8). The knockdown also appeared to 
be specific for SPHK1 with no noticeable effect on α-tubulin levels. These results 
showed that shSPHK1_S2 produced a more efficient knockdown compared to 
shSPHK1_S1 in both cell lines and based on the mRNA levels, the knockdown of 
SPHK1 appeared to be more effective in HONE1 cells. Given that C666-1 cells do not 
exhibit the ability to migrate in response to S1P under serum-free conditions, only 
HONE1 cells were used for the subsequent experiments. 
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Figure 4.8: SPHK1 protein levels following SPHK1 knockdown in C666-1 and 
HONE1 cells 
Western blot analyses showed that the levels of both phospho-SPHK1 and total SPHK1 
proteins were decreased in (A) C666-1 and (B) HONE1 cells following SPHK1 
knockdown. The densitometric data are expressed as the mean relative density 
(normalised to α-tubulin) ±SD from three independent experiments. *** denotes 
p<0.001, ** denotes p<0.01, * denotes p<0.05. 
 
Figure 4.7: SPHK1 mRNA expression in C666-1 and HONE1 cells following 
knockdown of SPHK1  
C666-1 and HONE1 cells were stably transduced with plasmids carrying two 
independent sequences of SPHK1 shRNAs (shSPHK1_S1 and shSPHK1_S2) or the 
non-targeting shRNA sequence (NS). Compared to NS, knockdown of SPHK1 in C666-
1 and HONE1 cells resulted in approximately 40% and 62%-93% reduction of SPHK1, 
respectively.   The data presented are representative of two independent experiments. 
*** denotes p<0.001.  
A) B) 
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4.3.4  Effect of SPHK1 knockdown on cell proliferation 
The consequence of SPHK1 knockdown on the growth of HONE1 cells was 
determined using MTT assays over a period of 5 days. Compared to the controls, 
knockdown of SPHK1 significantly inhibited the growth of HONE1 cells from the third 
day onwards (p<0.001; Figure 4.9). As knockdown of SPHK1 would likely result in 
reduced levels of S1P, these data were unexpected because exogenous addition of S1P 
was previously shown to suppress the growth of NPC cells, including HONE1 cells 
(Figure 4.1). These contradictory results are discussed in chapter 7. 
4.3.5 Effect of SPHK1 knockdown on cell migration 
 Transwell migration assays were performed to determine the migratory ability of 
HONE1 cells following SPHK1 knockdown. Compared to HONE1/NS cells, SPHK1 
knockdown significantly suppressed the migration of HONE1/shSPHK1_S1 and 
HONE1/shSPHK1_S2 cells by 36% and 61%, respectively (p<0.001; Figure 4.10). 
These data were in agreement with the results obtained previously that addition of S1P 
enhanced the migration of NPC cells (Figure 4.2). 
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Figure 4.9: Knockdown of SPHK1 decreased NPC cell proliferation 
Following SPHK1 knockdown, HONE1 cells grew slower compared to the controls. 
The data presented are representative of two independent experiments (error bars are too 
small to be visible). *** denotes p<0.001. 
 
 
 
 
Figure 4.10: Knockdown of SPHK1 inhibited NPC cell migration 
The effect of SPHK1 knockdown on the migration of NPC cells was examined using 
Transwell assays in the presence of 10% FBS in the lower chambers. Compared to 
HONE1/NS, knockdown of SPHK1 significantly inhibited the migration of HONE1 
cells. The data presented are representative of three independent experiments. *** 
denotes p<0.001. 
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4.4 Activation of AKT and ERK pathways by S1P  
Next, I investigated the downstream signalling pathways that were activated by S1P 
in NPC cells. AKT and ERK signalling pathways were chosen because they represent 
two main downstream targets of S1P signalling (Pyne et al., 2010) and are also 
frequently activated in NPC (Tulalamba et al., 2012). The activation of AKT and ERK 
signalling was determined by measuring the levels of phosphorylated AKT (phospho-
AKT) and phosphorylated ERK (phospho-ERK), respectively. 
Following exogenous addition of S1P, the levels of phospho-AKT and phospho-ERK 
proteins were examined in two NPC cell lines, HONE1 and TW04. Western blot 
analyses showed that the levels of phospho-AKT were increased in HONE1 and TW04 
cells following S1P treatment (Figure 4.11). The phosphorylation of ERK was also 
found to be stimulated in HONE1 and TW04 cells by S1P treatment (Figure 4.12). 
These results suggested that both the AKT and ERK signalling pathways were activated 
in response to exogenous S1P in NPC cells. The levels of both total AKT and total ERK 
proteins in these two cell lines were unaffected by S1P treatment, implying that S1P did 
not modulate the translation process of AKT and ERK.  
To further confirm that the AKT and ERK pathways are targets of the S1P signalling 
cascade, the levels of phospho-AKT and phospho-ERK were determined in HONE1 
cells following SPHK1 knockdown. Western blot analyses demonstrated that 
knockdown of SPHK1 inhibited the phosphorylation of AKT in HONE1 cells, but not 
the levels of total AKT protein (p<0.05; Figure 4.13). In contrast, the levels of phospho-
ERK and total ERK proteins remained unchanged in these cells (Figure 4.14). Given 
that knockdown of endogenous SPHK1 appeared to only suppress the activation of 
AKT, subsequent experiments were focused on the involvement of AKT signalling in 
S1P-mediated migration of NPC cells. 
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Figure 4.11: S1P activated AKT signalling in NPC cells 
Compared to the untreated controls, the levels of phospho-AKT were increased in 
HONE1 cells at 30 minutes following treatment with 5μM S1P and remained activated 
at 60 minutes whereas the phosphorylation of AKT in TW04 cells was only observed at 
60 minutes post-S1P treatment. Representative western blot images of three 
independent experiments are presented. 
 
 
Figure 4.12: S1P activated ERK signalling in NPC cells 
HONE1 and TW04 cells showed increased levels of phospho-ERK 15 minutes and 30 
minutes following exogenous addition of 5μM S1P, respectively, compared to the 
untreated controls. The activation of ERK remained in both cell lines at 60 minutes 
post-S1P treatment. Representative western blot images of three independent 
experiments are presented. 
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Figure 4.13: Knockdown of SPHK1 in HONE1 cells suppressed the activation of 
AKT 
Compared to the HONE1/NS, knockdown of SPHK1 reduced the levels of phospho-
AKT, but not the total AKT proteins in HONE1 cells. The densitometric data are 
expressed as the mean relative density (normalised to α-tubulin) ±SD from three 
independent experiments ** denotes p<0.01, * denotes p<0.05. 
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Figure 4.14: Knockdown of SPHK1 in HONE1 cells did not affect the expression 
and activation of ERK 
Both the phosphorylated and total ERK proteins in HONE1 cells remained unchanged 
following knockdown of SPHK1. The densitometric data are expressed as the mean 
relative density (normalised to α-tubulin) ±SD from three independent experiments. 
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4.5 Involvement of AKT signalling in S1P-induced migration 
4.5.1 Establishment of LY294002 kill curves 
To investigate whether S1P induced NPC cell migration through the activation of 
AKT, HONE1 and SUNE1 cells were treated with a PI3K/AKT inhibitor, LY294002. 
Dose response experiments (LY294002, 0.5 – 10μM) in HONE1 and SUNE1 cells 
showed that 1μM LY294002 did not affect cell viability (Figure 4.15) but significantly 
reduced phospho-AKT levels in SUNE1 cells (Figure 4.16).  
4.5.2 Effect of LY294002 treatment on S1P-induced migration   
As shown in Figure 4.17, addition of S1P markedly increased the migration of 
HONE1 and SUNE1 cells. Treatment with LY294002 alone had no effect on the 
migration of both cell lines. In the presence of S1P, the migration of HONE1 and 
SUNE1 cells was reduced by approximately 50% compared to their respective controls 
following LY294002 treatment. These data suggested the involvement of AKT 
signalling in S1P-induced migration.   
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Figure 4.16: LY294002 treatment in SUNE1 cells inhibited the activation of AKT 
Western blot analyses demonstrated that treatment with 1μM LY294002 decreased the 
levels of phospho-AKT in SUNE1 cells. Representative western blot images of two 
independent experiments are shown. 
 
  
 
 
 
Figure 4.15: NPC cell viability following LY294002 treatment 
MTT cell viability assays were used to assess the viability of cells following treatment 
with LY294002 (0 - 10μM). Concentrations of LY294002 above 1μM were cytotoxic 
and reduced cell viability.  The data presented are representative of two independent 
experiments. *** denotes p<0.001, ** denotes p<0.01. 
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Figure 4.17: Inhibition of AKT suppressed S1P-induced NPC cell migration 
The migration of HONE1 and SUNE1 cells were examined using Transwell assays in 
the absence or presence of S1P (5μM) and/or LY294002 (1μM). In the presence of S1P, 
the migration of both cell lines was significantly inhibited following treatment with 
LY294002. The data presented are representative of two independent experiments. *** 
denotes p<0.001. 
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4.5.3 Expression of constitutively active AKT reverses the anti-migratory effects of 
SPHK1 knockdown in NPC cells 
Having shown that knockdown of SPHK1 inhibited the activation of AKT in 
HONE1 cells, rescue experiments were carried out to determine whether expression of a 
constitutively active AKT could reverse the suppressive effect of SPHK1 knockdown 
on cell migration. Western blot analyses confirmed the expression of phospho-AKT in 
HONE1 following the transfection of a constitutively active AKT (Figure 4.18). While 
SPHK1 knockdown significantly suppressed the migration of HONE1 cells, the 
expression of constitutively active AKT led to an increase in the migration of SPHK1-
knockdown cells by approximately 20% (p<0.001; Figure 4.19). These results supported 
previous observations that S1P induced the migration of NPC cells through the 
activation of AKT (Figure 4.17). 
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Figure 4.18: Expression of phospho-AKT protein following transfection of a 
constitutively active AKT  
Western blot analyses confirmed the expression of phospho-AKT in SPHK1-
knockdown HONE1 cells following the transfection of a constitutively active AKT 
construct. Representative western blot images of two independent experiments are 
presented. 
 
 
 
 
 
 
 
Figure 4.19: Expression of constitutively active AKT rescued the suppressive effect 
of SPHK1 knockdown on HONE1 cell migration 
SPHK1-knockdown HONE1 cells were transfected with a constitutively active AKT 
and the migratory ability was determined using Transwell assays in the presence of 10% 
FBS. Expression of a constitutively active AKT restored the migration of SPHK1-
knockdown HONE1 cells. The data presented are representative of two independent 
experiments. *** denotes p<0.001. 
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4.6 Summary 
In this chapter, the effects of S1P on the behaviour of NPC cells were investigated 
using assays of cell proliferation, migration and invasion. Although exogenous S1P 
reduced NPC cell proliferation, it significantly promoted the migration and invasion of 
NPC cells.  
High expression of SPHK1 in tumour cells is predicted to result in elevated levels of 
S1P. Therefore, to determine whether endogenous SPHK1 has a similar effect on cell 
migration and proliferation as the addition of S1P, knockdown of SPHK1 in C666-1 and 
HONE1 cells was performed using two shRNA sequences. Since the knockdown was 
more effective in HONE1 cells and they retained the ability to migrate in response to 
S1P under serum-free conditions, only this cell line was used in the subsequent 
experiments. In agreement with the previous results that S1P enhanced NPC cell 
migration, knockdown of SPHK1 resulted in decreased migration of HONE1 cells. 
However, while treatment of cells with S1P reduced cell proliferation, knockdown of 
SPHK1 also inhibited the growth of HONE1 cells. 
Next, the downstream targets of S1P signalling in NPC cells were examined. 
Western blot analyses showed that S1P induced the phosphorylation of AKT and ERK 
in HONE1 and TW04 cells. However, knockdown of SPHK1 in HONE1 cells reduced 
only the phosphorylated levels of AKT, but not ERK. The involvement of AKT 
signalling in S1P-induced migration was further explored using the PI3K/AKT 
inhibitor, LY294002. Treatment of HONE1 and SUNE1 cells with LY294002 
significantly suppressed S1P-induced migration. In agreement with these data, 
expression of a constitutively active AKT was able to rescue the suppressive effect of 
SPHK1 knockdown on HONE1 cell migration. Collectively, these results demonstrate 
that S1P induced the migration of NPC cells via the activation of AKT. 
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CHAPTER 5:   
IDENTIFICATION OF THE S1P RECEPTORS THAT MEDIATE S1P-
INDUCED MIGRATION IN NPC 
5.1 Introduction 
S1P is produced in the cytoplasm and transported out from the cells by various 
transporter proteins, including ABCA1, ABCC1, ABCG2 and SPNS2 (Takabe et al., 
2014). Extracellular S1P binds to one or more of its five S1P receptors, S1PR1-5, in a 
paracrine or autocrine manner, to trigger several signalling pathways such as 
PI3K/AKT, ERK and JNK (Rosen et al., 2009; Takabe et al., 2008). This process is 
referred to as “inside-out” signalling (Spiegel et al., 2011).  
The oncogenic effects of S1P have been suggested to be a consequence of alterations 
in the expression or function of the S1P receptors (Blaho et al., 2014). S1PR1 and 
S1PR3 promote cancer progression by increasing cell growth, survival, angiogenesis, 
migration, invasion and chemotherapeutic drug resistance (Pyne et al., 2012; Watters et 
al., 2011). S1PR2 is generally considered as a tumour suppressor that inhibits cell 
proliferation, motility and angiogenesis (Takuwa et al., 2011), but accumulating 
evidence also shows that it can exhibit tumour-promoting effects by increasing cell 
growth, survival, migration and invasion (Adada et al., 2013; Patmanathan et al., 2016). 
The functional properties of S1PR4 and S1PR5 in cancer development remain largely 
unclear. 
In this chapter, I identified which S1PR(s) were responsible for the S1P-mediated 
NPC cell migration described in the previous chapter.  
5.2 Expression of S1PRs in NPC primary tissues and cell lines 
Two published microarray datasets, GSE12452 (Sengupta et al., 2006) and 
GSE34573 (Hu et al., 2012) that compared the expression profiles of micro-dissected 
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NPC tissues and non-malignant nasopharyngeal epithelium were re-analysed by Dr 
Wenbin Wei (University of Birmingham, UK) to determine the expression of five 
S1PRs in NPC primary tissues. The GSE12452 dataset consists of 31 NPC samples and 
10 non-malignant controls, whereas the GSE34572 dataset comprises of 15 NPC 
samples and 3 non-malignant controls. The analyses showed that only S1PR3 was 
significantly and consistently overexpressed in NPC in both datasets, with an increase 
of 1.7- and 4-fold in GSE12452 and GSE34573, respectively (p<0.05, Figure 5.1). 
Upregulation of S1PR2 and S1PR5 in NPC was only evident in GSE12452 with a fold 
change of 1.2 (p<0.05) and 1.7 (p<0.01), respectively.   
Q-PCR analyses were used to determine the expression of all five S1PRs in a panel 
of NPC cell lines. The results showed that the expression of S1PR2 and S1PR5 were 
readily detected in all the eight NPC cell lines examined while the levels of S1PR3 
varied (Figure 5.2). Although there were some variations in the expression of S1PR1 
and S1PR4, NPC cell lines generally expressed low levels of S1PR1 and S1PR4 
compared to other S1PRs. Given that the reagents to study S1PR5 are limited, S1PR2 
and S1PR3 were selected as the candidate receptors for subsequent experiments.  
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Figure 5.1: Expression of S1PR2, S1PR3 and S1PR5 in NPC primary tissues 
Re-analyses of the GSE12452 and GSE34572 microarray datasets showed that S1PR3 (A) was over-expressed in micro-dissected primary NPC tissues 
compared to nasopharyngeal epithelium in both datasets, whereas overexpression of S1PR2 (B) and S1PR5 (C) was only evident in the GSE12452 
dataset. 
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Figure 5.2: Expression profile of S1PRs in NPC cell lines 
Q-PCR analyses showed that the expression of S1PR2 and S1PR5 were readily detected in all eight NPC cell lines, (A) C666-1, (B) CNE1, (C) CNE2, 
(D) HK1, (E) HONE1, (F) SUNE1, (G) TW01 and (H) TW04 while the expression of S1PR3 varied and the levels of S1PR1 and S1PR4 were 
generally low. The data presented are representative of two independent experiments. 
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Figure 5.2, continued 
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5.3 Involvement of S1PR2 and S1PR3 in S1P-induced migration 
To determine the roles of S1PR2 and S1PR3 in S1P-mediated migration, several 
pharmacological reagents targeting these receptors were used.  
5.3.1 JTE-013 
JTE-013 is a S1PR2/S1PR4 antagonist that inhibits the binding of S1P to S1PR2 
and/or S1PR4 (Long et al., 2010b; Ohmori et al., 2003). Kill curves of JTE-013 in 
HONE1 and SUNE1 cells were generated using MTT cell viability assays following 
treatment with JTE-013 (0.1 – 10μM) for 24 hours. The results showed JTE-013 was 
not cytotoxic at any of the concentrations tested (Figure 5.3); 1μM JTE-013 was 
selected for subsequent migration assays because this is the most commonly used 
concentration in published studies (Salomone et al., 2011).  
The migratory ability of HONE1 and SUNE1 cells following JTE-013 treatment was 
examined using Transwell migration assays with fibronectin-coated membranes. 
Compared to the vehicle controls, addition of JTE-013 alone did not affect the migration 
of either cell line (Figure 5.4). However, in the presence of S1P, treatment with JTE-013 
significantly inhibited the migration of HONE1 and SUNE1 cells by 16% and 39%, 
respectively (p<0.001). These results suggested that S1PR2 might play a role in S1P-
induced migration of NPC cells. 
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Figure 5.3: NPC cell viability following treatment with JTE-013 (a S1PR2/S1PR4 
antagonist) 
Viability of HONE1 and SUNE1 cells following JTE-013 treatment was determined by 
MTT assays. Treatment with up to 10μM JTE-013 did not affect the viability of either 
cell line. The data presented are representative of two independent experiments (error 
bars for most of the concentrations are too small to be visible). 
 
 
 
 
 
Figure 5.4: Inhibition of S1PR2 suppressed S1P-induced migration of NPC cells 
The migration of HONE1 and SUNE1 cells was examined using Transwell assays in the 
absence or presence of S1P (5μM) and/or JTE-013 (1μM). Similar to the previous 
results (Figure 4.2), S1P increased the migration of HONE1 and SUNE1 cells and these 
effects were significantly suppressed by JTE-013. The data presented are representative 
of two independent experiments. *** denotes p<0.0001.  
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5.3.2 CYM-5478 
Having shown that JTE-013 inhibited S1P-induced migration of HONE1 and SUNE1 
cells, the role of S1PR2 on NPC cell migration was further explored using a S1PR2 
allosteric agonist, CYM-5478. CYM-5478 does not compete with JTE-013 for binding 
to S1PR2 and the responses triggered by CYM-5478 can be inhibited by JTE-013 (Herr 
et al., 2016; Satsu et al., 2013). Since HONE1 and SUNE1 cells expressed similar 
levels of S1PR2 (Figure 5.2), only SUNE1 cells were used in these experiments. 
SUNE1 cells were treated with CYM-5478 (1 – 10μM) for 24 hours and none of these 
concentrations was shown to be cytotoxic to the cells (Figure 5.5). Therefore, 10μM 
CYM-5478 was chosen for subsequent experiments as this concentration has previously 
been shown to activate S1PR2 effectively in cell-based assays (Herr et al., 2016). 
While S1P significantly increased the migration of SUNE1 cells as previously 
shown, treatment with CYM-5478 did not affect their migratory ability (Figure 5.6). 
These results were contrasted with the previous observations that HONE1 and SUNE1 
cells showed decreased migration following JTE-013 treatment (Figure 5.4), suggesting 
that S1PR2 might not be the primary receptor involved in S1P-mediated migration of 
NPC cells.   
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Figure 5.5: NPC cell viability following treatment with CYM-5478 (a S1PR2 
agonist) 
Treatment of SUNE1 cells with CYM-5478 did not affect cell viability. The data 
presented are representative of two independent experiments. 
 
 
 
 
Figure 5.6: Activation of S1PR2 did not increase the migration of SUNE1 cells 
The migration of SUNE1 cells was determined using Transwell assays in the absence or 
presence of S1P (5μM) or CYM-5478 (10μM). While S1P markedly enhanced the 
migration of SUNE1 cells, no effect was observed following treatment with CYM-5478. 
The data presented are representative of three independent experiments. *** denotes 
p<0.0001, ns denotes not significant. 
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5.3.3 VPC23019 
To investigate the contribution of S1PR3 to S1P-induced NPC cell migration, NPC 
cells were treated with a S1PR1/S1PR3 antagonist, VPC23019. VPC23019 acts as a 
competitive inhibitor of S1P binding to S1PR1 and/or S1PR3 (Davis et al., 2005). The 
cytotoxicity of VPC23019 in HONE1 and SUNE1 cells was determined by MTT 
assays. Both cell lines were treated with VPC23019 (1 – 10μM) for 24 hours, and the 
results showed that concentrations up to 8μM did not affect the viability of these cells 
(Figure 5.7). 5μM VPC23019 was selected for subsequent migration assays as this 
concentration has been shown to effectively block the migration of cancer cells such as 
ovarian cancer, thyroid cancer and hepatocellular carcinoma (Balthasar et al., 2006; Bao 
et al., 2012; Park et al., 2007). 
As shown in Figure 5.8, treatment with VPC23019 alone did not affect the migration 
of HONE1 and SUNE1 cells in the absence of S1P. However, in the presence of S1P, 
VPC23019 treatment significantly reduced the migration of HONE1 and SUNE1 cells 
by 63% and 52%, respectively (p<0.001). These results suggested that S1PR1 and/or 
S1PR3 might involve in the S1P-induced migration of NPC cells. 
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Figure 5.7: NPC cell viability following treatment with VPC23019 (a S1PR1/S1PR3 
antagonist) 
MTT assays showed that treatment with up to 8μM VPC23019 did not affect the 
viability of HONE1 and SUNE1 cells. The data presented are representative of two 
independent experiments. * denotes p<0.05, *** denotes p<0.0001. 
 
 
 
 
Figure 5.8: Inhibition of S1PR1 and/or S1PR3 suppressed NPC cell migration 
The migration of HONE1 and SUNE1 cells was examined using Transwell assays in the 
absence or presence of S1P (5μM) and/or VPC23019 (5μM). Addition of S1P increased 
the migration of HONE1 and SUNE1 cells and these effects were significantly 
suppressed following treatment with VPC23019. The data presented are representative 
of two independent experiments. *** denotes p<0.0001. 
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5.4 Contribution of S1PR3 to S1P-induced migration 
To further explore the contribution of S1PR3 to the S1P-induced migration of NPC 
cells, knockdown of S1PR3 was performed in SUNE1 cells. SUNE1 cells were selected 
for these experiments based on their high expression of S1PR3 (Figure 5.2). To 
determine the optimum conditions for siRNA transfection, SUNE1 cells were 
transfected with a pool of four siRNAs against S1PR3 (siS1PR3) or non-targeting 
siRNA (NT) at two concentrations (25nM or 50nM) for 48 hours and 72 hours. 
Compared to the NT, transfection of SUNE1 cells with 25nM or 50nM siS1PR3 
significantly reduced the levels of S1PR3 by approximately 90% at both time points 
(p<0.001; Figure 5.9). 25nM siRNA with a time point of 48 hours was chosen as the 
condition for subsequent experiments to minimise any possible off-target effect. 
Transwell migration assays were then performed to examine the consequence of 
S1PR3 knockdown on SUNE1 cell migration. In the absence of S1P, the migration of 
SUNE1/siS1PR3 cells was not statistically different from SUNE1/NT cells (Figure 
5.10). In the presence of S1P, knockdown of S1PR3 significantly reduced the migration 
of SUNE1 cells by 50% (p<0.001). These results were consistent with the previous data 
using VPC23019 (Figure 5.8) and indicate that S1P-induced NPC cell migration was 
mediated through S1PR3. 
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Figure 5.9: Optimisation of the conditions for siRNA knockdown of S1PR3 
Compared to SUNE1/NT cells, transfection of (A) 25nM or (B) 50nM of siS1PR3 for 
48 hours or 72 hours markedly decreased the expression of S1PR3. The data presented 
are representative of two independent experiments. *** denotes p<0.0001. 
 
 
 
 
 
 
Figure 5.10: Knockdown of S1PR3 inhibited the migration of SUNE1 cells  
The migration of SUNE1 cells following transfection of siS1PR3 or NT siRNA was 
examined using Transwell assays in the absence or presence of S1P (5μM). Addition of 
S1P significantly promoted the migration of the SUNE1 cells and these effects were 
suppressed following knockdown of S1PR3. The data presented are representative of 
three independent experiments. *** denotes p<0.0001. 
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5.5 The role of S1PR3 and AKT activation in S1P-induced NPC cell migration 
Next, I examined whether S1P induced NPC cell migration by activating AKT 
through S1PR3. Western blot analyses showed that while the levels of the total AKT 
protein remained unchanged, the phosphorylation of AKT was suppressed following 
S1PR3 knockdown in SUNE1 cells (Figure 5.11). Furthermore, rescue experiments 
were performed by co-transfecting SUNE1 cells with siS1PR3 and a constitutively 
active AKT construct. Western blot analyses confirmed the increased levels of phospho-
AKT following the expression of a constitutively active AKT in SUNE1/siS1PR3 cells 
(Figure 5.12). Transwell migration experiments showed that expression of the 
constitutively active AKT significantly rescued the suppressive effect of S1PR3 
knockdown on the migration of SUNE1 cells (p<0.001; Figure 5.13). These results 
suggested that S1P induces the migration of NPC cells through the activation of AKT 
via S1PR3. 
It has been shown that SPHK1 and S1PR3 form an amplification loop to promote the 
migration of breast cancer cells (Long et al., 2010a). To examine whether SPHK1 can 
regulate S1PR3 expression in NPC cells, Q-PCR analyses were used to determine the 
expression of S1PR3 in HONE1 cells following knockdown of SPHK1. However, no 
change in the S1PR3 levels was observed in these cells (p=0.468; Figure 5.14). 
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Figure 5.11: Knockdown of S1PR3 in SUNE1 cells inhibited the activation of AKT  
Knockdown of S1PR3 did not affect the levels of total AKT protein but markedly 
suppressed the activation of AKT in SUNE1 cells. Representative western blot images 
of two independent experiments are presented. 
 
 
Figure 5.12: Expression of the AKT protein following transfection of SUNE1 cells 
with a constitutively active AKT  
Western blot analyses confirmed the increased levels of both total and phospho-AKT 
proteins in SUNE1 cells co-transfected with siS1PR3 and a constitutively active AKT 
construct. Representative western blot images of two independent experiments are 
presented. 
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Figure 5.13: Expression of a constitutively active AKT rescued the suppressive 
effect of S1PR3 knockdown on the migration of SUNE1 cells 
The migration of SUNE1 cells following S1PR3 knockdown and expression of a 
constitutively active AKT was examined using Transwell assays in the presence of S1P 
(5μM). While knockdown of S1PR3 significantly decreased the migration of SUNE1 
cells, these effects were partially reversed following expression of constitutively active 
AKT. The data presented are representative of three independent experiments. *** 
denotes p<0.0001. 
 
 
 
 
 
 
 
 
Figure 5.14: Knockdown of SPHK1 did not affect the expression of S1PR3 
Compared to NS, the expression of S1PR3 was not significantly different following 
knockdown of SPHK1 in HONE1 cells (p=0.468). The data presented are representative 
of two independent experiments . 
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5.6 Summary 
The re-analyses of two published microarray datasets (GSE12452 and GSE34573) 
revealed significant and consistent up-regulation of S1PR3 in micro-dissected NPC cells 
compared to normal epithelium. Upregulation of S1PR2 and S1PR5 in NPC cells was 
only evident in the GSE12452 dataset. Q-PCR profiling of the five S1P receptors in a 
panel of eight NPC cell lines showed that S1PR2 and S1PR5 mRNAs were readily 
detected in all cell lines whilst the expression of S1PR3 was variable. Since limited 
reagents are available for the studies of S1PR5, only the roles of S1PR2 and S1PR3 
were studied in subsequent experiments. 
In order to examine the contribution of S1PR2 to S1P-mediated migration of NPC 
cells, a S1PR2 antagonist (JTE-013) and an agonist (CYM-5478), were used. Following 
treatment with JTE-013, the migration of HONE1 and SUNE1 cells was significantly 
inhibited in the presence of S1P. However, addition of CYM-5478 did not affect the 
migration of SUNE1 cells. These contradictory data implied that S1PR2 might not be 
the primary receptor involved in the S1P-mediated NPC cell migration.  
To determine the involvement of S1PR3 in S1P-induced NPC cell migration, the 
S1PR1/S1PR3 antagonist, VPC23019, and siRNA knockdown of S1PR3 were used. In 
the presence of S1P, the migration of HONE1 and SUNE1 cells was significantly 
reduced following addition of VPC23019. These results were supported by S1PR3 
knockdown in SUNE1 cells, in which reduction of S1PR3 expression markedly 
suppressed the S1P-induced migration of SUNE1 cells. These findings suggested that 
S1P enhanced NPC cell migration through S1PR3.  
Next, the association of S1P/S1PR3 and AKT activation in NPC cell migration was 
investigated. Knockdown of S1PR3 in SUNE1 cells was accompanied by a reduction in 
the levels of phospho-AKT and the expression of a constitutively active AKT restored 
104 
the suppressive effect of S1PR3 knockdown on the migration of these cells. 
Collectively, these data demonstrate that S1P induced the migration of NPC cells, at 
least in part, via the activation of AKT through S1PR3. 
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CHAPTER 6:   
CONTRIBUTION OF EBV INFECTION TO THE EXPRESSION OF SPHK1 
AND S1PR3 
6.1 Introduction 
Non-keratinising NPC is consistently associated with EBV infection (Niedobitek, 
2000). In endemic regions, EBV genomes are detected in almost all NPC cases 
regardless of the histopathological type (Pathmanathan et al., 1995). EBV establishes 
type II latency in NPC in which EBV gene expression is restricted to EBNA1, LMP1, 
LMP2, EBERs, BARTs and BARF1 (Young et al., 2014). 
It has been shown that immortalised nasopharyngeal epithelial cells displaying pre-
malignant genetic changes (e.g. p16 deletion or overexpression of cyclin D1) are 
susceptible to EBV infection (Tsang et al., 2012). Once infected, EBV genes provide 
growth and survival benefits by inducing additional alterations leading to the 
development of NPC (Tsao et al., 2015). In particular, EBV genes such as LMP1 and 
LMP2A exhibit oncogenic properties and activate a number of signalling pathways in 
NPC, including NF-κB, PI3K/AKT and MAPK/ERK (Young et al., 2014). Despite the 
fact that EBV infection is closely linked to NPC, the exact contribution of EBV to the 
pathogenesis of NPC remains enigmatic.  
From the Q-PCR analyses, the only EBV-positive NPC cell line, C666-1, expressed 
the highest levels of SPHK1 (Figure 4.5) and S1PR3 (Figure 6.1) compared to a panel of 
EBV-negative NPC cell lines and immortalised nasopharyngeal cells, implying that 
EBV infection might regulate the expression of these genes. The aims of this study 
were: 1) to establish EBV-infected NPC cell lines and, 2) to use these cell lines to 
determine the contribution of EBV infection to the expression of SPHK1 and S1PR3 in 
NPC cells.  
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6.2 Establishment of EBV-infected NPC cell lines 
Two NPC cell lines, CNE1 and TW04, were selected to be stably infected with a 
recombinant EBV (Akata strain) based on their low levels of SPHK1 (Figure 4.5) and 
S1PR3 (Figure 6.1). A Burkitt’s lymphoma-derived cell line that carries the 
recombinant EBV, Akata, was used and EBV virions were produced by inducing the 
lytic cycle using an anti-human IgG antibody (Shimizu et al., 1996). EBV-infected 
CNE1 (CNE1/EBV) and TW04 (TW04/EBV) cells were established by co-culturing 
with the induced Akata cells, followed by selection in G418 for 7 days.  
To determine whether CNE1/EBV and TW04/EBV cells exhibit EBV type II 
latency, Q-PCR and immunofluorescence analyses were performed to examine the 
mRNA and protein levels of the EBV latent genes (EBNA1, LMP1 and LMP2A), 
respectively. The results showed that EBNA1 and LMP2A mRNA (Figure 6.2) and 
protein (Figure 6.3) were expressed in both CNE1/EBV and TW04/EBV cells, but 
LMP1 was not detectable in either cell line.  
To compare the EBV gene expression pattern in CNE1/EBV and TW04/EBV cells 
with those in other established EBV(Akata)-infected NPC cell lines, Q-PCR analyses 
were performed in EBV-infected CNE2, HK1, HONE1, SUNE1 and TW01 cells (gifts 
from Dr Christopher Dawson, University of Birmingham and Prof George Tsao, 
University of Hong Kong). Similar expression patterns were observed in these cells, in 
which the levels of EBNA1 and LMP2A mRNA were readily detected whereas LMP1 
was not expressed (Figure 6.4). These results confirmed that LMP1 expression is rarely 
detected in NPC cells stably infected with the Akata EBV strain.  
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Figure 6.1: Expression of S1PR3 in NPC cell lines 
The expression of S1PR3 in NPC cell lines and an immortalised nasopharyngeal cell 
line, NP460hTert was determined by QPCR. The highest levels of S1PR3 were detected 
in C666-1, the only EBV-positive NPC cell line. The data presented are representative 
of two independent experiments. 
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Figure 6.2: Expression of EBV latent genes in EBV-infected CNE1 and TW04 
Expression of (A) EBNA1 and (C) LMP2A, but not (B) LMP1, was detected in CNE1 
and TW04 cells stably infected with a recombinant EBV (Akata strain) by QPCR. Rael-
BL served as a positive control for EBNA1 whereas LCL X50-7 served as a positive 
control for LMP1 and LMP2A. The data presented are representative of two 
independent experiments. 
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Figure 6.3: Expression of EBV latent proteins in EBV-infected CNE1 and TW04 cells 
Immunofluorescence analyses showed that (A) CNE1/EBV and (B) TW04/EBV cells expressed only EBNA1 and LMP2 proteins, but not LMP1 
protein. 
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Figure 6.3, continued 
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Figure 6.4: Expression of EBV latent genes in EBV-infected NPC cells 
Similar to CNE1/EBV and TW04/EBV cells, only EBNA1 and LMP2A, but not LMP1, 
were detected in EBV-infected (A) CNE2, (B) HK1, (C) HONE1, (D) SUNE1 and (E) 
TW01 cells using QPCR. The data presented are representative of two independent 
experiments. 
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6.2.1 Phenotypic characteristics of CNE1/EBV and TW04/EBV cells 
In order to determine whether CNE1/EBV and TW04/EBV cells possess similar 
phenotypic properties as other EBV-infected NPC cells, the proliferation, migratory and 
invasive potential of these cells were assessed. Similar to the previously established 
HK1/EBV cells (Lo et al., 2006), the growth of CNE1/EBV and TW04/EBV cells was 
significantly slower than their respective parental controls (Figure 6.5).  
It is known that EBV infection promotes the migration and invasion of NPC cells 
(Lui et al., 2009; Teramoto et al., 2000; Wu et al., 2003). Consistent with this concept, 
the migration (Figure 6.6) and invasion (Figure 6.7) of CNE1/EBV and TW04/EBV 
cells were significantly increased compared to their respective parental controls 
(p<0.001). These results suggested that CNE1/EBV and TW04/EBV cells behaved 
similarly to other established EBV-infected cell lines and can be used as in vitro models 
to study the roles of EBV infection in NPC cells.  
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Figure 6.5: EBV infection reduced NPC cell proliferation 
Compared to respective parental controls, (A) CNE1, (B) TW04 and (C) HK1 cells grew slower following EBV infection. The data presented are 
representative of two independent experiments. * denotes p<0.05, *** denotes p<0.001. 
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Figure 6.6: EBV infection promoted NPC cell migration 
The migration of CNE1/EBV and TW04/EBV cells were examined using Transwell 
assays in the presence of 10% FBS in the lower chambers. The migration of CNE1/EBV 
and TW04/EBV cells was markedly higher compared to their respective parental 
controls. The data presented are representative of two independent experiments. *** 
denotes p<0.0001. 
 
 
 
 
Figure 6.7: EBV infection increased NPC cell invasion 
The invasion of CNE1/EBV and TW04/EBV cells was determined using matrigel-
coated Transwell assays in the presence of 10% FBS in the lower chambers. 
CNE1/EBV and TW04/EBV cells showed increased invasive potential compared to 
their respective parental controls. The data presented are representative of two 
independent experiments. *** denotes p<0.0001. 
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6.3 Contribution of EBV infection to the expression of SPHK1 and S1PR3  
Seven EBV-infected NPC cell lines (CNE1, CNE2, HK1, HONE1, SUNE1, TW01 
and TW04) and an EBV-infected immortalised nasopharyngeal cell line (NP460hTert) 
were used to determine whether EBV can regulate the expression of SPHK1 and 
S1PR3.  
6.3.1 SPHK1 
Q-PCR analyses showed that compared to the respective parental cells, the 
expression of SPHK1 mRNA was significantly increased in six of the eight EBV-
infected cell lines (HK1, CNE1, SUNE1, HONE1, CNE2 and TW01) whereas no 
change was detected in NP460hTert/EBV and TW04/EBV cells (Figure 6.8). Western 
blot analyses showed that the expression of both the total and phosphorylated SPHK1 
proteins was elevated in HK1/EBV, CNE1/EBV, SUNE1/EBV, HONE1/EBV and 
CNE2/EBV cells, but unchanged in TW01/EBV cells (Figure 6.9).  
6.3.2 S1PR3 
In contrast to SPHK1 expression, following EBV infection, the expression of S1PR3 
was only increased in three (HK1, TW04 and NP460hTert) out of the eight cell lines 
examined and decreased in the other three cell lines (CNE2, SUNE1 and HONE1). The 
levels of S1PR3 were unchanged in TW01/EBV and CNE1/EBV cells (Figure 6.10). 
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Figure 6.8: EBV infection increased the mRNA expression of SPHK1 in NPC cells  
Q-PCR analyses showed that six out of the eight EBV-infected cell lines expressed 
higher levels of SPHK1 than their respective parental controls. The data presented are 
representative of two independent experiments. ** denotes p<0.01; *** denotes 
p<0.001. 
 
 
Figure 6.9: EBV infection upregulated both the total and phosphorylated SPHK1 
proteins in NPC cells 
Among the six NPC cell lines that showed elevated SPHK1 mRNA levels following 
EBV infection, five of them (HK1, CNE1, SUNE1, HONE1 and CNE2) also 
demonstrated an increase in the expression of both total and phosphorylated SPHK1 
proteins. Representative western blot images of two independent experiments are 
presented. 
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Figure 6.10: Expression of S1PR3 in nasopharyngeal cell lines following EBV 
infection  
Compared to the respective parental controls, Q-PCR analyses showed that following 
EBV infection, three out of eight cell lines (HK1, TW04 and NP460hTert) expressed 
higher levels of S1PR3 whilst CNE2, SUNE1 and HONE1 showed lower expression of 
S1PR3. The levels of S1PR3 were unchanged in TW01/EBV and CNE1/EBV. ^ 
Expression of S1PR3 was not detected in either CNE1 or CNE1/EBV cells. The data 
presented are representative of two independent experiments. * denotes p<0.05; ** 
denotes p<0.01, *** denotes p<0.001. 
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6.3.3 Correlation between SPHK1 and S1PR3 expression 
Among the eight cell lines, only HK1 cells consistently showed the upregulation of 
both SPHK1 and S1PR3 following EBV infection (Table 6.1). Spearman’s correlation 
analysis was performed to determine the association of SPHK1 and S1PR3 expression in 
the other seven EBV-infected cell lines. A significant negative correlation was found in 
the expression of SPHK1 and S1PR3 in these cells (Spearman’s rho = -0.9727, p<0.01) 
(Figure 6.11), indicating that EBV-mediated upregulation of SPHK1 and S1PR3 
expression could be mutually exclusive in nasopharyngeal epithelial cells. 
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Table 6.1: Significant changes in the levels of SPHK1 and S1PR3 following EBV 
infection 
Cell lines 
Changes in SPHK1 levels 
following EBV infection 
Changes in S1PR3 levels 
following EBV infection 
HK1 Upregulated Upregulated 
CNE2 Upregulated Downregulated 
HONE1 Upregulated Downregulated 
SUNE1 Upregulated Downregulated 
CNE1 Upregulated No change 
TW01 Upregulated No change 
TW04 No change Upregulated 
NP460hTert No change Upregulated 
 
 
 
 
 
 
 
 
Figure 6.11: Correlation of the SPHK1 and S1PR3 expression 
The expression of SPHK1 is negatively correlated with the expression of S1PR3 in 
EBV-infected cells. 
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6.4 Expression of SPHK1 and S1PR3 following transfection of individual EBV 
latent genes 
To determine which EBV latent gene was responsible for the upregulation of 
SPHK1, HONE1 cells stably transfected with EBNA1, LMP1 or LMP2A gene (Port et 
al., 2013) and HK1 cells transiently transfected with these latent genes were used. 
Transiently transfected HK1 cells were also used to examine the regulation of S1PR3 
expression. 
6.4.1 SPHK1 
Q-PCR analyses showed that compared to the vector controls, SPHK1 mRNA levels 
were significantly elevated in HONE1 cells stably transfected with EBNA1, LMP1 or 
LMP2A (Figure 6.12). In agreement with the changes in mRNA levels, the expression 
of both total and phosphorylated SPHK1 proteins were also increased in these cells 
(Figure 6.13). These results suggested that EBNA1, LMP1 and LMP2A could 
upregulate the expression of SPHK1 in NPC cells. 
Since LMP1 and LMP2A are known to promote the migration of NPC cells (Tsao et 
al., 2015), the contribution of these two EBV latent genes to the expression of SPHK1 
was further determined in HK1 cells transiently transfected with LMP1 or LMP2A. Q-
PCR analyses confirmed the expression of LMP1 and LMP2A in the transfected HK1 
cells (Figure 6.14). The levels of SPHK1 remained unchanged in these cells (Figure 
6.15), showing that LMP1 and LMP2A did not upregulate the expression of SPHK1 in 
HK1 cells.  
6.4.2 S1PR3 
Although EBV infection of HK1 cells enhanced the expression of S1PR3 (Figure 
6.11), transient transfection of HK1 with LMP1 or LMP2A did not alter the expression 
levels of S1PR3 (Figure 6.16).    
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Figure 6.12: EBV latent genes upregulated the expression of SPHK1 in NPC cells 
Compared to the vector control, increased expression of SPHK1 was detected in 
HONE1 cells stably transfected with EBV latent genes (EBNA1, LMP1 or LMP2A). 
The data presented are representative of three independent experiments. *** denotes 
p<0.001. 
 
 
Figure 6.13: EBV latent genes increased both the total and phosphorylated SPHK1 
proteins in NPC cells 
HONE1 cells stably transfected with EBNA1, LMP1 or LMP2A genes exhibited 
upregulated levels of phospho-SPHK1 and total SPHK1 proteins compared to the vector 
control. Representative western blot images of two independent experiments are shown. 
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Figure 6.14: Confirmation of LMP1 and LMP2A expression in transfected HK1 
cells 
Q-PCR analyses confirmed the expression of (A) LMP1 and (B) LMP2A in HK1 cells 
transiently transfected with LMP1 and LMP2A for 72 hours. The data presented are 
representative of two independent experiments. 
 
 
 
 
 
 
Figure 6.15: Expression of SPHK1 in LMP1- and LMP2A-transfected HK1 cells  
Compared to the vector control, the levels of SPHK1 were unchanged in transiently (A) 
LMP1- and (B) LMP2A-transfected HK1 cells. The data presented are representative of 
two independent experiments. 
  
HK1 Vector HK1/LMP1
0.0000
0.0002
0.0004
0.0006
0.0008
0.0010
R
e
la
ti
v
e
 E
x
p
re
s
s
io
n
 t
o
 G
A
P
D
H
HK1 Vector HK1/LMP2A
0.0000
0.0010
0.0020
0.0030
0.0040
R
e
la
ti
v
e
 E
x
p
re
s
s
io
n
 t
o
 G
A
P
D
H
A) B)
HK1/Vector HK1/LMP1
0.0
0.5
1.0
1.5
R
e
la
ti
v
e
 S
P
H
K
1
 E
x
p
re
s
s
io
n
HK1/Vector HK1/LMP2A
0.0
0.5
1.0
1.5
R
e
la
ti
v
e
 S
P
H
K
1
 E
x
p
re
s
s
io
n
A) B)
 123 
 
  
 
 
 
 
 
 
 
 
Figure 6.16: Expression of S1PR3 in LMP1- and LMP2A-expressing HK1 cells 
Compared to the vector control, the expression of S1PR3 was not significantly altered in 
HK1 cells following transient transfection of (A) LMP1 and (B) LMP2A. The data 
presented are representative of two independent experiments. 
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6.5 Summary 
Among a panel of NPC cell lines, C666-1, the only EBV-positive NPC cell line, 
showed the highest levels of SPHK1 and S1PR3, implying that EBV infection could 
upregulate the expression of SPHK1 and S1PR3. To generate in vitro models to study 
the role of EBV infection in NPC, CNE1 and TW04 cells were stably infected with a 
recombinant EBV (Akata strain) using the established cell-to-cell contact protocol. 
Similar to other previously established EBV-infected cells, EBNA1 and LMP2, but not 
LMP1, were expressed in CNE1/EBV and TW04/EBV cells. In addition, CNE1/EBV 
and TW04/EBV cells grew slower but had increased migratory and invasive properties 
compared to their respective parental controls. These phenotypic characteristics were 
also found in the other established EBV-infected NPC cells, demonstrating that 
CNE1/EBV and TW04/EBV cells could be used as additional in vitro models for 
studies of EBV infection in NPC cells. 
Among the eight EBV-infected nasopharyngeal epithelial cells (two newly 
established and six obtained from collaborators), EBV infection upregulated both the 
mRNA and protein expression of SPHK1 in five of the cell lines (HK1, CNE1, SUNE1, 
HONE1 and CNE2) whereas the expression of S1PR3 was only increased in three of 
these cell lines (HK1, TW04 and NP460hTert) and decreased in another three cell lines 
(CNE2, SUNE1 and HONE1). Spearman’s correlation analyses revealed a negative 
correlation of SPHK1 and S1PR3 expression (Spearman’s rho = -0.9727) in these cells, 
implying that the upregulation of SPHK1 or S1PR3 modulated by EBV might be 
mutually exclusive in nasopharyngeal epithelial cells. 
To determine which EBV latent gene was responsible for the expression of SPHK1, 
HONE1 cells stably transfected with EBV latent genes (EBNA1, LMP1 or LMP2A) 
were used. All these EBV latent genes were found to upregulate the mRNA and protein 
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levels of SPHK1. The contribution of LMP1 and LMP2A to the expression of SPHK1 
and S1PR3 was also determined in HK1 cells transiently transfected with these two 
EBV genes. However, the levels of SPHK1 and S1PR3 were unchanged in LMP1- and 
LMP2A-expressing HK1 cells compared to the controls, suggesting that the effects of 
EBV latent genes are context dependent. 
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CHAPTER 7: DISCUSSION 
7.1 Introduction  
It is evident that S1P signalling plays an important role in promoting tumorigenesis 
in a wide range of cancer types by increasing cancer cell proliferation, survival, 
migration, invasion and angiogenesis (Takabe et al., 2014). Targeting SPHK1, S1P 
itself and/or S1PRs is now a promising new cancer therapeutic strategy (Kunkel et al., 
2013). Although high expression of SPHK1 was shown to be associated with poorer 
survival in NPC patients (Li et al., 2015b), the biological consequence of aberrant 
activation of S1P signalling in the pathogenesis of NPC has not been studied. Therefore, 
the present study was initiated to investigate how aberrant S1P signalling influences the 
malignant phenotypes of NPC cells and whether EBV infection contributes to the 
dysregulation of this pathway. Since elevated expression of SPHK1 has been detected in 
primary NPCs (Li et al., 2015b), high levels of S1P are likely to be present in NPC 
tissues. The results of this study showed that exogenous S1P increased the migration of 
NPC cells, whilst knockdown of SPHK1 suppressed cell migration. Next, the 
mechanisms of S1P-induced migration were elucidated and S1P was shown to induce 
NPC cell migration by activating AKT via S1PR3. Lastly, EBV infection was found to 
be able to upregulate the expression of SPHK1 and S1PR3 in NPC cell lines. 
For ease of interpretation, this Discussion chapter has been subdivided such that 
consideration is given to the data reported in each results chapter. The following 
sections discuss some of the limitations of this study and present proposals for future 
work.   
7.2 Phenotypic impact of exogenous S1P and knockdown of SPHK1  
Over-expression of SPHKs has been shown to transform NIH3T3 cells and promote 
tumour formation in NOD/SCID mice, pointing a role for SPHKs as an oncogene (Xia 
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et al., 2000). High expression of SPHK1 is reported in various types of cancers, and 
correlates with a number of clinicopathological parameters, including advanced stage, 
metastasis and shorter patient survival (Pyne et al., 2010). SPHK1 was found to be 
highly expressed in primary NPC tissues (Li et al., 2015b), hence high levels of S1P are 
likely to be present in NPC cells. In the first part of this study, the biological function of 
exogenous S1P on NPC cell proliferation, migration and invasion was examined. The 
effects of inhibiting endogenous SPHK1 were examined by knocking down SPHK1 in 
NPC cells using a lentiviral shRNA system to achieve a stable and long-term 
knockdown of SPHK1. SPHK1 produces S1P following activation through 
phosphorylation by ERK1/2 (Pitson et al., 2003). A reduction in the levels of both total 
and phosphorylated SPHK1 proteins was demonstrated following SPHK1 knockdown, 
indicating that the activated form of SPHK1 was decreased and this was likely to result 
in a reduction in S1P levels.   
7.2.1 Effects on cell proliferation 
Whilst S1P is generally considered to stimulate the growth of cancer cells through 
the activation of several signalling pathways including PI3K/AKT and MAPK/ERK 
(Datta et al., 2014; Nava et al., 2002; Van Brocklyn et al., 2002; Xia et al., 2012), there 
are also reports to demonstrate an anti-proliferative role for this lipid in cancer 
(Balthasar et al., 2006; Hong et al., 1999; Ling et al., 2011; Shin et al., 2007; 
Yamashita et al., 2006). Although there is a paucity of information on how S1P inhibits 
the growth of cancer cells, the possible mechanisms could be inferred from data in non-
malignant cells. For example, S1P inhibited the proliferation of human keratinocytes 
through rapid phosphorylation of Smad3 and interaction with Smad4 independently of 
transforming growth factor-beta (TGF-β) secretion (Sauer et al., 2004). S1P can also 
suppress the growth of hepatic myofibroblasts by rapidly increasing prostaglandin E2 
production that in turn elevated the production of a growth inhibitory messenger, cyclic 
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adenosine monophosphate (cAMP) (Davaille et al., 2000). In the present study, 
exogenous addition of S1P consistently inhibited the growth of four NPC cell lines 
(CNE1, HK1, HONE1 and TW04). However, knockdown of SPHK1 also reduced the 
proliferation of HONE1 cells. There are two possible explanations for these 
contradictory results. Firstly, addition of S1P might disrupt the sphingolipid rheostat 
such that excess S1P was converted to pro-apoptotic sphingosine and ceramide (Taha et 
al., 2006b). Ceramide has been shown to induce cell cycle arrest by dephosphorylating 
retinoblastoma protein (Dbaibo et al., 1995), inactivating CDK2 (Lee et al., 2000) as 
well as activating p21 (Phillips et al., 2007) and p27 (Zhu et al., 2003). This possibility 
could be examined by determining the levels of ceramide, sphingosine and S1P in NPC 
cells following S1P addition. Secondly, the reduction in S1P levels following SPHK1 
knockdown might not be sufficient to overcome the anti-mitogenic effects of 
endogenous S1P (Igarashi et al., 2003; Maceyka et al., 2005) and this speculation could 
be tested by measuring the levels of S1P in HONE1 cells following SPHK1 
knockdown.  
7.2.2 Effects on migration and invasion 
Cell migration and invasion are key events in cancer metastasis. Given that NPC is a 
highly metastatic cancer and distant metastasis is the major cause of death in NPC 
patients, this study examined the effects of S1P on the migratory and invasive potential 
of NPC. The results showed that S1P treatment consistently enhanced the migration of 
three NPC cell lines (HONE1, SUNE1 and TW04) and also the invasion of SUNE1 
cells. In line with these data, knockdown of SPHK1 significantly suppressed the 
migration of HONE1 cells. These results were in agreement with the general notion that 
aberrant activation of S1P signalling enhances the migration and invasion of cancer 
cells and is associated with cancer metastasis in vivo (Brocklyn, 2010). 
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7.3 Identification of the S1P receptors that mediate S1P-induced migration in 
NPC cells 
S1P acts as a specific ligand for the five S1P receptors, S1PR1 – S1PR5 (Rivera et 
al., 2008). A large body of evidence has reported the deregulation of S1PRs in cancer 
and the effects of S1P are dependent on the expression profile of S1PRs (Pyne et al., 
2010; Takuwa, 2002). S1PRs couple to different heterotrimeric G proteins to elicit their 
functions. S1PR1 couples primarily to Gi, S1PR2 and S1PR3 couple to Gi, Gq and 
G12/13, whereas S1PR4 and S1PR5 couple to Gi and G12/13 (Rosen et al., 2009). The 
differential G protein-coupling of the individual S1PR activates a complex downstream 
signalling cascade and results in distinct phenotypic changes of the cells (Brinkmann, 
2007). S1PR1 and S1PR3 are over-expressed in various types of cancer and contribute 
to cancer progression in vitro and in vivo by promoting cell growth, survival, invasion, 
migration, angiogenesis and chemotherapeutic drug resistance (Balthasar et al., 2006; 
Bao et al., 2012; Chae et al., 2004; Harris et al., 2012; Herr et al., 2009; Hsu et al., 
2012; Kim et al., 2014; Kim et al., 2011; Watson et al., 2010). S1PR2 is generally 
considered to be anti-tumorigenic (Arikawa et al., 2003; Du et al., 2010; Lepley et al., 
2005; Yamaguchi et al., 2003) although its tumour-promoting effects have also been 
reported (Patmanathan et al., 2016; Ponnusamy et al., 2012; Salas et al., 2011). To date, 
there are a limited number of studies investigating the roles of S1PR4 and S1PR5 in 
carcinogenesis. In breast cancer cells, S1PR4 activates the ERK1/2 pathway in a human 
epidermal growth factor 2 (HER2)-dependent manner (Long et al., 2010b). 
Upregulation of S1PR5 was found in gliobastoma multiforme (Quint et al., 2014), but it 
has also been shown that S1PR5 exhibits anti-tumorigenic effects by inducing 
autophagy in prostate cancer cells (Chang et al., 2009) and inhibiting the proliferation 
and migration of esophageal cancer cells (Hu et al., 2010). Since opposing functions 
have been reported for both S1PR2 and S1PR5, their roles could be cancer type-
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dependent. It will be important to determine the functional properties of these two 
receptors to target them effectively. 
Re-analyses of two published microarray studies in the present study demonstrated 
that S1PR3 were consistently and significantly (p<0.05) over-expressed in micro-
dissected NPC tumour samples compared to normal nasopharyngeal epithelium in both 
datasets, while S1PR2 and S1PR5 were upregulated in only one of the datasets. These 
data were in line with previous studies showing the over-expression of these receptors 
in cancers. For example, over-expression of S1PR2 was detected in oral cancer and 
glioblastoma multiforme (Bien-Moller et al., 2016; Patmanathan et al., 2016), S1PR3 
was upregulated in liver and colon cancers (Wang et al., 2014a), and upregulation of 
S1PR5 was found in gliobastoma multiforme (Quint et al., 2014). Furthermore, their 
expression has been negatively correlated with patient survival (Bien-Moller et al., 
2016; Quint et al., 2014; Watson et al., 2010). Q-PCR analyses showed that S1PR2 and 
S1PR5 were readily detected in NPC cell lines whereas the expression of S1PR3 was 
variable. The role of S1PR2 and S1PR3 in NPC cell migration was investigated by 
utilising several pharmacological agents, namely a S1PR2 antagonist (JTE-013), a 
S1PR2 agonist (CYM-5478) and a S1PR1/S1PR3 antagonist (VPC23019). Although the 
present study did not explore the biological function of S1PR5 due to the limitation of 
reagents, the involvement of this receptor in S1P-induced migration of NPC cells cannot 
be ruled out. It remains a possibility that by coupling to Gi, S1PR5 can trigger Rac that 
lead to an increase in NPC cell migration as suggested by Hu et al. (Hu et al., 2010). 
Coupling to other G proteins such as G12/13 might induce an inhibitory effect in the cells 
(Sugimoto et al., 2003). 
7.3.1 S1PR2 
Whilst S1PR2 is thought to exhibit anti-migratory effects in general (Arikawa et al., 
2003; Lepley et al., 2005; Malchinkhuu et al., 2008; Yamaguchi et al., 2003; Young et 
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al., 2007), there is evidence to show that increased expression of S1PR2 enhances the 
migration of tumour cells in vitro and in vivo (Miller et al., 2008; Patmanathan et al., 
2016; Ponnusamy et al., 2012; Sekine et al., 2011; Wang et al., 2008). In the present 
study, addition of JTE-013 suppressed the migration of two NPC cell lines (HONE1 and 
SUNE1) in the presence of S1P, however, treatment with CYM-5478 did not affect the 
migration of SUNE1 cells. One possible reason for the inconsistent results is that the 
suppressive effects of JTE-013 might be due to the inhibition of S1PR4 because JTE-
013 is also a S1PR4 antagonist that led to the reduction of ERK1/2 activation in breast 
cancer cells (Long et al., 2010b). In addition, treatment with JTE-013 has been found to 
suppress not only S1P-mediated constriction of rat basilar artery, but also constriction 
induced by prostanoid, endothelin-1, and KCl, and the inhibitory effects of JTE-013 
were also observed in mice lacking S1PR2 (Salomone et al., 2008). These data suggest 
that the decreased S1P-induced migration of NPC cells following JTE-013 treatment 
might be due to the inhibition of S1PR4. Another possible reason is that JTE-013 is an 
orthosteric antagonist whereas CYM-5478 is an allosteric agonist, hence the difference 
in their binding sites might result in coupling to a different subset of G proteins that 
induce distinct action of S1PR2 in NPC cells (Digby et al., 2010). For instance, 
coupling of S1PR2 to Gi promotes the migration of esophageal cancer cells (Miller et 
al., 2008) whereas G12/13 coupling inhibits Rac expression and the migration of CHO 
cells (Sugimoto et al., 2003). 
7.3.2 S1PR3 
Treatment of two NPC cell lines (HONE1 and SUNE1) with VPC23019 inhibited 
S1P-induced migration, indicating that S1PR1 and S1PR3 might be involved in the 
migration of NPC cells. It has been shown that S1P-mediated migration of endothelial 
cells involved the phosphorylation of S1PR1 at T236 by AKT (Lee et al., 2001). 
However, the present study focused only on S1PR3 because S1PR3 was the only 
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receptor whose expression was consistently upregulated in primary NPC in both 
microarray datasets. To confirm the contribution of S1PR3 to S1P-induced migration of 
NPC cells, knockdown of S1PR3 was performed using the RNA interference system, a 
well-recognised option to study the specific role of a candidate molecule (Appasani, 
2005). The promoting role of S1PR3 in cell migration has been shown in various types 
of cancers, including gastric and breast cancer (Kim et al., 2011; Yamashita et al., 
2006). In agreement with these observations, the present study showed that siRNA 
knockdown of S1PR3 reduced the migration of NPC cells in the presence of S1P. 
Importantly, sensitive RNA in situ hybridization (RNAscope) analyses performed by 
our collaborator, Professor Kwok Wai Lo from The Chinese University of Hong Kong, 
have confirmed the over-expression of S1PR3 in primary NPC tissues compared to 
normal epithelium and epithelium adjacent to the carcinoma (Appendix A). 
Interestingly, high expression of S1PR3 significantly correlated with poorer overall 
survival in NPC patients (Appendix B), data that are similar to those of Watson and co-
workers who reported a relationship between S1PR3 expression and patient survival in 
breast cancer patients (Watson et al., 2010). Taken together, these findings indicated 
that SPHK1/S1P/S1PR3 signalling plays a crucial role in promoting a migratory 
phenotype in NPC cells.  
7.4 The mechanisms of S1P-induced NPC cell migration 
To explore the mechanisms of S1P-induced migration of NPC cells, the involvement 
of AKT and ERK signalling were examined. There were two reasons for selecting these 
pathways; firstly, AKT and ERK represent two main downstream targets of the S1P 
signalling pathway, as they have been shown to be the central players in mediating the 
oncogenic effects of S1P and their activation promotes cancer cell migration in various 
types of solid tumours (Kim et al., 2011; Park et al., 2007; Pyne et al., 2010; Van 
Brocklyn et al., 2003; Yamashita et al., 2006). Secondly, activation of the PI3K/AKT 
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and MAPK/ERK pathways is a common feature of NPC and these pathways are 
stimulated by the EBV-encoded LMP1 and LMP2A genes to promote the migration and 
invasion of NPC cells (Tsao et al., 2015; Wang et al., 2014b). Furthermore, high 
expression of phosphorylated AKT and ERK in primary NPC is related to lymph node 
metastasis and radioresistance (Jiang et al., 2014; Yuan et al., 2016).  
7.4.1 Activation of AKT and ERK 
In the present study, exogenous addition of S1P increased the levels of phospho-
AKT and phospho-ERK whereas knockdown of SPHK1 suppressed only the 
phosphorylation of AKT. The unchanged levels of phospho-ERK following SPHK1 
knockdown could possibly be due to the fact that basal levels of phospho-ERK in 
HONE1 cells were relatively low and, therefore, reduced levels of S1P might not be 
sufficient to modulate the pathway. Of note, the levels of total AKT and ERK proteins 
were not altered following the treatment with S1P or SPHK1 knockdown, suggesting 
that SPHK1/S1P only activates these two proteins but does not regulate their 
transcription. 
7.4.2 S1P/S1PR3 signalling promotes NPC cell migration through the activation of 
AKT 
Focusing on the involvement of AKT signalling in S1P-induced cell migration, NPC 
cells were treated with a PI3K/AKT inhibitor (LY294002). The treatment significantly 
reduced the phosphorylation of AKT and suppressed the migration of NPC cells in the 
presence of S1P. These data were supported by the reduction of phospho-AKT levels in 
HONE1 cells observed following knockdown of SPHK1 and expression of a 
constitutively active AKT restored the migration of these cells, suggesting that S1P 
induced the migration of NPC cells through activation of AKT. These results are in 
agreement with previous studies showing that S1P activated AKT and promoted the cell 
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migration of thyroid, ovarian and breast cancers (Balthasar et al., 2006; Kim et al., 
2011; Park et al., 2007). Knockdown of S1PR3 inhibited the migration of NPC cells in 
the presence of S1P and this was accompanied by reduced levels of phospho-AKT. The 
migration of cells with reduced S1PR3 expression following gene knockdown was 
partly restored following the expression of a constitutively active AKT. These findings 
indicated S1PR3 is responsible for the pro-migratory effects of S1P in NPC cells by 
activating AKT. S1PR1 and S1PR3 are commonly implicated in enhancing cell 
migration by activating signalling pathways including PI3K/Rac and ERK1/2 (Bergelin 
et al., 2010; Li et al., 2009a; Long et al., 2010a). The involvement of S1PR3 in 
mediating S1P-induced cancer cell migration through activation of AKT has only been 
indirectly inferred previously in a limited number of studies. For example, S1P activated 
AKT in ovarian and thyroid cancer cells and treatment of these cells with a PI3K/AKT 
inhibitor (LY294002 or wortmannin) suppressed S1P-induced migration in a Gi-
dependent manner (Balthasar et al., 2006; Park et al., 2007). Although these studies 
revealed the possible involvement of S1PR1 and S1PR3 in mediating these effects by 
using the S1PR1/3 inhibitor, VPC23019, it was not clear which receptor was precisely 
responsible. Similar observations were reported in breast cancer cells, but S1P-induced 
migration was mediated through Gq (Kim et al., 2011). Although knockdown of Gq or 
S1PR3 inhibited AKT phosphorylation, the authors did not provide a direct role for 
S1PR3 in mediating the migration of breast cancer cells through AKT. Thus, the present 
study is the first to clearly show that S1P induced cancer cell migration by activating 
AKT via S1PR3. 
It has been shown that SPHK1 and S1PR3 function in an amplification loop to 
promote the migration of breast cancer cells (Long et al., 2010a). S1P was found to 
stimulate the translocation of SPHK1 to the plasma membrane of breast cancer cells via 
a S1PR3-dependent mechanism and SPHK1 was in turn required for the expression of 
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S1PR3 (Long et al., 2010a). The pro-migratory ability of S1P was mediated through 
S1PR3 by accumulating phosphorylated ERK1/2 into membrane ruffles/lamellipodia 
and nucleus of the breast cancer cells (Long et al., 2010a). However, in the present 
study, exogenous S1P induced the phosphorylation of ERK in NPC cells but 
knockdown of SPHK1 did not affect the levels of phospho-ERK. Furthermore, the 
expression of S1PR3 remained unchanged following knockdown of SPHK1 in HONE1 
cells. Nonetheless, the possibility that S1PR3 can also mediate the S1P-induced 
migration of NPC cells through mechanisms other than AKT activation cannot be ruled 
out. S1P/S1PR3 signalling has been shown to promote cancer cell migration/invasion 
by up-regulating the expression of EGFR, HIF-1α or CRP (Hsu et al., 2012; Kalhori et 
al., 2013; Kim et al., 2014). The identification of the downstream effector(s) of 
S1P/S1PR3/AKT signalling in stimulating NPC cell migration warrants further 
investigation. 
7.5 Contribution of EBV infection to the expression of SPHK1 and S1PR3 
7.5.1 Establishment of EBV-infected CNE1 and TW04 cells 
There is a strong etiological association between EBV infection and NPC, but the 
exact contribution of EBV to the development of NPC is still largely unclear (Tsao et 
al., 2015). A major challenge in establishing truly representative NPC cell lines is to 
develop tumour-derived cell lines that retain the EBV genome, which is commonly lost 
during prolonged culture (Chang et al., 1989; Glaser et al., 1989; Huang et al., 1980). 
By using the cell-to-cell contact method, which involves co-cultivation of EBV-
negative epithelial cells with Akata cells carrying a recombinant EBV (Imai et al., 
1998), several EBV-infected NPC cell lines (CNE2, HK1, HONE1, SUNE1, TW01) 
and an EBV-infected immortalised nasopharyngeal epithelial cell line (NP460hTert) 
have been established (Chang et al., 1999; Hau et al., 2011; Lo et al., 2006; Stewart et 
al., 2004; Tsang et al., 2010). However, the basal levels of SPHK1 and S1PR3 in these 
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cell lines are readily detected and might not be ideal models to examine whether EBV 
can modulate the expression of these two molecules. Therefore, in the present study two 
NPC cell lines (CNE1 and TW04) with low or undetectable levels of SPHK1 and 
S1PR3 were chosen to generate additional EBV-positive epithelial in vitro models. 
Similar to other EBV (Akata)-infected nasopharyngeal epithelial cell lines, the newly 
established CNE1/EBV and TW04/EBV cell lines expressed EBNA1 and LMP2A, but 
not LMP1. 
Previous studies have shown that the expression of LMP1 was only detected in EBV-
infected nasopharyngeal epithelial cells at the early stages of EBV infection and lost in 
the later passages (Tsang et al., 2012; Tsang et al., 2010), implying that the expression 
of LMP1 was required to overcome the cellular stress caused by EBV infection (Hsiao 
et al., 2009). Although it remains uncertain, the absence of LMP1 might also be a 
specific characteristic of epithelial cells infected with the EBV Akata strain that was 
originally isolated from a BL patient. To date, the EBV Akata strain is the only 
recombinant EBV available for in vitro experiments in the EBV/NPC research 
community. Recently, an EBV strain, M81, isolated from a NPC patient was reported to 
show a strong tropism to epithelial cells (Tsai et al., 2013) and it could be a more 
relevant strain to be used to infect epithelial cells in vitro.  
Consistent with the characteristics of the previously established HK1/EBV cells (a 
kind gift from Prof Tsao, University of Hong Kong), EBV infection promoted the 
migration and invasion, but decreased the proliferation of CNE1 and TW04 cells. While 
EBV infection is well-recognised to enhance NPC cell migration and invasion (Lui et 
al., 2009; Teramoto et al., 2000; Wu et al., 2003), EBV-infected cells do not acquire 
proliferative advantage in vitro (Tsang et al., 2010; Tsao et al., 2012). The reduced 
proliferation of EBV-infected cells in vitro could possibly be due to  the induction of 
 137 
p16 and p21 expression (Tsang et al., 2012) as well as the lack of tumour 
microenvironment which consists of molecules that may support the growth of NPC 
cells following EBV infection (e.g. angiogenic factors and inflammatory cytokines) 
(Tsao et al., 2012). Indeed, EBV infection has been shown to confer a growth advantage 
to NPC cells in vivo because tumours formed in the athymic nude mice injected with 
EBV-infected NPC cells grew faster than those with the parental controls (Teramoto et 
al., 2000). Furthermore, since EBERs have been shown to induce the production of anti-
proliferative type-I IFN by activating RIG-1 and TLR3 signalling in BL cells (Iwakiri et 
al., 2009; Yoneyama et al., 2004), similar mechanisms might occur in NPC cells 
leading to a reduction in the proliferation of EBV-infected NPC cells in vitro. 
7.5.2 Expression of SPHK1 and S1PR3 
EBV infection contributes to the pathogenesis of NPC by modulating a number of 
key cellular gene expression programmes (Raab-Traub, 2002). The present study 
showed that the only EBV-positive NPC cell line, C666-1, expressed the highest levels 
of SPHK1 and S1PR3 compared to a panel of seven EBV-negative NPC cell lines. 
Since EBV is present in all NPC cells, and SPHK1 and S1PR3 are over-expressed in 
primary NPC tissues (Li et al., 2015b) (Appendix A), these observations indicated that 
EBV infection might regulate the expression of SPHK1 and S1PR3 in NPC.  
7.5.2.1 EBV-infected nasopharyngeal epithelial cells 
The regulation of SPHK1 expression can be induced in various cell types by several 
molecules, including platelet-derived growth factor (PDGF), histamine, 12-O-
tetradecanoylphorbol-13-acetate (TPA), nerve growth factor (NGF) and IL-1 (Francy et 
al., 2007; Huwiler et al., 2006; Paugh et al., 2009; Sobue et al., 2005). In addition, a 
wide variety of stimuli including cytokines, growth factors, GPCR agonists, hormones, 
phorbol esters, vitamin D3 and antigens can activate SPHK1 (Pyne et al., 2000). In the 
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present study, EBV infection increased SPHK1 mRNA expression as well as the levels 
of total and phosphorylated SPHK1 proteins in five of eight NPC/immortalised 
nasopharyngeal cell lines analysed. Although an increase of SPHK1 mRNA was 
demonstrated in EBV-infected TW01 cells, the levels of SPHK1 proteins remained 
unchanged. Since post-transcriptional or post-translational events are known to affect 
protein expression (Greenbaum et al., 2003), these events might have occurred in the 
regulation of SPHK1 protein expression in TW01 cells. A study in gastric cancer cells 
has demonstrated that the expression of SPHK1 can be regulated by lysophosphatidic 
acid (LPA) through the crosstalk between lysophosphatidic acid receptor 1 (LPAR1) 
and EGFR (Shida et al., 2008a). Previous work from our laboratory has shown that 
autotaxin, the enzyme that produces LPA, is highly expressed in NPC (Yap et al., 
2015). Furthermore, EBV infection has been shown to increase the expression of 
autotaxin in Hodgkin lymphoma (Baumforth et al., 2005) and EGFR in cervical cancer 
(Miller et al., 1995), suggesting that EBV may increase the expression of SPHK1 in 
NPC through the regulation of LPA and EGFR. Nonetheless, the present study 
identified a novel role for EBV in stimulating SPHK1 expression and activation in NPC 
cells. 
Unlike SPHK1, EBV infection of nasopharyngeal epithelial cells did not consistently 
alter the expression of S1PR3, with an increase in three cell lines (HK1, TW04 and 
NP460hTert) but decrease in another three cell lines (CNE2, SUNE1 and HONE1) and 
unchanged in two cell lines (CNE1 and TW01). There is a paucity of information on the 
regulation of S1PR3 expression. A previous study has demonstrated that TGF-β1 can 
increase the expression of S1PR3 in a Smad2/3- and Smad4-dependent manner in 
skeletal myoblasts (Cencetti et al., 2010). Whilst EBV infection has been reported to 
induce the expression of TGF-β1 in cervical cancer (Cayrol et al., 1995), there are also 
studies showing that EBV infection can reduce the levels of Smad2 and Smad4 proteins 
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in Hodgkin lymphoma and gastric cancer (Flavell et al., 2008; Kim et al., 2016). It 
remains to be explored whether EBV can regulate the expression of S1PR3 through 
Smad-dependent TGF-β1 signalling in NPC cells. 
Of note, the upregulation of SPHK1 and S1PR3 expression was only consistently 
shown in HK1 cells following EBV infection and their expression appeared to be 
negatively correlated in the other seven EBV-infected cell lines, suggesting that EBV 
could regulate the expression of SPHK1 and S1PR3 in a mutually exclusive manner. 
While this speculation needs to be tested and since all the cell lines analysed express 
varied levels of SPHK1 and S1PR3, it is unlikely that the endogenous levels of these 
two genes would determine whether EBV can regulate their expression. Nonetheless, 
these results revealed a possible role for EBV in modulating the expression of S1PR3 
that warrants further investigation. 
7.5.2.2 NPC cells transfected with EBV latent genes  
EBV exhibits a latency II programme in NPC and the expression of EBV latent 
genes is restricted to EBNA1, LMP1, LMP2, EBERs, BART miRNAs and BARF1 
(Tsao et al., 2015). Having shown that EBV infection can upregulate the expression and 
activation of SPHK1, HONE1 cells stably transfected with EBNA1, LMP1 or LMP2A 
were used to determine which of these latent genes was responsible. The results showed 
that all three EBV latent genes could increase both the mRNA and protein levels of 
SPHK1 in HONE1 cells. Both LMP1 and LMP2A can activate the MAPK/ERK 
pathway in NPC, suggesting that these two EBV genes could possibly stimulate the 
phosphorylation of SPHK1 (Pitson et al., 2003). LMP1 and LMP2A are also well 
known to promote NPC cell migration (Chen et al., 2014; Fotheringham et al., 2012; 
Lan et al., 2012; Liu et al., 2012a), via a variety of mechanisms including the 
upregulation of wingless-type MMTV integration site family member 5A (WNT5A) 
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which was identified during the course of this study (Yap et al., 2014) (Appendix C). 
Therefore, the expression of SPHK1 was examined in HK1 cells transiently transfected 
with LMP1 or LMP2A by Q-PCR. However, the expression of SPHK1 remained 
unchanged in HK1 cells transfected with either LMP1 or LMP2A. HONE1 cells were 
derived from an undifferentiated NPC tumour, whereas HK1 cells established from a 
well-differentiated squamous cell carcinoma and, therefore, the mechanisms by which 
EBV regulates SPHK1 expression might be different depending on the genetic 
background of the cells (Glaser et al., 1989; Huang et al., 1980). In addition, it is 
possible that the activation of SPHK1 is mediated by other EBV-encoded latent genes. 
For example, the EBERs can induce the production of IGF-1, a growth factor that has 
been shown to activate SPHK1 in other cell systems (El-Shewy et al., 2006; Iwakiri et 
al., 2005). 
In the present study, EBV infection was shown to upregulate the expression of 
S1PR3 in HK1 cells and therefore, the EBV latent gene(s) responsible for this effect 
was investigated in these cells. However, transient transfection of either LMP1 or 
LMP2A did not increase the expression of S1PR3 in HK1 cells. It is possible that other 
EBV-encoded latent genes (e.g. EBNA1, EBERs, BART miRNAs and BARF1) could 
regulate the expression of S1PR3 independently or jointly. Furthermore, given that 
EBV-encoded genes can activate multiple signalling pathways, the expression of S1PR3 
could be regulated by highly complex mechanisms. 
7.6 Limitations of the study 
Although this study has been carefully designed to address the specific research 
questions, there are a number of limitations that could potentially influence the broader 
conclusions drawn from the data. Careful consideration of such limitations should be 
given before generalisation and application to practice. 
 141 
Firstly, both microarray and RNAscope analyses demonstrated the over-expression 
of S1PR3 mRNA in primary NPC tissues compared to non-malignant nasopharyngeal 
epithelium, but post-transcriptional and post-translational modifications might occur to 
alter the protein expression. Therefore, it would be beneficial to confirm the over-
expression of S1PR3 at the protein level in NPC tissues. 
Secondly, the analyses of the effects following SPHK1 knockdown are based on the 
assumption that S1P levels would be reduced. Measurement of S1P levels by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) in conditioned media 
following SPHK1 knockdown would be helpful to confirm the conclusions. 
Thirdly, the interpretations of the findings deduced from the use of pharmacological 
agents in this study are limited by the assumption that they specifically and effectively 
modulate their specified target(s). The contradicting data on the roles of S1PR2 could be 
due to the “off-target” effects of the pharmacological drugs. Therefore, the use of more 
specific approaches such as ectopic expression or knockdown of S1PR2 would be 
beneficial to confirm the results. 
Lastly, the results of the present study represent the first pre-clinical, proof of 
concept in vitro studies to identify a role for S1P in the pathogenesis of NPC. However, 
currently the main challenge in NPC research is the lack of truly representative NPC 
cell lines that are EBV-positive. Therefore, it would obviously be important to 
determine if these results could be recapitulated using relevant in vitro and in vivo 
models. 
7.7 Future Work 
The results of this study convincingly show that aberrant activation of S1P signalling 
promotes the migratory phenotype of NPC cells and EBV infection can contribute to the 
 142 
dysregulation of this signalling pathway. There are a number of areas of research arising 
from this work that are likely to have fundamental implications for a better 
understanding of the contribution of S1P signalling to the pathogenesis of NPC and 
subsequently the development of new strategies to target this pathway therapeutically. 
Both microarray and RNAscope analyses showed that the mRNA levels of S1PR3 
are overexpressed in primary NPC tissue samples compared to non-malignant 
nasopharyngeal epithelium. Currently a suitable anti-S1PR3 antibody for 
immunohistochemistry is not available for use in NPC tissues. The generation of an 
antibody suitable for immunohistochemical analyses using paraffin-embedded (FFPE) 
NPC tissues would be very useful. Examination of the association between S1PR3 
protein levels and clinicopathological parameters in vivo would be informative and 
crucial.  
In addition to SPHK1 and the S1PRs, it would be informative to evaluate whether the 
expression of other key regulators of S1P signalling, such as SPHK2, S1P transporters 
and S1P lyase, is altered in NPC and how their deregulation influences NPC cell 
behaviour. Collectively, this information will provide a fuller understanding of the 
contribution of aberrant S1P signalling to the pathogenesis of NPC. 
It is now recognised that the tumour microenvironment plays a crucial role in 
tumorigenesis. In particular, undifferentiated NPC is characterised by a prominent 
lymphocytic infiltration, pointing to an important role for the immune 
microenvironment in the pathogenesis of NPC. A comprehensive study of the 
association of S1P signalling with the NPC tumour microenvironment, including 
potential crosstalk with immune cells and CAFs, would greatly strengthen our 
understanding of the contribution of S1P signalling to NPC development and the 
therapeutic relevance of targeting this pathway. 
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The present study demonstrated that S1P induced NPC cell migration through the 
activation of AKT via S1PR3. However, the knockdown of S1PR3 and transfection of a 
constitutively active AKT only partially reduced/restored the migration of NPC cells, 
indicating that S1P-mediated migration of NPC cells might involve the activation of 
other molecules or S1PR. Therefore, exploring more downstream targets of S1P or 
signalling crosstalk with other oncogenic pathways might provide additional insights 
into the underlying mechanisms contributing to the oncogenic effects of S1P in NPC.  
Having shown in vitro that EBV infection contributes to the aberrant activation of 
S1P signalling, it would be informative to identify the mechanisms employed by EBV 
to deregulate this pathway and investigate the therapeutic potential of inhibitors or 
modulators of the S1P signalling pathway in vivo. Furthermore, functional studies on 
the role of S1P in relation to EBV infection in nasopharyngeal epithelial cells, such as 
EBV infection rate or persistence of EBV, would also be useful. 
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CHAPTER 8: CONCLUDING REMARKS 
The present study reveals for the first time, an oncogenic role of S1P signalling in the 
pathogenesis of NPC and the contribution of EBV infection to the deregulation of this 
pathway. In the context of NPC cell migration, a working model can be proposed to 
demonstrate the link between EBV infection and S1P signalling (Figure 8.1).  
The presence of EBV is invariably detected in non-keratinising NPC cells. The 
present study shows that EBV infection can upregulate the expression and activation of 
SPHK1 and therefore, high levels of S1P are likely to be present in NPC cells. S1P 
binds to S1PR3 which was found to be overexpressed in micro-dissected primary NPC 
tissue samples compared to normal nasopharyngeal epithelium. The SPHK1/S1P/S1PR3 
signalling pathway stimulates the phosphorylation of AKT, leading to the migration of 
NPC cells. The data demonstrate a direct role for S1PR3 in mediating the S1P-induced 
migration of NPC cells through activation of AKT. These observations are novel and 
relevant to the field of both NPC pathogenesis and S1P signalling. 
From the proposed model, there are three possible ways to abrogate the oncogenic 
effects of S1P signalling in NPC within a therapeutic context. One option would be to 
inhibit the activity of SPHK1, which would reduce the amount of S1P produced by the 
tumour cells. Secondly, S1P itself could be targeted with therapeutic neutralising 
antibodies and thirdly, specific inhibitors of S1PR3 could be employed to inhibit NPC 
cell migration and invasion. Taken together, the present study has identified the 
SPHK1/S1P/S1PR3 axis as a promising target for the development of novel treatment 
strategies for NPC patients. 
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Figure 8.1: A proposed model of S1P-mediated migration of EBV-associated NPC 
cells 
EBV infection can upregulate the levels of SPHK1 and/or S1PR3. High expression of 
SPHK1 is most likely to result in elevated levels of S1P in NPC cells. S1P can promote 
the migration of NPC cells by stimulating the phosphorylation of AKT through S1PR3.  
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OVER-EXPRESSION OF S1PR3 IN PRIMARY NPC TISSUES 
 
 
As determined by RNAscope analyses, (a,b) two separate examples of normal 
epithelium showed negative S1PR3 staining and representative NPC cases demonstrated 
(c) negative, (d) weak and (e,f) strong expression of S1PR3 in the carcinoma (red 
arrows) (magnification: X400). 
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REDUCED SURVIVAL IN PATIENTS WITH HIGH S1PR3 
EXPRESSION 
 
 
Kaplan-Meier survival analysis revealed that high expression of S1PR3 in NPC was 
associated with reduced patient survival (p<0.05). 
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EBV INFECTION STIMULATES THE EXPRESSION OF WNT5A 
 
 
(A) In NPC cell lines, Q-PCR analysis showed that the only EBV-positive cell line, 
C666-1, had markedly increased levels of WNT5A when compared to a panel of EBV-
negative cell lines. Shown here are data comparing cell lines with NP460 cells, an 
immortalised nasopharyngeal epithelial cell line. (B) Q-PCR analysis showed that the 
expression of WNT5A transcripts was significantly increased in HONE1 cells 
expressing EBV-encoded EBNA1 and LMP2A (p<0.01). (C) The ability of LMP2A to 
stimulate the expression of WNT5A was further confirmed in CNE2 cells expressing 
LMP2A (p < 0.01). Data are expressed as the relative expression between the cells 
transfected with EBV latent genes and their respective controls. The expression levels 
of the controls were normalised to 1. 
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